Contents

1. INTRODUCTION

2. AN OVERVIEW OF PHARMACEUTICALS INDUSTRY

3. PHARMACEUTICALS INDUSTRY

4. NATIONAL PHARMACEUTICALS PRICING AUTHORITY

5. PUBLIC SECTOR UNDERTAKINGS

6. NATIONAL INSTITUTES OF PHARMACEUTICALS EDUCATION & RESEARCH (NIPERs)

7. NEW INITIATIVES

8. IMPLEMENTATION OF RAJBHASHA

9. GENERAL ADMINISTRATION

10. CITIZEN CENTRIC GOVERNANCE

11. INFORMATION AND COMMUNICATION TECHNOLOGY

12. ANNEXURES
Brief Contents

1. INTRODUCTION 1
   Mandate of Department of Pharmaceuticals

2. AN OVERVIEW OF PHARMACEUTICALS INDUSTRY 5
   2.1 Financial Performance of the Drugs and Pharmaceuticals Industry
   2.2 Imports
   2.3 Exports
   2.4 PharmaExport Promotion Council (Pharmexcil)
   2.5 International Cooperation/Export Promotion of Pharmaceuticals
   2.6 Proposed Major areas of International Cooperation
   2.7 India Pharma Summit – 2015
   2.8 Pharmaceuticals Promotion Development Scheme
   2.9 Workshops for Capacity Building of Pharma Industry and Regulation

3. PHARMACEUTICALS INDUSTRY- OTHER ACTIVITIES 11
   3.1 Pharmaceuticals Industry
   3.2 Creation of IPR Facilitation Centers in Pharmexcil
   3.3 Pharmaceuticals Policy
   3.4 Foreign Direct Investment in Pharmaceuticals Sector

4. NATIONAL PHARMACEUTICALS PRICING AUTHORITY 15
   4.1 NPPA
   4.2 Drug Prices Equalization Account (DPEA)

5. PUBLIC SECTOR UNDERTAKINGS 21
   5.1 Central Public Sector Undertakings
   5.2 Joint Sector Undertakings
   5.3 Wholly Owned Subsidiaries
   5.4 Status of Annual Accounts
   5.5 Generic Drugs Campaign – The Jan Aushadhi Scheme

6. NATIONAL INSTITUTES OF PHARMACEUTICAL EDUCATION & RESEARCH (NIPERs) 41

7. NEW INITIATIVES 59
   7.1 Cluster Development Programme for Pharma Sector (CDP-PS)
   7.2 New initiatives taken BY National Pharmaceutical Pricing Authority (NPPA)
   7.3 National Centre for Research & Development in Bulk Drugs at NIPER, Hyderabad
   7.4 Collaborative TB and Kala Azar Research Project of NIPER, Mohali
8. IMPLEMENTATION OF RAJBHASHA

9. GENERAL ADMINISTRATION
   9.1 Organizational Set Up

10. CITIZEN CENTRIC GOVERNANCE
   10.1 Our Vision
   10.2 Our Mission
   10.3 Our Clients
   10.4 Our Commitment
   10.5 Our Services
   10.6 Our Activities
   10.7 RTI-2005
   10.8 CPGRAMS

11. INFORMATION AND TECHNOLOGY
   11.1 Local Area Network (LAN)
   11.2 IT Infrastructure
   11.3 Website and Social Media
   11.4 Video Conferencing
   11.5 File Tracking System
   11.6 E. Governance

12. ANNEXURES
    Annexure –I [A] (List of PSUs and other Organizations)
        [B] (Address and Name of various Organizations & PSUs)
        [C] (List of Responsibility Centers and Subordinate Organizations)
    Annexure –II (Organizational Chart of NPPA)
    Annexure –III (Result Framework Document 2013-14)
Chapter 1

INTRODUCTION

1.1 Mandate of Department of Pharmaceuticals
CHAPTER – 1
INTRODUCTION

1.1 MANDATE OF DEPARTMENT OF PHARMACEUTICALS

The Cabinet Secretariat notified creation of a new Department, namely the Department of Pharmaceuticals, under the Ministry of Chemicals & Fertilizers which came into being w.e.f. 1st July 2008 with the objective to give greater focus and thrust on the development of pharmaceutical sector in the country and to regulate various complex issues related to pricing and availability of medicines at affordable prices, research & development, protection of intellectual property rights and international commitments related to pharmaceutical sector which required integration of work with other ministries.

Following works have been allocated to the Department of Pharmaceuticals:

1) Drugs and Pharmaceuticals, excluding those specifically allotted to other departments.
2) Promotion and co-ordination of basic, applied and other research in areas related to the Pharmaceuticals sector.
3) Development of infrastructure, manpower and skills for the Pharmaceuticals sector and management of related information.
4) Education and training including high end research and grant of fellowships in India and abroad, exchange of information and technical guidance on all matters relating to pharmaceutical sector.
5) Promotion of public – private – partnership in pharmaceutical related areas.
6) International cooperation in pharmaceutical research, including work related to international conferences in related areas in India and abroad.
7) Inter-sectoral coordination including coordination between organizations and institutes under the Central and State Governments in areas related to the subjects entrusted to the Department.
8) Technical support for dealing with national hazards in pharmaceutical sector.
9) All matters relating to National Pharmaceuticals Pricing Authority including related functions of price control/monitoring.
10) All matters relating to National Institutes for Pharmaceuticals Education and Research.
11) Planning, development and control of; and assistance to, all industries dealt with by the Department.
12) Bengal Chemicals and Pharmaceuticals Limited.
13) Hindustan Antibiotics Limited & its subsidiaries as & JVs.
14) Indian Drugs and Pharmaceuticals Limited & its subsidiaries
15) Karnataka Antibiotics and Pharmaceuticals Limited.
16) Rajasthan Drugs and Pharmaceuticals Limited.
17) Bengal Immunity Limited.
18) Smith Stainstreet Pharmaceuticals Limited.

The work of the Department has been divided into three Divisions viz. Pharmaceuticals Industry Division, Public Sector Undertakings Division and R& D Division comprising of National Institute of Pharmaceutical Education & Research (NIPER) and Research & Development. The National Pharmaceuticals Pricing Authority an attached office of this Department, is entrusted with the work of fixation and revision of prices of pharmaceuticals products under Drug Price Control Order 2013.

Dr. V.K. Subburaj is Secretary who holds charge of this Department w.e.f 01.10.2014.
Chapter 2

AN OVERVIEW OF PHARMACEUTICALS INDUSTRY
2.1 Financial Performance of the Drugs and Pharmaceuticals Industry
2.2 Imports
2.3 Exports
2.4 Pharma Export Promotion Council (Pharmexcil)
2.5 International Cooperation/Export Promotion of Pharmaceuticals
2.6 Proposed Major areas of International Cooperation
2.7 India Pharma Summit – 2015
2.8 Pharmaceutical Promotion Development Scheme (PPDS)
2.9 Workshops for Capacity Building of Pharma Industry and Regulation
CHAPTER 2
AN OVERVIEW OF THE PHARMACEUTICALS INDUSTRY

2.1 FINANCIAL PERFORMANCE OF THE DRUGS AND PHARMACEUTICALS INDUSTRY

The financial performance of the Drugs and Pharmaceuticals Industry for the years 2011-12 to 2013-14 and the quarterly performance during the year 2014-15 (up to September 2014) are given in the table below. The figures reported in the table show the percentage change in the respective items of income, expenditure, profitability etc as compared to the corresponding period the previous year.

Drugs and Pharmaceuticals: Growth and Profitability in the Year 2014-15

<table>
<thead>
<tr>
<th>No.</th>
<th>Particulars</th>
<th>Quarterly</th>
<th>Annual</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>March’14</td>
<td>June’14</td>
</tr>
<tr>
<td>1</td>
<td>Net Sales</td>
<td>14.07</td>
<td>18.38</td>
</tr>
<tr>
<td>2</td>
<td>Total expenses</td>
<td>13.34</td>
<td>11.11</td>
</tr>
<tr>
<td>3</td>
<td>Raw Materials, Stores &amp; spares</td>
<td>10.90</td>
<td>3.62</td>
</tr>
<tr>
<td>4</td>
<td>Salaries &amp; Wages/ Compensation</td>
<td>15.74</td>
<td>13.63</td>
</tr>
<tr>
<td>5</td>
<td>Power &amp; fuel</td>
<td>5.95</td>
<td>-2.03</td>
</tr>
<tr>
<td>6</td>
<td>Depreciation</td>
<td>8.34</td>
<td>27.95</td>
</tr>
<tr>
<td>7</td>
<td>Interest expenses</td>
<td>20.13</td>
<td>-9.31</td>
</tr>
<tr>
<td>8</td>
<td>Direct Tax provision</td>
<td>23.19</td>
<td>77.78</td>
</tr>
<tr>
<td>9</td>
<td>PBDIT net of P&amp;E</td>
<td>29.04</td>
<td>93.14</td>
</tr>
<tr>
<td>10</td>
<td>PAT net of P&amp;E</td>
<td>84.64</td>
<td>308.75</td>
</tr>
<tr>
<td>11</td>
<td>PBDIT net of P&amp;E as % of Net Sales</td>
<td>17.81</td>
<td>23.21</td>
</tr>
<tr>
<td>12</td>
<td>No. of Companies data -count</td>
<td>153</td>
<td>152</td>
</tr>
</tbody>
</table>

Source: Centre for Monitoring Indian Economy (CMIE) Pvt Ltd data as on February 13, 2015.

The net sales of the Drugs & Pharmaceuticals Industry registered a y-o-y growth of 16.20%, 9.82% and 12.71% respectively during the years 2011-12 to 2013-14, for the selected sample of companies, as per CMIE data. Net sales of the industry grew by 14.07% in the March 2014 quarter and 18.38% in the June 2014 quarter. In the September 2014 quarter, sales growth witnessed a deceleration, when net sales grew by merely 4.6% y-o-y. The industry had clocked sales growth of 9-19% during the preceding three quarters.

The Profit after Tax (PAT) net of prior period and extraordinary items grew by 84.64% in the March 2014 quarter, 308.75% in the June 2014 quarter and by 17.82% in the September 2014 quarter as compared to the corresponding period last year. The increased growth in profits in June 2014 quarter was on account of strong sales growth, control over operating costs and rise in other income. In the September 2014 quarter, operating expenses of the industry increased by 6.5%. Among operating expenses, raw material expenses (major cost head of the industry) increased by 8.4% and wage bill by 13.9%. Even though the industry did not perform well at the operating level, its PAT increased by 17.8% in the September 2014 quarter. This was possible due to a sharp rise in other income and fall in interest expenses.

2.2 IMPORTS

Imports of medicinal and pharmaceuticals products for the last three years were as under:

<table>
<thead>
<tr>
<th>Year</th>
<th>Import of Medicines &amp; Pharmaceuticals Products (Rupees in Crore)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011-12</td>
<td>14287.66</td>
</tr>
<tr>
<td>2012-13</td>
<td>16965.09</td>
</tr>
<tr>
<td>2013-14</td>
<td>17944.05</td>
</tr>
</tbody>
</table>

Source: industryoutlook.cmie.com

The country is almost self-sufficient in case of formulations. The imports are being made on quality and economic considerations and not necessarily due to non-availability from domestic sources. Manufacturers of Drugs and Pharmaceuticals are free to produce any drug approved by the Drug Control authorities.
Imports of Drugs and Pharmaceuticals is done as per Foreign Trade Policy. However, import of some drugs and drug intermediates is still restricted under current Foreign Trade Policy. Imports which are restricted are basically due to common HS codes for some narcotic substances or similarity to some Ozone Depleting Substances (ODS).

2.3 EXPORTS

Exports of medicinal and pharmaceuticals products for the last three years were as under: -

<table>
<thead>
<tr>
<th>Year</th>
<th>Exports of Medicines &amp; Pharmaceuticals Products (Rs. in Crore)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011-12</td>
<td>544906.73</td>
</tr>
<tr>
<td>2012-13</td>
<td>620166.70</td>
</tr>
<tr>
<td>2013-14</td>
<td>690236.77</td>
</tr>
</tbody>
</table>

Source: Industryoutlook.cmie.com

INTERNATIONAL COOPERATION/ EXPORT PROMOTION OF PHARMACEUTICALS

An important focus area for the Department of Pharmaceuticals is promotion of Indian Pharmaceutical Products in global market. The Department participated in the following International Cooperation events during 2014-2015:-

(i) 11th India-Kazakhstan Inter-Governmental Commission (IGC) on Trade, Economic, Scientific, Technological, Industrial and Cultural Cooperation between India and Kazakhstan was held on 24-25 April, 2014 at Astana under the Chairmanship of Secretary (P&NG).

(ii) 5th Joint Commission Meeting (JCM) between India and Surinam held on 13th January, 2015 at New Delhi.

(iii) Second meeting of India-Vietnam Joint Sub-Commission on Trade and related issues held under the Co-chairmanship of Commerce Secretary on 19th-22nd January, 2015 at Hanoi, Vietnam.

(iv) Meeting of India-US High Technology Cooperation Group (HTCG) and G2G Working Group on Biotechnology and Life Science under India-US High Technology Cooperation Group (HTCG) was held on 20th and 21st November, 2014 at New Delhi.

2.4 PHARMA EXPORT PROMOTION COUNCIL (PHARMEXCIL)

The Department had played a pivotal role in the formation of Pharmexcil consequent to the recommendation from 9th Five Year Plan Working Group Report on Drugs and Pharmaceuticals. In the light of this, the Department constantly interacts with Pharmexcil in their work areas. The role of Pharmexcil is for facilitation of exports of Drugs, Pharmaceuticals, Biotechnology products, Herbal medicines and Diagnostics, to name a few. It is authorized to issue Registration-cum-Membership Certificate (RCMC) which is one of the requirements for the importers and exporters of commodities. In addition to this, Pharmexcil is concerned with giving export thrust to the various products through visits of delegations to various markets abroad, organizing of seminars, workshops and exhibitions. As a major area of work, Pharmexcil also holds Buyers/Sellers meets and compiles detailed data base on pharma exports and problems in exporting pharma products.

2.5 GRANT-IN-AID

The Department of Pharmaceuticals also provided financial assistance for the following activities/events for promotion and development of Pharma sector from Pharmaceuticals Promotion Development Scheme (PPDS) during Financial Year – 2014-15:-

1. Grant in aid to M/s MITCON Consultancy & Engineering Services Ltd, Pune for conducting ‘Evaluation Study’ on Working of ‘Pharmaceutical Promotion and Development Scheme’ during 11th Five Year Plan period

2. Grant in aid to Centre for Monitoring Indian Economy for subscribing CMIE products 2014-15

3. Grant in aid to IIDM for conducting Evaluation study of creation of IPR facilitation Centre


5. Grant in aid to CII in connection with 12th National Pharmaceutical Conclave held on 12-13 December, 2014 at New Delhi

6. Grant in aid to NIPER, Guwahati in connection with Pharma Conference at Guwahati

7. Grant in aid to NIPER Mohali in connection with Academia Industry Business Meet

8. Grant in aid to FICCI for conducting Workshop at Chennai, Mumbai, Bangalore, Indore and Gandhinagar/ Ernakulam on Capacity Building for Pharma Industry

9. Grant in aid to Pharmexcil for conducting Seminar on Export opportunities in Pharmaceutical in Uzbekistan and Peru at Mumbai

10. Grant in aid to PHD Chamber for 3rd Annual Conference on Pharma Med 2014

11. Grant in aid to FABA for organizing BioAsia 2015: New Era of Life Sciences Opportunities in Transition


13. Grant in aid to ASSOCHAM for organizing 3rd National Conference on ‘Waste to Wealth: The action Agenda’

14. Grant in aid to NIPER Hyderabad for organizing National Conference/Workshop at Nipper Hyderabad

2.6 PROPOSED MAJOR AREA OF INTERNATIONAL COOPERATION

- Pharmexcil has organized the Seminar on Export Opportunities of Pharmaceuticals products in Latin American Countries (LAC) on 10th February 2015 in Mumbai and another seminar on Export opportunities in Pharmaceuticals in Uzbekistan is also proposed to be organized by Pharmexcil in March, 2015.
• India-EU Joint Working Group (JWG) on Pharmaceuticals was constituted under the aegis of the India-EU Sub-commission on Economic Cooperation for which Department of Commerce is the nodal Department. This JWG is co-chaired by the Joint Secretary, Department of Pharmaceuticals from the Indian side and there are representatives from other concerned Departments. 6th Meeting of India-EU Joint Working Group on Pharmaceuticals, Biotechnology and Medical Devices is proposed at New Delhi on 30th April and 1st May, 2015.

• 6th meeting of the India-Tunisia Joint Working Group on Drugs and Pharmaceuticals under the aegis of the Indo-Tunisian Joint Commission is proposed to be held in February-March, 2015 at Tunis, Tunisia.

2.7 INDIA PHARMA SUMMIT 2015

Department of Pharmaceuticals is going to organize 6th India Pharma Summit 2014-2015 on 23rd March, 2015 at Mumbai in association with Federation of Indian Chamber of Commerce and Industry (FICCI) and WHO India. The theme for this year’s deliberations is – “Policy Landscape Reforms for Strengthening Indian Pharmaceuticals Industry”.

2.8 PHARMACEUTICALS PROMOTION DEVELOPMENT SCHEME (PPDS)

The Objective of Pharmaceuticals Promotion Development Scheme (PPDS) is promotion, development and export promotion in Pharmaceutical sector by extending financial support for conduct of seminars, conferences, exhibitions, mounting delegations to and from India for promotion of exports as well as investments, conducting studies/ consultancies, for facilitating growth, exports as well as critical issues affecting Pharma sector. Under PPDS the Department of Pharmaceuticals on its own or through financial support by way of Grant-in aid to the Institutions, organizations, Voluntary organizations or Non Government Organizations as mentioned in Rule 206 of GFR 2005,

i) Conduct Training/knowledge improvement programs/activities on issues/subjects relevant to growth of pharmaceutical industry. An indicative list of subject is as under:-
  a) Quality Management System/Quality Improvement Program
  b) How to handle USFDA notice?
  c) Success Story Presentation-Pharmaceutical Entrepreneur
  d) Government regulations/guidelines for clinical trials in India versus USA, EU etc.
  e) Waste Management

ii) Organize Summits, Convention, Exhibitions, Pharmacy week, meetings etc. in India and abroad and produce promotional materials like films, displays etc.

iii) Conduct research studies, sector reports etc.

iv) Purchase books, quality standards, pharmacopoeias, magazines, directories, software for developing information data banks, developing e-learning modules etc.

v) Give awards to achievers in pharmaceutical industry.

vi) For any other activity not covered under above categories which may be decided by the Department of Pharmaceuticals from time to time.

2.9 WORKSHOPS FOR CAPACITY BUILDING OF PHARMA INDUSTRY FOR COMPLIANCE TO WHO GMP STANDARD

Department of Pharmaceuticals in association with Federation of Indian Chamber of Commerce and Industry (FICCI) and WHO is organizing the workshops on Capacity Building of SME’s in strengthening quality management systems and best practices for the process improvements, global regulatory requirements and compliance, including WHO GMP requirements of Pharma Industry and Regulation at Bengaluru, Chennai, Gandhinagar, Indore and Mumbai.
Chapter 3

PHARMACEUTICAL INDUSTRY-OTHER ACTIVITIES
3.1 Pharmaceuticals Industry
3.2 Creation of IPR Facilitation Centers in Pharmexcil
3.3 Pharmaceuticals Policy
3.4 Foreign Direct Investment in Pharmaceuticals Sector
CHAPTER – 3
PHARMACEUTICAL INDUSTRY

3.1 PHARMACEUTICALS INDUSTRY-OTHER ACTIVITIES

The annual turnover of the Indian Pharmaceutical Industry is estimated to be about Rs. 128044.29\(^1\)Crores during the year 2013-14. The share of export of Drugs, Pharmaceuticals and Fine Chemicals is Rs. 63293.91\(^2\)Crores. This segment of Industry has shown tremendous progress in terms of infrastructure development, technology base and wide range of products. The industry has developed excellent GMP (Good Manufacturing Practices) compliant facilities for the production of different dosage forms. The strength of the industry is in developing cost effective technologies in the shortest possible time for drug intermediates and bulk activities without compromising on quality. This is realized through the country’s strengths in organic chemicals’ synthesis and process engineering.

The domestic Pharma Industry has recently achieved some historic milestones through a leadership position and global presence as a world class cost effective generic drugs’ manufacturer of AIDS medicines. Many Indian companies are part of an agreement where major AIDS drugs based on Lamivudine, Stavudine, Zidovudine, Nevirapine are supplied to Mozambique, Rwanda, South Africa and Tanzania which have about 33% of all people living with AIDS in Africa. Many US Schemes are sourcing Anti Retrovirals from Indian companies whose products are already US FDA approved.

The Indian Pharmaceutical companies maintain highest standards in Purity, Stability and International Safety, Health and Environmental(SHE) protection in production and supply of bulk drugs. This speaks of the high standards maintained by a large number of Indian Pharma companies as these bulk active ingredients are used by the buyer companies in manufacture of dosage forms which are again subjected to stringent assessment by various regulatory authorities in the importing countries. More of Indian companies are now seeking regulatory approvals in USA in specialized segments like Anti-infectives, Cardiovasculars, CNS group. Along with Brazil & PR China, India has carved a niche for itself by being a top generic Pharma player.

Many Indian companies have got various international regulatory approvals for their plants, from agencies like USFDA, MHRA-UK, TGA-Australia, MCC-South Africa etc. Outside USA India has the highest number of USFDA approved plants for generic drugs’ manufacture. Major share of Indian Pharma exports is going to developed western countries and it speaks not only about excellent quality of Indian pharmaceuticals but also about the reasonableness of the prices. Some of the leading Indian Pharma companies derive 50% of their turnover from International business.

1 Source CMIE (Industry Outlook)
2 Source CMIE (Industry Outlook)

3.2 CREATION OF IPR FACILITATION CENTRES IN PHARMEXIL

After appraising the working of IPR Facilitation Centre Scheme during 11\(^{th}\) Five Year Plan (2007-2012), the Scheme has been revised with following three components with a total plan outlay of Rs. 5 Crore during 12\(^{th}\) Five Year Plan:

(A) AWARENESS/SENSITIZATION PROGRAMME ON IPR

This programme is for granting financial assistance of upto Rs. 1 lakh for organizing sensitization programmes to equip the Pharma Industries to effectively use IP as part of their business strategy. It will result in increasing awareness and understanding of IP issues within the Pharma business community, particularly through awareness raising campaigns and targeted training programs. Optimal use of modern information and communication technologies, will help so as to enhance the capacity of Pharma Industry to maximize their benefits form the use of the IP systems.

(B) INTERACTIVE SEMINARS/WORKSHOPS

This programme/scheme is for granting financial assistance of upto Rs. 2 lakhs to organize seminars/workshops which will provide a forum to pharma Industry Associations and other stakeholders, including professionals having working experience of the sector to share knowledge, experience and create mass awareness on various aspects of IPR.

(C) ASSISTANCE FOR SETTING UP OF IPR FACILITATION CENTRE FOR PHARMACEUTICALS

The primary objective is setting up of IP Facilitation Centres near the Pharma Clusters to provide the IPR related services primarily to Medium and Small Pharmaceutical manufacturers. In the remaining period of the 12\(^{th}\) Five Year Plan, the scheme will focus on creating additional IPR Facilitation Centres at Ahmedabad and Chandigarh (Mohali) and the existing IPR Facilitation Centres at Hyderabad managed by Pharmexcil will be supported. The scheme provides for Rs. 75 lakh as one time grant and Rs. 23 lakh as recurring expenses for three years for a single IPR facilitation centre and a provision of Rs. 2.00 lakh towards contingencies and other miscellaneous charges.

3.3 PHARMACEUTICAL POLICY

The Department of Pharmaceuticals notified the National Pharmaceutical Pricing Policy-2012(NPPP-2012) on 07.12.2012 with the objective to put in place a regulatory framework for pricing of drugs to ensure availability of required medicines – “essential medicines” – at reasonable prices, even while providing sufficient opportunity for innovation and competition to support the growth of industry, thereby meeting the goals of employment and shared economic well being for all. The salient features of this policy are as under:
• All the medicines, as under National List of Essential Medicines (NLEM) -2011, that takes care of the healthcare needs of the majority of the population of the country, have come under Price Control.

• Nearly 680 formulations, spread over 27 therapeutic categories including HIV, diabetes, heart diseases, cancer etc have come under price control.

Subsequently, to implement the NPPP-2012, the new Drugs (Prices Control) Order, 2013 was notified on 15.05.2013 to control the prices of specified dosages and strengths as under National List of Essential Medicines-2011(NLEM-2011). The medicines of dosages and strengths as specified under the National List of Essential Medicines (NLEM)-2011 have been brought under price control based on a concept of Ceiling Price by having the Simple Average Price of all the branded and/or generic versions of such medicine having market share more than and equal to 1% of the total domestic market turnover of that medicine. The medicines not listed under NLEM-2011 are under monitoring and no manufacturer can increase the maximum retail price of a drug more than ten percent of maximum retail price during preceding twelve months. As per the provisions of Drugs (Prices Control) Order, 2013, all the existing manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, are required to revise the prices of all such formulations downward not exceeding the ceiling price (plus local taxes as applicable).

3.4 FOREIGN DIRECT INVESTMENT IN PHARMACEUTICAL SECTOR

Foreign Direct Investment (FDI) up to 100% has been in operation in Pharmaceutical Sector since 2001. However, during the period of August 2006 to December 2010, acquisitions of some of the major Indian Pharma Companies like Ranbaxy and Piramal, led to a strong apprehension that these takeovers could affect the domestic Pharma Industry especially the Generic Medicines. Department of Industrial Policy & Promotion in November, 2011 revised the FDI Policy which at present provides that 100% FDI in pharmaceutical sector is permissible through automatic route for greenfield investment and through Government approval route for brownfield investment. Further in brownfield investment ‘non-compete’ clause is not allowed except in special circumstances with the approval of the Foreign Investment Promotion Board (FIPB). Also, FDI upto 100% through automatic route for manufacturing of medical devices has been allowed.
Chapter 4

NATIONAL PHARMACEUTICAL PRICING AUTHORITY

4.1 NPPA

4.2 Drug Price Equalization Account (DPEA)
CHAPTER 4
NATIONAL PHARMACEUTICAL PRICING AUTHORITY (NPPA)

4.1 NPPA The National Pharmaceutical Pricing Authority (NPPA), an independent body of experts in the Ministry of Chemicals and Fertilizer was formed by the Govt. of India vide Resolution published in the Gazette of India No. 159 dated 29.08.97. The functions of NPPA, inter-alia include fixation and revision of prices of scheduled drug under the Drugs (Prices Control) Order (DPCO), as well as monitoring and enforcement of prices. NPPA also provides inputs to Government for policy formulation on other specific issues concerning making available affordable medicines to the consumers.


Salient features of DPCO, 2013.

- Drug formulations listed under the National List of Essential Medicines under price control.
- Ceiling price calculations are based on “market based data” as opposed to cost based under DPCO, 1995.
- Controls only drug formulation price as opposed to both bulk drugs and their formulations under DPCO, 1995.

The functions of the National Pharmaceutical Pricing Authority (NPPA) are:

(i) To implement and enforce the provisions of the Drugs (Prices Control) Order (DPCO), 1995 / 2013 in accordance with powers delegated to it.

(ii) To undertake and/or sponsor relevant studies in respect of pricing of drugs/formulations.

(iii) To monitor the availability of drugs, identify shortages, if any, and to take remedial steps.

(iv) To collect/maintain data on production, exports and imports, market share of individual companies, profitability of companies etc. for bulk drugs and formulations.

(v) To deal with all legal matters arising out of the decisions of the Authority.

(vi) To render advice to the Central Government of changes/revisions in the drug policy.

(vii) To render assistance to the Central Government in parliamentary matters relating to drug pricing.

The organizational structure of NPPA is given as per Annexure II:

Price Fixation:

Under the provisions of the Drugs (Price Control) Order, 2013, the prices of scheduled formulations which are based on National List of Essential Medicines (NLEM)-2011 issued by the Ministry of Health and Family Welfare are to be fixed based on market based data. No one is permitted to sell any scheduled drug / formulation at a price higher than the ceiling price fixed by NPPA/Government.

NPPA has fixed the ceiling prices of 509 formulation packs under DPCO, 2013. NPPA is in the process of collecting market based information for fixing the prices of remaining formulations.

Out of NLEM-2011, NPPA has fixed the ceiling prices of 509 formulations packs under DPCO, 2013. Status on the progress on pricing under DPCO, 2013 is given as under:

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Particulars</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Total number of NLEM medicines</td>
<td>680</td>
</tr>
<tr>
<td>2.</td>
<td>Medicines appearing in more than one therapeutic group of DPCO, 2013</td>
<td>52</td>
</tr>
<tr>
<td>3.</td>
<td>Net medicines for which prices are to be fixed</td>
<td>628</td>
</tr>
<tr>
<td>4.</td>
<td>Ceiling prices fixed upto 19th Authority Meeting (held on 10.12.2014)</td>
<td>509</td>
</tr>
<tr>
<td>5.</td>
<td>Ceiling price fixation pending due to non-availability of Market based price data</td>
<td>102</td>
</tr>
<tr>
<td>6.</td>
<td>Common items under DPCO, 1995 and DPCO, 2013 for which price notification is due in April, 2015.</td>
<td>17</td>
</tr>
</tbody>
</table>

Total = (4)+(5)+(6) = 628

Statement showing range of reduction in price with respect to the highest price on the basis of data furnished by IMS-Health/Companies

<table>
<thead>
<tr>
<th>S. No.</th>
<th>% reduction with respect to Maximum PTR</th>
<th>No. of drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>0&lt;= 5%</td>
<td>52</td>
</tr>
<tr>
<td>2.</td>
<td>5&lt;=10%</td>
<td>45</td>
</tr>
<tr>
<td>3.</td>
<td>10&lt;=15%</td>
<td>56</td>
</tr>
<tr>
<td>4.</td>
<td>15&lt;=20%</td>
<td>44</td>
</tr>
<tr>
<td>5.</td>
<td>20&lt;=25%</td>
<td>66</td>
</tr>
<tr>
<td>6.</td>
<td>25&lt;=30%</td>
<td>55</td>
</tr>
<tr>
<td>7.</td>
<td>30&lt;=35%</td>
<td>30</td>
</tr>
<tr>
<td>8.</td>
<td>35&lt;=40%</td>
<td>34</td>
</tr>
<tr>
<td>9.</td>
<td>Above 40%</td>
<td>127</td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td>509</td>
</tr>
</tbody>
</table>

The prices are notified through Gazette Notifications which are also uploaded on NPPA’s website at www.nppaindia.nic.in.

NPPA has also notified 139 retail price of new drugs on request of the manufacturers till 31st December, 2014.

As per the provisions of DPCO, 2013, no person shall sell the scheduled formulations at prices higher than the ceiling price (plus
local taxes as and wherever applicable) so fixed and notified by the Government.

**Monitoring and Enforcement:**

The prices of medicines which are not covered in the Schedule - I of DPCO, 2013 are also monitored by NPPA. As provided in the DPCO, 2013, no manufacturer shall increase the maximum retail price of a non-scheduled drug more than ten percent of maximum retail price during preceding twelve months. Wherever the increase is beyond ten percent of maximum retail price, NPPA is empowered to reduce price to the level of ten percent of maximum retail price for next twelve months. The manufacturer shall be liable to deposit the Overcharged amount, if any, along with interest thereon from the date of increase in price in addition to the penalty. However, there is no control on the launch price of non-scheduled medicines. Concerned manufacturer of such medicines fix the launch price themselves.

NPPA is also empowered, in case of extra-ordinary circumstances, if it considers necessary so to do in public interest, to fix the ceiling price or retail price of any Drug for such period, as it may deem fit and where the ceiling price or retail price of the drug is already fixed and notified, the NPPA may allow an increase or decrease in the ceiling price or the retail price, as the case may be, irrespective of annual wholesale price index for that year. Accordingly, NPPA has fixed prices of 108 non-scheduled anti-diabetic and cardiovascular medicines under paragraph 19 of Drug Price Control Order, 2013 on 10.7.2014 based on the internal guideline issued by the NPPA on 29.05.2014. Although the said internal guideline of the NPPA has been withdrawn with effect from 22.09.2014 but the concerned notification for price fixation of the said non-scheduled medicines continue to be in force.

A separate Enforcement Division was created during the year 2007-08 to facilitate suo-moto detection of violations of DPCO, 1995 with the following objectives:

(i) Market Surveillance of prices of scheduled drugs;

- Purchase of samples by NPPA officers all over India to ensure compliance; and
- Examine complaints by individuals / NGOs/VIP references.

(ii) Based on the analysis, specific cases are identified for

- Recovery of overcharged amounts; and
- Fixation of prices, wherever required.

NPPA is also entrusted with the job of monitoring the availability of drugs and to identify shortages, if any, and to take remedial steps to make the drugs available. NPPA is carrying out this responsibility mainly through the State Drugs Controllers and other available information. As and when the reports for shortages of particular drug(s), in any part of the country are received, the concerned company is asked to rush the stock and to make the drugs available.

The achievements from 2007-08 to 2014-15 (upto Dec., 2014) are given as under:

<table>
<thead>
<tr>
<th>Year</th>
<th>No. of Samples Collected</th>
<th>Prima Facie Violations detected</th>
<th>Referred for Overcharging</th>
<th>Identified for Price fixation Para 8(6) violation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007-2008</td>
<td>1450</td>
<td>840</td>
<td>456</td>
<td>384</td>
</tr>
<tr>
<td>2008-2009</td>
<td>520</td>
<td>284</td>
<td>172</td>
<td>112</td>
</tr>
<tr>
<td>2009-2010</td>
<td>464</td>
<td>246</td>
<td>208</td>
<td>38</td>
</tr>
<tr>
<td>2010-2011</td>
<td>553</td>
<td>225</td>
<td>216</td>
<td>9</td>
</tr>
<tr>
<td>2011-2012</td>
<td>559</td>
<td>156</td>
<td>152</td>
<td>4</td>
</tr>
<tr>
<td>2012-2013</td>
<td>626</td>
<td>165</td>
<td>163</td>
<td>2</td>
</tr>
<tr>
<td>2013-2014</td>
<td>993</td>
<td>389</td>
<td>389</td>
<td>0</td>
</tr>
<tr>
<td>2014-2015 *</td>
<td>993</td>
<td>290</td>
<td>290</td>
<td>0</td>
</tr>
</tbody>
</table>

*125 cases under process on 05.01.2015
Recovery of Overcharged amount:

Since inception of NPPA, there are 1108 cases as on 31.12.2014 (1079 cases under DPCO 1995 & 29 cases under DPCO 2013) where demand notices have been issued by NPPA to Pharmaceutical companies amounting to Rs.4030.22 crore (Rs.3897.77 crore under DPCO 1995 & Rs.132.45 crore under DPCO 2013) for selling their medicines at prices higher than the price fixed by NPPA / Govt. of which Rs.344.75 crore (Rs.290.17 crore under DPCO 1995 & Rs.54.58 crore under DPCO 2013) has been recovered till 31.12.2014 leaving a balance of Rs.3685.47 crore (Rs.3607.60 crore under DPCO 1995 & Rs.77.87 crore under DPCO 2013). Out of the balance amount of Rs.3685.47 crore, Rs.3469.20 crore (Rs.3467.01 crore including cases in r/o M/s Cipla Ltd. & its associate companies wherein no coercive action can be taken in pursuance of the order of Supreme Court of India under DPCO 1995 & Rs.2.20 crore under DPCO 2013) is pending in various High Courts & Supreme Court, Rs.50.59 crore is pending for recovery with Collectors of various States under DPCO 1995, Rs.5.05 crore is pending with BIFR / Official liquidators under DPCO 1995 & Rs.160.63 crore (Rs.84.95 crore under DPCO 1995 & Rs.75.68 crore under DPCO 2013) is under process.

Action for recovery of the overcharged amount alongwith interest thereon is a continuous process and NPPA takes action as per the provisions of DPCO’1995/ DPCO’2013 read with EC Act 1955. The recovery of the overcharged amount is affected due to Court orders passed by the various High Courts and also by Supreme Court in cases filed by the pharmaceutical companies challenging the price fixation order / notification issued by NPPA / Government under DPCO 1995. Inclusion of some Bulk Drugs under Price Control (schedule-I of DPCO, 1995) has also been challenged by the pharma companies in different courts of India. NPPA / Government is defending such cases through SG, ASG’s and Senior Government Counsels. Whenever necessary, NPPA files urgent application in the Courts for vacation of interim orders and also for early Hearing / disposal of the case.


(Amount in Rs. crore)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>No. of cases</td>
<td>334</td>
<td>67</td>
<td>116</td>
<td>134</td>
<td>88</td>
<td>42</td>
<td>40</td>
<td>103</td>
<td>88</td>
<td>2</td>
<td>67</td>
</tr>
<tr>
<td>2.</td>
<td>Overcharged amount demanded including interest whenever updated</td>
<td>1883.38</td>
<td>48.4</td>
<td>366.57</td>
<td>337.71</td>
<td>69.99</td>
<td>106.84</td>
<td>58.57</td>
<td>128.76</td>
<td>383.22</td>
<td>0.00</td>
<td>514.33</td>
</tr>
<tr>
<td>3.</td>
<td>Total amount realised till date against the demand raised during the year</td>
<td>141</td>
<td>0.8</td>
<td>17.76</td>
<td>31.74</td>
<td>23.24</td>
<td>20.27</td>
<td>8.82</td>
<td>9.46</td>
<td>34.69</td>
<td>0.02</td>
<td>2.39</td>
</tr>
<tr>
<td>4.</td>
<td>Amount outstanding</td>
<td>1742.38</td>
<td>47.60</td>
<td>348.81</td>
<td>305.97</td>
<td>46.75</td>
<td>86.57</td>
<td>49.75</td>
<td>119.30</td>
<td>348.53</td>
<td>-0.02</td>
<td>511.94</td>
</tr>
<tr>
<td>5.</td>
<td>Amount still under litigation including cases referred to collector and contested by the companies in the court of law</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>3467.01</td>
</tr>
<tr>
<td>6.</td>
<td>Cases referred to collector &amp; amount still to be recovered</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>50.69</td>
</tr>
<tr>
<td>7.</td>
<td>Pending with BIFR/ Official Liquidator</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>5.05</td>
</tr>
<tr>
<td>8.</td>
<td>Amount pending relating to the overcharging cases under process</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>--</td>
<td>84.95</td>
</tr>
</tbody>
</table>
**Achievements for the Period June, 2014 to December, 2014 in Respect of NPPA**

**Pricing**

Since May, 2014, prices of 69 more scheduled drugs have been notified bringing the total number of scheduled drugs where prices have been notified to 509. A statement showing reduction in price of formulations with respect to Highest PTR of NLEM formulations (From May to December, 2014) as a result of pricing exercise of NPPA for these 69 scheduled drugs is given below:

<table>
<thead>
<tr>
<th>S. No.</th>
<th>% reduction with respect to Maximum PTR</th>
<th>Formulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>0&lt;=5%</td>
<td>14</td>
</tr>
<tr>
<td>2.</td>
<td>5&lt;=10%</td>
<td>4</td>
</tr>
<tr>
<td>3.</td>
<td>10&lt;=15%</td>
<td>9</td>
</tr>
<tr>
<td>4.</td>
<td>15&lt;=20%</td>
<td>4</td>
</tr>
<tr>
<td>5.</td>
<td>20&lt;=25%</td>
<td>5</td>
</tr>
<tr>
<td>6.</td>
<td>25&lt;=30%</td>
<td>11</td>
</tr>
<tr>
<td>7.</td>
<td>30&lt;=35%</td>
<td>5</td>
</tr>
<tr>
<td>8.</td>
<td>35&lt;=40%</td>
<td>0</td>
</tr>
<tr>
<td>9.</td>
<td>Above 40%</td>
<td>17</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>69</td>
</tr>
</tbody>
</table>

In addition to above, NPPA has fixed the prices of 106 non-scheduled formulations on 10.9.2014 under Para 19 of DPCO, 2013. Out of 106 non-scheduled formulations, 22 are of diabetic formulations and remaining 84 are cardio-vascular formulations. The price benefit likely to accrue to the common man is estimated to be close to Rs. 350 crores per annum.

Since May 2014, NPPA has notified prices of 251 formulations (i.e., 69 Ceiling Prices, 76 Retail Prices and 106 prices of Non-Scheduled formulations) under DPCO 2013 which has resulted into an estimated benefit of Rs. 558 crore to the end consumers. These formulations/drugs are used in cancer, diabetes, HIV, AIDS, heart diseases, etc.

**New Drugs**

Since May 2014 NPPA has also notified retail price of 76 new drug formulations on request of the manufacturers/marketing companies as per DPCO 2013.

**Monitoring**

From June, 2014 to December, 2014, 592 cases of overcharging were identified. They are being processed further for recovering the overcharged amount from the pharma companies.

**Overcharging**

NPPA has issued 76 demand notices for Rs.431.90 crore (Rs.352.99 crore under DPCO 1995 & Rs.78.91 crore under DPCO 2013) consisting of overcharged amount alongwith interest thereon from 01.06.2014 to 31.12.2014. During the said period, NPPA has received 78 demand drafts for an amount of Rs.12.38 crore (Rs.5.68 crore under DPCO 1995 & Rs.6.70 crore under DPCO 2013) from the Pharmaceuticals companies against the demand raised in the past and the aforesaid period.

**Consultation with Stakeholders**

NPPA conducted detailed consultations with stakeholders including civil society organizations, public health experts, State Drug Controllers and representatives of Pharma industry & trade.

**4.2 Drug Price Equalization Account (DPEA)**

Drug Prices Equalisation Account (DPEA) has been maintained by Government under the provisions of Drugs (Prices Control) Order, 1979. Under the Drugs (Prices Control) order, 1979 (DPCO, 1979), there were 345 bulk drugs under price control. The Department computed tentative liabilities in respect of 47 bulk drugs only on suo-motu basis covering 172 cases till the Interim stay dated 30.6.1997 was granted by the Hon’ble Bombay High court in the Writ petition No. 2368/1996 filed by the Indian Drugs Manufacturer’s Association (IDMA) and Organisation of pharmaceutical producers of India (OPPI) restraining the Department and its committees etc., from issuing fresh notices to the drug companies calling for information required for determining liabilities. Out of these 172 cases where the liabilities have already been determined tentatively and communicated to the companies, only 72 such cases during the period 1994-97 could be referred to the Drugs Prices Liabilities Review Committee (DPLRC) constituted on 21.3.1994 under the Chairmanship of a judge of Hon’ble Delhi High Court retired in October, 1994) alongwith two Members to review/ determine the liability in such cases. Out of these 72 cases, the Committee after deliberation in each case and giving adequate opportunity of Hearing to the drug companies to present their point of view gave reports in 47 cases. In view of the stay granted by the Hon’ble Bombay High Court the Committee had not taken up the other 25 cases and also any fresh case. On the basis of the recommendations of the DPLRC, Department issued demand notices in 45 cases (no liability in one cases and one case linked with another case). Most of these companies filed Writ petition in the different High Courts against the demand notices. The total amount of liability on the basis of the recommendations of the DPLRC is to the tune of Rs. 228.47 crore (aprx). Total amount in DPEA as on 31.12.2014 is Rs. 299.50 crores (Approximately).

Since, no new cases could be taken up by DPLRC for determination of the DPEA liability because of the stay granted by the Hon’ble Bombay High Court, there was no work with the DPLRC. Hence a conscious decision was taken by the Government to keep the DPLRC under suspended animation w.e.f. 31 December, 2005 vide Resolution dated 16th December, 2005. At that time 25 cases were pending with the DPLRC because of stay, where no quantification could be done. In addition to these 25 cases, there may be a large number of DPEA liability cases in respect of 298 bulk drugs where information from the companies concerned is to be gathered for determination of the DPEA liability. The aforesaid W. P. No. 2368/1996 has since been dismissed by Hon’ble High Court vide its judgement dated 22.12.2011.
Chapter 5

PUBLIC SECTOR UNDERTAKINGS
5.1 Central Public Sector Undertakings
5.2 Status of Annual Accounts
5.3 The Jan Aushadhi Scheme
CHAPTER - 5
PUBLIC SECTOR UNDERTAKINGS

5.1 CENTRAL PUBLIC SECTOR UNDERTAKINGS

There are five Central Public Sector Enterprises (CPSEs) under the administrative control of this Department of Pharmaceuticals. Of the five, three viz. Indian Drug & Pharmaceuticals Limited (IDPL), Hindustan Antibiotic Limited (HAL) & Bengal Chemicals & Pharmaceuticals Limited (BCPL) are sick and are referred to Board for Industrial & Financial Reconstruction (BIFR) while the Rajasthan Drugs & Pharmaceuticals Limited (RDPL) reported losses for the first time during the last year 2013-14. Karnataka Antibiotic & Pharmaceuticals Limited (KAPL) is the only profit making CPSE.

Production & Sales of 5 CPSEs during the last 3 years is as under:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>KAPL</td>
<td>25100.00</td>
<td>22310.00</td>
<td>24739.00</td>
<td>21421.00</td>
<td>27573.00</td>
<td>24159.00</td>
<td>20549.00</td>
<td>18390.00</td>
</tr>
<tr>
<td>RDPL</td>
<td>8225.85</td>
<td>8271.89</td>
<td>8622.03</td>
<td>8567.27</td>
<td>5493.36</td>
<td>4350.55</td>
<td>1218.00</td>
<td>1251.00</td>
</tr>
<tr>
<td>HAL</td>
<td>4873.00</td>
<td>5209.00</td>
<td>2766.00</td>
<td>3011.00</td>
<td>793.00</td>
<td>805.00</td>
<td>1218.00</td>
<td>1251.00</td>
</tr>
<tr>
<td>BCPL</td>
<td>517.00</td>
<td>4825.00</td>
<td>3632.00</td>
<td>2737.00</td>
<td>197.00</td>
<td>1687.00</td>
<td>4679.00</td>
<td>3190.00</td>
</tr>
<tr>
<td>IDPL</td>
<td>5078.00</td>
<td>5069.00</td>
<td>5871.00</td>
<td>5947.00</td>
<td>6283.00</td>
<td>6018.00</td>
<td>5299.00</td>
<td>4600.00</td>
</tr>
</tbody>
</table>

Initiatives taken to improve the performance of CPSEs during 2014-15 are as follows:

2. IDBI – Operating Agency submitted Modified Draft Rehabilitation Scheme (MDRS) for HAL and IDPL
3. Exploring Pharma Park Development at –
   a. IDPL Hyderabad.
   b. IDPL Rishikesh
   c. IDPL Chennai
4. Revival of RDPL –
   a. Raw material arrangement in collaboration with KAPL
   b. WHO-GMP
   c. Pursuing with Government of Rajasthan for preferential policy towards RDPL in drugs procurement.
5. BCPL - Completion of Betalactam & Cephalosporin Blocks.

I) KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED (KAPL)

BACKGROUND

KAPL is a profit making joint sector Company incorporated in the year 1981 [with 59% shares by Government of India and 41% shares by Government of Karnataka through KSIIDC]. The basic objective of the company was to make available life saving drugs of good quality to Karnataka Government hospitals and other institutions. The Company has been manufacturing facilities for Dry Powder Injectables, Tablets, Capsules, Dry Syrups and Suspensions. The paid – up share capital of the company as on date is Rs. 13.49 crores.

PAST ACHIEVEMENTS:

- Mini Ratna CPSE
- ISO 9001 (qms) AND iso 14001 (EMS)

PLANT MACHINERY AND CAPACITY

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Particulars</th>
<th>2011-12</th>
<th>2012-13</th>
<th>2013-14</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Liquid Parenterals</td>
<td>146</td>
<td>172</td>
<td>140</td>
</tr>
<tr>
<td>2.</td>
<td>Vials</td>
<td>95</td>
<td>81</td>
<td>82</td>
</tr>
<tr>
<td>3.</td>
<td>Tablets</td>
<td>203</td>
<td>212</td>
<td>127</td>
</tr>
<tr>
<td>4.</td>
<td>Capsules</td>
<td>182</td>
<td>150</td>
<td>148</td>
</tr>
</tbody>
</table>
PRODUCT PROFILE AND RANGE:

**PHARMA - TRADE**

<table>
<thead>
<tr>
<th>VOLUME BRANDS [HIGH]</th>
<th>REGULAR BRANDS [LOW]</th>
<th>CARDIO – DIABETIC BRANDS</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRENIL [ANTIMIGRAINE]</td>
<td>KAMADOL-P / INJ [ANALGESIC]</td>
<td>KAPRIL [CARDIAC]</td>
</tr>
<tr>
<td>GRENIL-+ [ANTIMIGRAINE]</td>
<td>VERIXIME [ANTIBIOTIC]</td>
<td>KAPRIL – H [CARDIAC]</td>
</tr>
<tr>
<td>CYFOLAC FORTE (SYMBIOTIC)</td>
<td>VITATROL PLUS [ANTIARTHRITIC]</td>
<td>LOTACE [CARDIAC]</td>
</tr>
<tr>
<td>CYFOLAC [PROBIOTIC]</td>
<td>VITALPHA – C [ANTIARTHRITIC]</td>
<td>LOTACE – 50H [CARDIAC]</td>
</tr>
<tr>
<td>REMCC XP (EXPECTORANT)</td>
<td>MAXIFLAM-SP [ANALGESIC]</td>
<td>CIDOGREL – A [CARDIAC]</td>
</tr>
<tr>
<td>REMCCCLM [ANTIALLERGIC]</td>
<td>HUSKY [BOWEL REGULATOR]</td>
<td>GLIMKAP [ANTI-DIABETIC]</td>
</tr>
<tr>
<td>ZINFE XT / SYP (HAEMATINIC)</td>
<td>FUBAC [SKIN CREAM]</td>
<td>GLIMKAP – M [ANTI-DIABETIC]</td>
</tr>
<tr>
<td>VERCLAV [ANTIBIOTIC]</td>
<td>CETRIAX [ANTIBIOTIC]</td>
<td>PIOKAP [ANTI DIABETIC]</td>
</tr>
<tr>
<td>NUMOL MR [MUSCLE RELAXANT]</td>
<td>PIPMAX [ANTIBIOTIC]</td>
<td>APIFEAST [HERBAL APPETISER]</td>
</tr>
</tbody>
</table>

**POPULAR BRANDS:**

**PHARMA - TRADE**

<table>
<thead>
<tr>
<th>No</th>
<th>Products</th>
<th>Therapy Segments</th>
<th>NLEM</th>
<th>Monopoly</th>
<th>Market Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Grenil Group</td>
<td>Anti-migraine</td>
<td>NO</td>
<td>NO</td>
<td>Rs. 12.00 Crores</td>
</tr>
<tr>
<td>2.</td>
<td>Cyfolac Forte Group</td>
<td>Pre &amp; Probiotics</td>
<td>NO</td>
<td>NO</td>
<td>Rs. 4.00 Crores</td>
</tr>
<tr>
<td>3.</td>
<td>Remcc Group</td>
<td>Cough &amp; Cold</td>
<td>NO</td>
<td>NO</td>
<td>Rs. 3.00 Crores</td>
</tr>
<tr>
<td>4.</td>
<td>Zinfe Group</td>
<td>Haematinic</td>
<td>NO</td>
<td>NO</td>
<td>Rs. 2.00 Crores</td>
</tr>
<tr>
<td>5.</td>
<td>Verclav Group</td>
<td>Antimicrobial</td>
<td>YES</td>
<td>NO</td>
<td>Rs. 4.00 Crores</td>
</tr>
</tbody>
</table>

**MANPOWER AS ON 31.03.2014**

<table>
<thead>
<tr>
<th>EXECUTIVES</th>
<th>NON-EXECUTIVES</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>240</td>
<td>498</td>
<td>738</td>
</tr>
</tbody>
</table>

**DISTRIBUTION NET WORK:**

**Pharma**

The Company has been expanding its operations in Retail Trade Sector with a planned effort so as to cater to the needs of the Private Medical Practitioners. In this direction the Company has been periodically launching New Products in the various Therapeutic Segments. The Domestic operations spans throughout the country manned by a highly dedicated Professional Field Force and backed by a well knit Channel of Distribution ensuring KAPL's presence at the Metro as well as Micro Markets.

KAPL has its Branches located in all the State Head Quarters. The Company also has an excellent Distribution Network at almost 19 Branches at Major Cities catering to the respective State areas through Channel Marketing. The supplies are made effective through approved Stockists to Retailers, Nursing Homes & Dispensing Doctors in the Trade Segment and directly to Institutions in Rate Contract [RC] & Non-Rate Contract [NRC] Sectors.

**Marketing: Share of Institutions and retail:**

**PHARMA:**

The Company has been mainly focusing on Prescription Market as Medical Professional as our Customers, where many of the MNCs and Private Pharma Players have a major share. The Company is also dependant on PPP Policy for Institutional Business, where our concentration is on Govt. Hospitals, State Govt. Hospitals, Corporates, PSU Hospitals, Defence & Insurance. Has potential to expand in Trade Segment & also to increase volumes by focusing on CPSE Hospitals and large Corporate Hospitals. Also need to look at increase in Product Mix and Injectable Range. Another opportunity for expansion is in Ayurvedic Range, where Ayurveda, a holistic & complete treatment was invented by India.

**AGROVET:**

Agro dealers and Department of Agriculture / Horticulture for Agro products.

Veterinary Practitioners, Farmers.
NEW PRODUCTS:

PHARMA

<table>
<thead>
<tr>
<th>No</th>
<th>Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Numol MR Tablets</td>
</tr>
<tr>
<td>2.</td>
<td>Remcc LM Tablets</td>
</tr>
<tr>
<td>3.</td>
<td>Toprazol D Capsules</td>
</tr>
<tr>
<td>4.</td>
<td>Zinfe Syrup</td>
</tr>
<tr>
<td>5.</td>
<td>Apifeast Syrup</td>
</tr>
</tbody>
</table>

FUTURE PLANS:

Presently Cephalosporin Project is under progress. Likely to be completed by end of Financial year.

Targets for 2015-16.

Rs. 265 crores net of Excise is proposed under MOU.

II RAJASTHAN DRUGS & PHARMACEUTICALS LIMITED (RDPL)

Background:

a. Joint Venture of: Govt. of India (51 %) & RIICO Ltd. (Govt. of Raj. Entps.) (49 %)
b. Authorised Capital: Rs.1000 Lacs (With paid up capital: Rs. 498.61 Lacs)
c. Manufacturing facilities & registered office at Road no. 12, VKI Industrial Area, Jaipur (Rajasthan).
d. Incorporated on 2nd November , 1978
e. Commencement of Business on 05th July, 1979
f. Production Started in Year March, 1981.
g. Share Transfer from IDPL to President of India : 17th August, 2010
h. The company is engaged in manufacture and selling of medicines of high quality at reasonable rates to the Govt. of Rajasthan, Central Government Institutions, viz ESIC, Defence, Railways, other PSUs and also to other State Govt. Institutions with its marketing activities spread throughout the country.
i. RDPL is proud to be a prime partner in the novel and noble endeavor of Govt. of India in the implementation of ‘JANAUSHADHI’ programme where quality generic medicines (unbranded) are made available to the public at large in the country at affordable prices.
j. The company is further diversifying its activities into Pharma Prescription Markets (Open Trade Sales), Veterinary Markets, Marketing of Ayurvedic and other Indian system of medicines in order to enhance its market share and also in its endeavour to achieve profitability for the organization.
Past Achievements:

RDPL is serving the nation from last 36 years (approximate) in the field of providing quality medicines at affordable price with the motto “Health for All”. RDPL supplied medicines in the Jan Aushadhi Scheme (A novel scheme by Department of Pharmaceuticals, Ministry of Chemical & Fertilizers, GoI), Free distribution scheme (Like for Govt. of Rajasthan), NRHM, NVBDS, Antimalarial programmes etc. We always emerged as contingent medicine provider to Governments and institutions, for example we supplied medicines to in case of Surat (Gujrat) plague epidemic, Latur (Maharastra) & Bhuj (Gujrat) earthquakes and now we are supplying medicine for Swine flu to various states.

Sickness and Revival, if any:

Currently no sickness, but reported loss first time during 2013-14.

Plant Machinery and Capacity recognition:

k. RDPL is a formulation unit engaged in production of dosage forms Tablets, Capsules (Beta-Lactums & Non Beta-Lactums), Liquid - Orals & Externals, ORS Powder & Ophthalmic medicines in a Schedule ‘M’ compliant facility.

l. The company, under the quality management, has a well-equipped laboratory with modern equipments.

Capacity utilization of RDPL was as follows:

<table>
<thead>
<tr>
<th>Product Group</th>
<th>Unit</th>
<th>Installed</th>
<th>Capacity Utilization (In Units &amp; % of installed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablets</td>
<td>Millions / 2 Shift</td>
<td>720.00</td>
<td>630.76</td>
</tr>
<tr>
<td></td>
<td></td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Capsule</td>
<td>Millions / Shift</td>
<td>144.00</td>
<td>129.61</td>
</tr>
<tr>
<td>Liquids</td>
<td>K L / Shift</td>
<td>300.00</td>
<td>336.39</td>
</tr>
<tr>
<td>Powder</td>
<td>M Ton/ Shift</td>
<td>226.80</td>
<td>181.47</td>
</tr>
<tr>
<td>Eye Drops</td>
<td>Vials Lac / Shift</td>
<td>14.40</td>
<td>3.90</td>
</tr>
</tbody>
</table>

* Sometimes section run on double shift basis because of additional orders.

Modernisation of Plants (Government assistance projects and status):

<table>
<thead>
<tr>
<th>Year</th>
<th>Project</th>
<th>Scheme</th>
<th>Funds Released</th>
<th>Status of Project</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013-14</td>
<td>Expansion, Modernisation, Schedule – M &amp; WHO-cGMP project</td>
<td>Project based support is given by the Dept. of Pharm., Ministry of Chem. &amp; Ferti., GoI</td>
<td>Rs. 455.00 Lacs received as first installment out of total sanctioned Rs.1139.00 lacs.</td>
<td>Project is under progress.</td>
</tr>
</tbody>
</table>

Product Profile and Range:

The Company has been manufacturing and marketing total 190 products in following therapeutic category range:

- Anti-Infectives, Anti-Malarial, NSAIDS, Antacids, Analgesic, Anti-Pyretics & Anti-Inflammatory, Anti-Emetics, Anti-Spasmodics, Anti-Diarrhoeal / Anti-Amoebic, Anti-Allergic, Anti-Bacterial, Anti-Fungal,
- Cough ExpectorantsVitamins & Minerals
- Ophthalmic Preparations
- Oral Rehydration Salt (ORS).

Popular Brands:

Currently RDPL is not in ethical i.e. trade business so do not have any popular brands but RDPL shall start this in financial year 2015 – 16. Premium products by sale value in year 2013-14 was as under:

- Ciprofloxacin Tablets : 30.83 %
- Azithromycin Tablets : 30.81 %
- Omeprazole Capsules : 11.39 %
- Oral Rehydration Salts: 7.07 %
- Amoxycillin Capsules : 6.03 %

RDPL do not have any monopoly or established brand since RDPL currently do not have trade sales.

Manpower:

No. of manpower employed as on 31.03.2014 are as under:

Managers : 40
Officers & Supervisors : 40
Workers & Staff : 207
Total : 287

Distribution Network, if any:

Distribution network for medicines can be depicted as under:
**Performance:**

**Production / Turnover and Profit / Loss:**

<table>
<thead>
<tr>
<th>Years</th>
<th>Total Production* (Own + Loan Licence)</th>
<th>Gross Turnover</th>
<th>Profit Before Tax (PBT)</th>
<th>Profit After Tax (PAT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009-10</td>
<td>7612.76</td>
<td>8535.46</td>
<td>118.52</td>
<td>99.15</td>
</tr>
<tr>
<td>2010-11</td>
<td>8379.71</td>
<td>8067.37</td>
<td>150.07</td>
<td>119.86</td>
</tr>
<tr>
<td>2011-12</td>
<td>8225.85</td>
<td>8271.89</td>
<td>174.59</td>
<td>144.77</td>
</tr>
<tr>
<td>2012-13</td>
<td>8622.03</td>
<td>8567.27</td>
<td>77.49</td>
<td>79.87</td>
</tr>
<tr>
<td>2013-14</td>
<td>5493.36</td>
<td>4350.55</td>
<td>(-1943.52)</td>
<td>(-1939.73)</td>
</tr>
</tbody>
</table>

**Marketing: Share of institutions and retail:**

% Share of distribution of total sale was as under for the year 2013-14-

**MARKETING SCENARIO**

**% OF TOTAL SALES : DISTRIBUTION (2013-14)**

- Govt. of Rajasthan: 16.92%
- Ayush: 34.05%
- Institutional Sales (ESIC, DEFENCE, NRHM etc.): 46.73%
- Trade/Jan Aushadhi & Other: 2.30%

New products:

In year (2013-14), RDPL added two new products:

- Amlodipine & Atenolol Tablets
- Losartan Potassium Tablets

Future projects:

a. RDPL is going to diversify its business in Ayurveda and Veterinary segment. In Ayurveda RDPL has good exposure of marketing and achieved a sale of Rs. 8.50 crore (Approximate) by product manufactured on loan licence basis. Now RDPL is planning to set up in house manufacturing facility for manufacturing facility in RDPL premises for Tablets & Powder dosage forms in year 2015-16 with support of Dept. of Pharmaceuticals. Similarly RDPL wants to set up a facility to manufacture the Veterinary Products in RDPL premises in year 2015-16 with support of Dept. of Pharmaceuticals.

b. To complete the ongoing Expansion, Modernisaton, Schedule – M and WHO-cGMP project.

**Targets for Year 2015-16:**

The targets for year 2015 – 16 shall be as follows-

a. As per MOU of RDPL submitted to DPE Sales Projection Estimates for year 2015- 16 shall be Rs. 55 Crore.

b. To achieve ISO 9001-2008 certification.

c. To set up inhouse facility for manufacturing of Ayurveda Tablets & Powder dosage forms.

d. To start Agrovet marketing division.

e. To start manufacturing of Veterinary and Feed supplements.
Background and Past achievements

Hindustan Antibiotics Ltd (HAL) is wholly owned Government company engaged in the Manufacturing & Marketing of Life Saving Drugs. HAL was established in 1954 with WHO / UNICEF assistance. HAL is the first Company to Manufacture the Antibiotics like Bulk drugs Penicillin, Streptomycin and Gentamycin.

HAL has rare distinction of inventing two new molecules viz. Hamycin and Aureofungin

HAL has been instrumental in ensuring the availability of life saving drugs at affordable prices in the Country.

Sickness and Revival

HAL was referred to BIFR in 1997. Rehabilitation Scheme was approved by BIFR on 5th June 2007 after series of hearings.

As the Rehabilitation Scheme was not fully implemented, IFCI Ltd. was engaged in 2011 to evaluate the performance in implementation of sanctioned scheme, identifying reasons to achieve performance, suggest business plan for the company with future corporate strategy to make HAL's operation viable. HAL has prepared Business Plan based on recommendations of IFCI with following features:-

- Focus only on formulation business.
- Drastic cost cutting measures including VRS
- New utility set-up for Formulation

Second Rehabilitation package

HAL had prepared Rehabilitation Scheme as directed and submitted to Ministry in June’12. This scheme has undergone changes many times and company has submitted revised scheme in Jan.’15 covering liabilities upto March.’14 This scheme is under consideration Features of the scheme are as under:-

i. Liabilities were covered upto March.’14.
ii. VRS for 500 persons
iii. Capital investment of Rs. 111.50 crores
iv. Outsourcing of the non-core area
v. Cost of scheme was as follows:-

### Cost of Scheme

<table>
<thead>
<tr>
<th>S. No</th>
<th>Particulars</th>
<th>Estimated Cost (Rs. Crores)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Capital Expenditure</td>
<td>111.50</td>
</tr>
<tr>
<td>2.</td>
<td>VRS cost – 500 employees</td>
<td>104.95</td>
</tr>
<tr>
<td>3.</td>
<td>Employee related dues</td>
<td>100.04</td>
</tr>
<tr>
<td>4.</td>
<td>Statutory dues</td>
<td>73.38</td>
</tr>
<tr>
<td>5.</td>
<td>Working capital requirement</td>
<td>44.00</td>
</tr>
<tr>
<td>6.</td>
<td>Bank loan</td>
<td>178.14</td>
</tr>
<tr>
<td>7.</td>
<td>ONGC loan</td>
<td>17.05</td>
</tr>
<tr>
<td>8.</td>
<td>Other Pressing Creditors</td>
<td>13.22</td>
</tr>
<tr>
<td>9.</td>
<td>Provision of contingencies</td>
<td>28.18</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>670.46</td>
</tr>
</tbody>
</table>

### Means of Finance

<table>
<thead>
<tr>
<th>S. No</th>
<th>Particulars</th>
<th>Estimated Cost (Rs. Crores)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Sale proceeds from the vacant land</td>
<td>670.46</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>670.46</td>
</tr>
</tbody>
</table>

### Plant Machinery and Capacity

HAL's product category has following installed capacities:

<table>
<thead>
<tr>
<th>S. No</th>
<th>Product Category</th>
<th>Unit</th>
<th>Installed Capacity (Annual)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Cephalosporin Powder Injectables</td>
<td>Lac Nos.</td>
<td>450</td>
</tr>
<tr>
<td>2.</td>
<td>Penicillin Powder Injectables</td>
<td>Lac Nos.</td>
<td>450</td>
</tr>
<tr>
<td>3.</td>
<td>Penicillin &amp; Non-Penicillin Tablets</td>
<td>Lac Nos.</td>
<td>2400</td>
</tr>
<tr>
<td>4.</td>
<td>Capsules (Penicillin)</td>
<td>Lac Nos.</td>
<td>2400</td>
</tr>
<tr>
<td>5.</td>
<td>IV Fluid</td>
<td>Lac Nos.</td>
<td>120</td>
</tr>
<tr>
<td>6.</td>
<td>Agro Chem</td>
<td>Lac Nos.</td>
<td>72</td>
</tr>
</tbody>
</table>
### Modernization of the plants (Govt. assistance projects and status)

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Projects</th>
<th>Scheme</th>
<th>Funds released (Rs. Crores)</th>
<th>Status of the project</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Upgradation of existing IV Fluid plant to WHO-GMP</td>
<td>Plan Funds for Project</td>
<td>6.28</td>
<td>Project under implementation</td>
</tr>
<tr>
<td>2.</td>
<td>Agro-vet upgradation &amp; expansion</td>
<td>Plan Funds for Project</td>
<td>6.00</td>
<td>Project under implementation</td>
</tr>
<tr>
<td>3.</td>
<td>Utility set-up for formulation</td>
<td>Plan Funds for Project</td>
<td>8.41</td>
<td>Project under implementation</td>
</tr>
<tr>
<td>4.</td>
<td>ERP System</td>
<td></td>
<td>Provision of Funds in the Rehabilitation</td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Expanding the capacity of Large Volume Parenteral</td>
<td></td>
<td>---do---</td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>Upgradation of Non-parenteral plant</td>
<td></td>
<td>---do---</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Provision for replacement &amp; renewals of old machineries &amp; facilities</td>
<td></td>
<td>---do---</td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Provision for new products know-how &amp; technology</td>
<td></td>
<td>---do---</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td><strong>20.69</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Product Profile and Range

#### MAJOR PRODUCTS

- **a)** Cephalosporin Power Injectable Products
  - i) Cefotaxime Sodium, ii) Ceftriaxone, iii) Cefaparazone & iv) Ceftazidime
- **b)** Betalactum Injectables
  - i) Benzyl Penicillin, ii) Meropenem & iii) Sodium Ampicillin
- **c)** Non-Parenteral Tablets
  - i) Ciprofloxacin, ii) Norfloxacin, iii) Lecofloxacin & iv) Erythromycin
- **d)** Penicillin Tablets
  - i) Penicillin V. Tabs, ii) Ampicillin Tabs & iii) Cefixime Tabs
- **e)** Penicillin Capsules
  - i) Ampicillin, ii) Amoxycillin & iii)cephalexin
- **f)** Large Volume Parenteral – IV Fluids
- **g)** Agro Products
  - i) Streptocycline, ii) Aureofungin, iii) Azotomeal, iv) Phosphomeal & v) Humaur

#### Manpower

Present manpower strength is 1058

### Distribution network if any

HAL has its own Marketing network with C&F agents throughout the country.

#### Performance (Rs. in Crores)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Production</td>
<td>14.88</td>
</tr>
<tr>
<td>2.</td>
<td>Sales Turnover</td>
<td>13.92</td>
</tr>
<tr>
<td>3.</td>
<td>Net profit / loss</td>
<td>(-) 75.35</td>
</tr>
<tr>
<td>4.</td>
<td>DPE rating</td>
<td>Poor for year 2013-14</td>
</tr>
<tr>
<td>5.</td>
<td>Marketing share</td>
<td>100% pharma products sale is to Govt. institutions and in Agro sector 100% sale is in trade. Share of Institutional sale for the year 2014-15 is 48.48% and trade sale is 51.60%</td>
</tr>
<tr>
<td>6.</td>
<td>New products</td>
<td>Potassium iodate Tab. and Normal saline with glycerin introduced in the year 2014-15</td>
</tr>
</tbody>
</table>

#### Target for the year 2015-16

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Particulars</th>
<th>2015-16</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Production</td>
<td>100.00</td>
</tr>
<tr>
<td>2.</td>
<td>Sales Turnover</td>
<td>100.00</td>
</tr>
<tr>
<td>3.</td>
<td>Net profit / loss</td>
<td>(-) 52.92</td>
</tr>
</tbody>
</table>
BENGAL CHEMICALS & PHARMACEUTICALS LTD. (BCPL)

BACKGROUND

Bengal Chemicals and Pharmaceuticals Limited (BCPL), erstwhile Bengal Chemical and Pharmaceutical Works Limited (BCPW) was set up in 1901 by Acharya Prafulla Chandra Roy, a renowned scientist and academician. Government of India nationalised BCPW in 1980 under the name Bengal Chemicals & Pharmaceuticals Limited (BCPL) in 1981. BCPL was declared sick in 1993 and was sanctioned scheme for revival in 1995 by Board for Industrial & Financial Reconstruction (BIFR). In 2004, the scheme of revival was modified and the plan was sanctioned by BIFR.

Business Operations

Headquartered in Kolkata, BCPL is engaged in production and selling of industrial chemicals (Alum), branded and unbranded generic pharmaceuticals, hair oil and disinfectants such as phenol, naphthalene balls, bleaching powder, toilet cleaners and floor cleaners. The Company currently has four factories, eleven Sales Outlets and ten C&F Agencies spread across the country.

Manufacturing Locations:

The registered and corporate offices of BCPL are located in Kolkata. At present BCPL has four factories at Maniktala and Panihati in West Bengal, Mumbai and Kanpur.

Maniktala Unit:

This unit primarily produces Division II products which include branded as well as unbranded generic pharmaceuticals. Under the BRPSE scheme several projects such as capacity expansion of tablets, capsules and ointment blocks, complete overhaul of ASVS and liquid blocks and implementation of Greenfield projects were envisaged for the Maniktala unit. The ASVS project is planned to be taken up during 2015-16. The Greenfield Projects (Betalactum & Cephaphosporin Blocks) and modernisation of Ointment block that were initiated as envisaged in the plan and will be commissioned by April 2015.

Panihati Unit

Panihati unit, located near Kolkata, primarily produces Alum and products like Pheneol, Naphthalene Balls, and other disinfectants. Commercial production in most of the renovated production-blocks such as Alum, Pheneol, Naphthalene and White Tiger have commenced.

Mumbai Unit:

Mumbai unit, produces Hair Oil under the brand name ‘Cantharidine’. The commercial space developed has been leased out to third parties for generation of additional sources of income. Commercial space of the order of 43,206 sq. ft. has presently been leased out by the company.

Kanpur Unit:

Kanpur Unit, set up in 1949, primarily produces Division II products which includes tablets and capsules and small quantity of Hair Oil.

Past Achievements:

The company has retained its brand position in home products even during the crisis period and well set to capitalise on tense brands now.

Sickness and Revival, if any:

The revival package for BCPL was approved by the Government on 21st December 2006. The package of Rs 490.60 Cr was approved which comprised of restructuring of exiting debts on the books of BCPL, capital investments, support for development of marketing infrastructure and promotional measures, grant for wage revision and implementation of VRS and funds for payment of non-Government dues.

### Plant Machinery and capacity & recognition:

<table>
<thead>
<tr>
<th>Sl. No</th>
<th>PRODUCTS</th>
<th>UNIT</th>
<th>INSTALLED CAPACITY/ YEAR</th>
<th>ACTUAL PRODUCTION UPTO JAN 2015</th>
<th>% OF CAPACITY UTILISATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>ALUMINA</td>
<td>MT</td>
<td>8000.00</td>
<td>4314.45</td>
<td>64.7%</td>
</tr>
<tr>
<td>2.</td>
<td>SPIRITUOUS (AGURU)</td>
<td>KL</td>
<td>300.00</td>
<td>34.848</td>
<td>348.48%</td>
</tr>
</tbody>
</table>
Modernisation of plants
(Government assistance projects and status)
(Rs.in Crores)

<table>
<thead>
<tr>
<th>Projects</th>
<th>Cost on completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ointment &amp; Common items –Maniktala</td>
<td>29.57</td>
</tr>
<tr>
<td>Betalactam Block-Maniktala</td>
<td>30.39</td>
</tr>
<tr>
<td>Cephalosporin Block- Maniktala</td>
<td>29.75</td>
</tr>
<tr>
<td>Panihati Project</td>
<td>27.95</td>
</tr>
<tr>
<td>OSD project at Kanpur</td>
<td>34.44</td>
</tr>
<tr>
<td>ASVS - Maniktala</td>
<td>29.64</td>
</tr>
<tr>
<td>Project salary, &amp;Other common expenses</td>
<td>17.07</td>
</tr>
<tr>
<td>Total</td>
<td><strong>198.81</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sl. No</th>
<th>PRODUCTS</th>
<th>UNIT</th>
<th>INSTALLED CAPACITY/ YEAR</th>
<th>ACTUAL PRODUCTION UPTO JAN 2015</th>
<th>% OF CAPACITY UTILISATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>TABLET</td>
<td>CR</td>
<td>15.00 (yet to be commissiond)</td>
<td>1.775</td>
<td>14.20%</td>
</tr>
<tr>
<td>4</td>
<td>CAPSULE</td>
<td>CR</td>
<td>5.00 (yet to be commissiond)</td>
<td>0.566</td>
<td>13.584%</td>
</tr>
<tr>
<td>5</td>
<td>OINTMENT</td>
<td>MT</td>
<td>60.00</td>
<td>48.533</td>
<td>97.066%</td>
</tr>
<tr>
<td>6</td>
<td>HAIR OIL</td>
<td>KL</td>
<td>800.00</td>
<td>262.66</td>
<td>97.066%</td>
</tr>
<tr>
<td>7</td>
<td>PHENEOL</td>
<td>KL</td>
<td>3000.00</td>
<td>1341.32</td>
<td>53.6528%</td>
</tr>
<tr>
<td>8</td>
<td>NAPTHALENE</td>
<td>MT</td>
<td>450.00</td>
<td>142.92</td>
<td>38.112%</td>
</tr>
<tr>
<td>9</td>
<td>DISINFECTANTS</td>
<td>KL</td>
<td>1200.00</td>
<td>244.89</td>
<td>24.489%</td>
</tr>
</tbody>
</table>

STATUS OF IMPLEMENTATION OF PROJECTS:

- Panihati: Civil Construction, plant & machinery, utilities ETP, Roads, drains, Stores, Admn. Office.
  - Completed. Commercial production commenced.
- Maniktala:
  - Stores Building
  - Completed.
  - Utilities, ETP, Roads, drains etc.
  - Completed.
  - Ointment Block
  - Commissioning progressing
  - Betalactam & Cephalosporin Block
  - Commissioning is in progress.
- ASVS Section
  - To be taken up in 2015-16
- Kanpur:
  - Tablet, ORS, renovation /upgradation of existing blocks, QA, Utilities, amenity, Sterile Block etc.
  - QA Block, Utilities, Amenities, ETP completed. Civil construction of OSD almost completed. HVAC, electrical work, utilities etc. not completed.

Product profile and range:
The products manufactured under each of these business segments are mentioned below:

Division wise Product Segmentation

Division I
- Ferric Aluminium Sulphate (Alum)

Division II
- Tablets
- Capsules
- Liquid Preparation
- Ointment
- Antiseptic Liquid
- Injectables
- Aqua Ptychotis
- Eutheria
- Kalmegh

Division III
- Pheneol
- Bleaching Powder
- Klin Toilet
- Lysol
- Cantharidine Hair Oil
- Naphthalene Balls
- Liquid Soap (For Industrial Use)
- White Tiger (Floor Cleaner)
- Aguru (Essence)


Manpower as on 01.02.2015:

<table>
<thead>
<tr>
<th>Particulars</th>
<th>01.02.2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXECUTIVES</td>
<td>68</td>
</tr>
<tr>
<td>SUPERVISORS</td>
<td>94</td>
</tr>
<tr>
<td>Workers</td>
<td>255</td>
</tr>
<tr>
<td>Grand Total</td>
<td><strong>417</strong></td>
</tr>
</tbody>
</table>

Distribution network if any:
The company has a strong distribution network pan India with 11 Depots and 7 C&F Agencies.

Performance:
Details of Production & Sales of BCPL from 2010-11 onwards are as under:
Future projects: ASVS Project

Targets for 2015-16

Rs. in Cr.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Production</td>
<td>80.4</td>
<td>51.7</td>
<td>36.32</td>
<td>19.7</td>
<td>46.79</td>
</tr>
<tr>
<td>Sales</td>
<td>54.85</td>
<td>48.25</td>
<td>27.37</td>
<td>16.87</td>
<td>31.90</td>
</tr>
<tr>
<td>Profit/Loss</td>
<td>(10.70)</td>
<td>(18.23)</td>
<td>(17.94)</td>
<td>(33.82)</td>
<td>(8.82)</td>
</tr>
</tbody>
</table>

Marketing: Share of Institutions and retail

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>DIV &amp; PRODUCTS</th>
<th>MARKET PROFILE/Major clients</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>DIV I – FERRIC ALUM</td>
<td>NTPC (KAHELGAON &amp; BARH) SAIL (DURGAPUR, IIISCO, BOKARO, REFRACTORY UNIT, IIISCO CHASNALA) BCCL (BOWRA &amp; BLOCK II) IPCL (FARAKKA, SAGARDIGHI, DISERGARH) PHE (MALDA, SILIGURI) OTHER PRIVATE PARTY</td>
</tr>
<tr>
<td>2.</td>
<td>DIV II – GENERIC TABLET, CAPSULE, INJECTION, LIQUID, OINTMENT</td>
<td>AFMSD, ESIC, RAILWAY, SAIL, DHS, APMSIDC, OTHER STATE GOVT, SECL AND OTHER PSU</td>
</tr>
<tr>
<td>3.</td>
<td>DIV III – COSMETIC &amp; HOME PRODUCTS</td>
<td>MAINLY TRADE BUSINESS (70-75%) AND (25 TO 30 %) INSTITUTION BUSINESS LIKE CSD, PHE, METRO RAILWAY, NMDC, JADAVPUR UNIVERSITY ETC.</td>
</tr>
</tbody>
</table>

Future projects: ASVS Project

Targets for 2015-16

Rs. in Cr.

<table>
<thead>
<tr>
<th>Production</th>
<th>72.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turnover</td>
<td>60.00</td>
</tr>
<tr>
<td>Net profit / loss</td>
<td>(23.42)</td>
</tr>
</tbody>
</table>
INFORMATION TECHNOLOGY

Indian Drugs & Pharmaceuticals Limited (IDPL) was incorporated as a public limited company on 5th April, 1961 under the Companies Act, 1956. The Registered Office of the Company is located at Dundahera, Gurgaon and its Head Office at SCOPE Complex, Lodhi Road, New Delhi. The main objectives of the company were creating self-sufficiency in respect of essential life saving medicines, to free the country from dependence on imports and to provide medicines to the millions at affordable prices. IDPL was basically conceived and established as a part of Healthcare Infrastructure and has played a pioneering infrastructural role in the growth of Indian Drugs Industry base.

IDPL has three main Plants at Rishikesh (Uttarakhand), Gurgaon (Haryana), Hyderabad (Telangana) and two wholly owned subsidiaries, namely, IDPL (Tamil Nadu) Ltd. Chennai (Tamil Nadu) and Bihar Drugs & Organic Chemicals Ltd. (BDOCL) at Muzaffarpur (Bihar). In addition, IDPL has one Joint Venture Undertaking, promoted in collaboration with the Odisha State Government, namely, Orrisa Drugs & Chemicals Ltd. (ODCL) Bhubaneswar. IDPL is a sick company in Public Sector within the meaning of Sick Industrial Companies (Special Provisions) act, 1985 (SICA).

Past Achievements:
The main objective of setting-up IDPL was not to earn profits but to encourage indigenous production of pharmaceuticals and to support various health programmes of the Central Government. IDPL did reasonably well on this account despite the fact that it was the first integrated and monolithic venture in the Public Sector engaged in production of low margin products. IDPL earned Profit before Depreciation, Interest & Tax (PBDIT) from 1965 to 1968 and again from 1971 to 1974. It earned net profit from five years continuously from 1974 to 1979; the Company lost its profitability primarily due to change in Government policy about import of bulk drugs for supplying to pharma Industry. The Imports which were canalized through IDPL till 1979 were entrusted to State Trading Corporation (STC). This was the task assigned to IDPL as per needs of the time. IDPL was thus divested of a profit making segment. Today, it can fulfill other needs to meet gaps in public health by supplying essential drugs.

Sickness and Revival if any
The role of IDPL was, however, not redefined even in the eighties. It continued to function on the basis of its old model of sixties which lost its relevance to a great extent by eighties. In circumstances, the net worth of the IDPL became negative in 1982-83. The causes were (i) large monolith-type integrated production facilities (typical model followed in 1950s-1960s) producing chemicals, bulk drugs & formulations (ii) outdated plant & machinery and obsolete technology for bulk drugs (but for formulations not outdated) (iii) excess manpower (13283 in 1983-84) and high wage bill and maintenance of huge township, schools and hospitals. (iv) frequent changes at top management (average tenure of Chairman & Managing Director was 18 months) (v) medicines produced by IDPL were under price control by the Government prior to liberalization in 1991 (vi) shift in Government policy resulting in shifting of the canalization agency from IDPL to STC (vii) intense competition from private pharma sector companies which did not have to bear burden of social infrastructure of setting up and maintaining townships, schools, hospitals etc. and had learner production facilities. Production has been stopped in October 1996 at Rishikesh & Hyderabad & Muzaffarpur Plant due to shortage of working capital.

Revival status since 1.4.1994
The Board for Industrial & Financial Reconstruction (BIFR) declared IDPL as a sick industrial Company on 12th August, 1992. On 10.2.1994 BIFR approved the Rehabilitation Scheme under Section 17(2) of SICA for its implementation w.e.f. 1.4.1994. The package sanctioned by BIFR in 1994 failed primarily because (i) full funds were not released to the Company as envisaged (ii) capital restructuring was not done (iii) banks did not provide adequate working capital requirements (iv) working capital funds were diverted to meet fixed expenses of subsidiary units. (v) Land could not be sold (vi) sales targets were fixed at very ambitious levels. On 23.1.1996, BIFR appointed Industrial Development Bank of India (IDBI) as Operating Agency (OA) for Techno-Economic Analysis and preparation of Revival Package. The issue of revival of the company remained pending in BIFR as well as with the Govt. Attempts were made in 2001-02 to privatize the Company, OA, however, did not find any proposal worthy of recommendations to BIFR.

After failure to privatize IDPL, BIFR ordered its winding up on 4.12.2003. Govt. filed an appeal before Appellate Authority for Industrial Financial Reconstruction (AAIFR) on 10.2.2002 against BIFR order. AAIFR admitted the appeal filed by the Government on 2.8.2005 and directed that a Road Map for revival of IDPL be submitted. Ministry/Department constituted an Expert Committee under the Chairmanship of Director NIPER and Technical Audit of the Plants & Machineries carried out by the Committee, it would be feasible to revive IDPL. Committee found the plant & machineries for production of formulations in a reasonably good shape which can be optimally utilized with minimal investment for compliance of Scheme-M requirements. It was also opined that the emerging position of IDPL in the present market scenario is to be conceptualized. IDBI supported the recommendations of the Expert Committee. Having regard to these developments, AAIFR set aside the impugned order of BIFR dated 4.12.2003 and...
remanded the matter back to BIFR for taking further action for rehabilitation of IDPL and to pass further orders in accordance with law.

Keeping in view of the above a DRS was prepared by IDPL in consultation with CDRA Management and submitted to the BRPSE for consideration and recommendation. After approval of the BRPSE and A Note for Cabinet Committee on Economic Affairs is prepared and submitted for approval on 11.5.2007. The Note was considered by CCEA in its meeting held on 17.5.2007 and referred the matter to Group of Minister (GoM). GoM in its meeting held on 11.10.2007 advised that IDPL’s revival plan should be based on public interest goals and ensuring the viability of the Company. The observations made by GoM, IDPL appointed a leading consultant Company E&Y to carry out the feasibility study. E&Y report submitted to the Ministry/DoP.

A revised DRS again prepared by IDPL in consultation with IDBI (OA) taking cut off date as 31st March, 2011. BIFR observation that cut off date needed the approval of BIFR bench. Thereafter in the BIFR meeting held on 20.8.2014 cut off date was approved as 31.3.2014. Accordingly, the revised updated DRS has been prepared taking cut off date 31.3.2014 and submitted to the DoP/Ministry in January 2015 for consideration and approval. The DRS of IDPL is self-financing in nature in other words no fund will be sought from the Govt rather the present assets will be sold off and the fund released will be used to payoff secured creditors.

**IDPL WHOLLY OWNED SUBSIDIARIES**

A) IDPL (Tamil Nadu), Chennai.

IDPL (Tamilnadu) Chennai was incorporated in September, 1965, initially it was a Surgical Instruments Plant and later diverted for formulations. In terms of revival package approved by BIFR in 1994 this Plant was converted into a wholly owned subsidiary in the name and style of IDPL (Tamilnadu) Limited, Chennai with effect from 1.4.1994. IDPL (Tamilnadu) is a Schedule-M plant and engaging in manufacture of pharmaceuticals formulations. The production achieved for the F.Y. 2013-14 was Rs. 12.00 crores.

B) Bihar Drugs & Organic Chemicals Ltd. (BDOCL), Muzaffarpur

Bihar Drugs & Organic Chemicals Ltd., Muzaffarpur was incorporated in 1979, converted into a wholly owned subsidiary with effect from 1.4.1994. IDPL holds the entire equity capital of this Unit. At present there is no production activity in this Plant since November, 1996.

C) Orissa Drugs and Chemicals Ltd (ODCL) (Joint Undertaking of IDPL and Orissa Govt)

Orissa Drugs & Chemicals Limited (ODCL) was incorporated in 1979 and commissioned fully for production from September, 1983. ODCL is a Joint Sector Undertaking promoted by Indian Drugs & Pharmaceuticals Ltd. (IDPL) and Industrial Promotion & Investment Corporate of Orissa (IPICOL). IDPL holds 51% of the equity shares and 49% is with IPICOL. BIFR passed orders for winding up in April, 2003 under the provisions of SICA Act, 1985. High Court of Orissa had appointed a provisional Liquidator. This has since been stayed by a larger Bench of the Odisha High Court.

The Company is engaged in manufacture of pharmaceuticals formulations in the form of Tablets, Capsules, Powder, ORS and Injectables etc. ODCL Plant is Schedule-M compliant and production for the F.Y. 2013-14 was Rs. 14.70 crores which is the highest ever achieved by ODCL.

**IDPL TODAY** - Presently IDPL is engaged in manufacturing formulations only. In-house production of formulation during the year 2013-14 was Rs.62.83 crores, items-wise details as under:

<table>
<thead>
<tr>
<th>S. No</th>
<th>Item</th>
<th>Unit</th>
<th>Annual Installed Capacity</th>
<th>Qty. Produced</th>
<th>Value (Rs.in lakhs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Tablets</td>
<td>Million Nos.</td>
<td>1623</td>
<td>527.81</td>
<td>3025.31</td>
</tr>
<tr>
<td>2</td>
<td>OCP</td>
<td>Million Nos.</td>
<td>1638</td>
<td>208.52</td>
<td>286.70</td>
</tr>
<tr>
<td>3</td>
<td>Capsules</td>
<td>Million Nos.</td>
<td>740</td>
<td>153.48</td>
<td>1985.74</td>
</tr>
<tr>
<td>4</td>
<td>Liquid Oral 110 ml.</td>
<td>Kilo Litres</td>
<td>696</td>
<td>308.44</td>
<td>325.72</td>
</tr>
<tr>
<td>5</td>
<td>Dry Syrup 60 ml</td>
<td>Lac Bottle</td>
<td>36</td>
<td>23.04</td>
<td>300.75</td>
</tr>
<tr>
<td>6</td>
<td>Injectables (Amp)</td>
<td>Million Nos.</td>
<td>24</td>
<td>1.99</td>
<td>67.11</td>
</tr>
<tr>
<td>7</td>
<td>ORS</td>
<td>Million Nos.</td>
<td>15</td>
<td>4.80</td>
<td>168.89</td>
</tr>
</tbody>
</table>
Modernization of Plants (Government assistance projects and status):

The Up-gradation & Modernization of IDPL Plants are in progress. It is expected to complete the modernization work soon. Schedule 'M' GMP compliant plants are Rishikesh, Rishikesh Plant is WHO-GMP compliant now whereas in Gurgaon Plant, Schedule-M is progressing. IDPL will restart its Hyderabad Formulation Unit during the year 2015-16.

<table>
<thead>
<tr>
<th>Year</th>
<th>Project</th>
<th>Scheme</th>
<th>Funds released (In crs)</th>
<th>Plant’s Allocation</th>
<th>Status of Project</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010-11</td>
<td>Sch-M Work</td>
<td>Loan to IDPL</td>
<td>4.45</td>
<td>1.70-Rishikesh 1.00-Gurgaon 1.75-Chennai</td>
<td>Rishikesh &amp; Chennai Plant -made Sch-M compliant. Sch-M work of Tab. Section of Gurgaon Plant -likely to be completed.</td>
</tr>
<tr>
<td>2011-12</td>
<td></td>
<td></td>
<td>3.40</td>
<td>0.80-Rishikesh 2.05-Gurgaon 0.55-Chennai</td>
<td></td>
</tr>
<tr>
<td>2012-13</td>
<td>Re-starting Formulation Work</td>
<td></td>
<td>5.00</td>
<td>Hyderabad Plant</td>
<td>Work in progress</td>
</tr>
<tr>
<td>2014-15</td>
<td></td>
<td></td>
<td>5.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2012-13</td>
<td></td>
<td></td>
<td>1.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2013-14</td>
<td></td>
<td></td>
<td>1.80</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Product profile and Range:

Presently, IDPL is manufacturing nearly 86 products (PPP) & 25 products (Non-PPP) in the form of Capsules, Tablets, Dry Syrup, Liquid Oral and Injection, based on mainly following therapeutic groups:

- Antibacterial /Antiinfective, Analgesic / Antiinflammatory, Gastrointestinal, Respiratory Tract, Contraceptive, Vitamins / Mineral, Anti allergic, Anti fungal Anti malarial Anti diabetic Cardiovascular.

Popular Brands: Deacos, 110 ml, Sukcee Tab, Cebxin Z are popular brands of IDPL.

Manpower:

Presently IDPL has 88 regular employees and 106 on contract in different location of the Company including 100% wholly owned Subsidiaries Company. The company has not been permitted to go for regular hiring being BIFR Company. Only contractual employees are hired by the company on yearly basis extendable subject to performance.

Distribution network if any: Company is selling its products to institutions through distribution networks of 19 depots(C&FA) located all over the country.

Performance

IDPL Key Financial Indicators (Production, and Sales, Profit/loss)

Figure from the year 2011 to 2014

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Production</td>
<td>50.78</td>
<td>58.71</td>
<td>62.83</td>
<td>52.99</td>
</tr>
<tr>
<td>Sales</td>
<td>50.69</td>
<td>59.47</td>
<td>60.18</td>
<td>46.00</td>
</tr>
<tr>
<td>Profit/loss (EBIDTA)</td>
<td>-7.91</td>
<td>-3.95</td>
<td>-2.25</td>
<td></td>
</tr>
<tr>
<td>Net Profit/loss</td>
<td>-251.32</td>
<td>-173.21</td>
<td>-171.56</td>
<td></td>
</tr>
<tr>
<td>DPE Rating</td>
<td>Good</td>
<td>Very Good</td>
<td>Good</td>
<td></td>
</tr>
</tbody>
</table>

Marketing:

Share of Institutions and retail; The company is only supplying to institutional clients and Govt departments who place orders on PPP. This policy was revised in February 2014. As per this policy Govt institutions can buy 103 medicines from 5 CPSU at NPPA certified prices.

Major Institutional clients of IDPL are ESI Corporation, Ministry of Health, Defence, Railways, State Governments/Corporations and Public Sector Enterprises Hospitals who place orders under different categories of Therapeutic Medicines.

Apart from above the company is fully supporting Jan Aushadhi Programme of Govt of India and is regularly supplying large numbers of medicines.
New Products launched.–Cefexime 100 mg, & 200 mg, Cefuroxime Axetil 250mg & 500mg, Aceclofenac 100mg, Aceclofenac 100mg. + Paracetamol 500mg, Calcium+Vitamin D3 500mg

Future Projects:-
To make all IDPL Plants s WHO-GMP compliant.

Targets for 2015-16:
Production : Rs 70 Crore
Sale : Rs 72 Crore

Conclusion:
IDPL has also played a major role in the strategic National Health Programmes like Family Welfare Programme & Population Control (Mala-D & Mala-N) anti-malarials (Chloroquine) and prevention of dehydration (ORS) by providing quality medicines. IDPL has encouraged indigenous production and intervention for price control in market by manufacturing generic drugs.

IDPL has been supporting Government in meeting emergent situations arising due to National calamities like Cyclone, Flood, Earthquake etc. Recently in Odisha, Uttarakhand and J&K floods. IDPL contributed significantly by providing life saving medicines on time.

Archive Room-Rishikesh

Blister Packing Machine -Rishikesh

ODCL Bhubaneswar

Microbiology Lab- Rishikesh

Injectible Section-ODCL

5.2 STATUS OF ANNUAL ACCOUNTS

Details of Annual Accounts finalized and laid on the table of Parliament till date are as under:-

<table>
<thead>
<tr>
<th>Company</th>
<th>Financial Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karnataka Antibiotics &amp; Pharmaceuticals Limited</td>
<td>2012-13</td>
</tr>
<tr>
<td>Rajasthan Drugs &amp; Pharmaceuticals Limited</td>
<td>2012-13</td>
</tr>
<tr>
<td>Hindustan Antibiotics Limited</td>
<td>2012-13</td>
</tr>
<tr>
<td>Indian Drugs &amp; Pharmaceuticals Limited</td>
<td>2010-11</td>
</tr>
<tr>
<td>Bengal Chemicals &amp; Pharmaceuticals Limited</td>
<td>2010-11</td>
</tr>
<tr>
<td>Bengal immunity Limited</td>
<td>2005-06</td>
</tr>
</tbody>
</table>
5.3 JAN AUSHADHI SCHEME

NEED FOR JAN AUSHADHI SCHEME

Making available quality medicines at affordable prices is a key challenge for the Government. The prices of branded medicines are generally higher than generic medicines due to various reasons. For example, some of the comparative prices illustrated here would show that there is a big difference in prices between the branded medicines sold in the market and generic medicines having the same efficacy being sold in Jan Aushadhi Outlets.

Price Comparison

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Product Name</th>
<th>Strength of Pack of 10</th>
<th>Ceiling Price*/Average Price of leading Brands#</th>
<th>Price of Jan Aushadhi</th>
<th>Price Difference of Branded Medicines V/s Jan Aushadhi</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Diclofenac</td>
<td>100mg</td>
<td>39.73</td>
<td>4.43</td>
<td>9 times</td>
</tr>
<tr>
<td>2</td>
<td>Paracetamol*</td>
<td>500mg</td>
<td>10.00</td>
<td>5.60</td>
<td>2 times</td>
</tr>
<tr>
<td>3</td>
<td>Nimesulide</td>
<td>100mg</td>
<td>33.93</td>
<td>3.42</td>
<td>10 times</td>
</tr>
<tr>
<td>4</td>
<td>Tramadol*</td>
<td>50mg</td>
<td>65.10</td>
<td>3.94</td>
<td>16 times</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Ciprofloxacin</td>
<td>250mg</td>
<td>47.37</td>
<td>16.54</td>
<td>3 times</td>
</tr>
<tr>
<td>2</td>
<td>Amoxycillin*</td>
<td>500mg</td>
<td>64.70</td>
<td>37.00</td>
<td>2 times</td>
</tr>
<tr>
<td>3</td>
<td>Azithromycin*</td>
<td>500mg</td>
<td>218.10</td>
<td>105.09</td>
<td>2 times</td>
</tr>
<tr>
<td>4</td>
<td>Cefixime*</td>
<td>100mg</td>
<td>81.80</td>
<td>30.12</td>
<td>3 times</td>
</tr>
<tr>
<td>5</td>
<td>Ofloxacine*</td>
<td>200mg</td>
<td>52.10</td>
<td>17.13</td>
<td>3 times</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Domperidone*</td>
<td>10mg</td>
<td>24.00</td>
<td>3.29</td>
<td>7 times</td>
</tr>
<tr>
<td>2</td>
<td>Pantaprazole*</td>
<td>40mg</td>
<td>50.96</td>
<td>7.72</td>
<td>7 times</td>
</tr>
<tr>
<td>3</td>
<td>Albendazole*</td>
<td>400mg</td>
<td>97.00</td>
<td>20.31</td>
<td>5 times</td>
</tr>
<tr>
<td>4</td>
<td>Aceclofenac+Paracetamol</td>
<td>100mg+500mg</td>
<td>36.67</td>
<td>11.22</td>
<td>3 times</td>
</tr>
<tr>
<td>5</td>
<td>Rabeprazol</td>
<td>20mg</td>
<td>57.84</td>
<td>6.12</td>
<td>9 times</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Atenolol*</td>
<td>50mg</td>
<td>22.00</td>
<td>3.07</td>
<td>7 times</td>
</tr>
<tr>
<td>2</td>
<td>Amlodipine*</td>
<td>5mg</td>
<td>30.10</td>
<td>2.51</td>
<td>12 times</td>
</tr>
<tr>
<td>3</td>
<td>Atorvastatin</td>
<td>20mg</td>
<td>174.85</td>
<td>10.32</td>
<td>17 times</td>
</tr>
<tr>
<td>4</td>
<td>Enalapril*</td>
<td>5mg</td>
<td>31.50</td>
<td>6.60</td>
<td>5 times</td>
</tr>
<tr>
<td>5</td>
<td>Losartan Potassium*</td>
<td>50mg</td>
<td>45.70</td>
<td>6.99</td>
<td>7 times</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Glimperide</td>
<td>2mg</td>
<td>54.00</td>
<td>3.11</td>
<td>17 times</td>
</tr>
<tr>
<td>2</td>
<td>Metformin HCL*</td>
<td>500mg</td>
<td>16.60</td>
<td>4.80</td>
<td>3.5 times</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Cetrizine*</td>
<td>10mg</td>
<td>19.20</td>
<td>3.09</td>
<td>6 times</td>
</tr>
<tr>
<td>2</td>
<td>Cough Syrup</td>
<td>110ml</td>
<td>29.33</td>
<td>19.48</td>
<td>1.5 times</td>
</tr>
</tbody>
</table>

* Product with Ceiling prices as fixed by NPPA
# Source : IDR

In view of the above, ensuring availability of quality medicines at affordable prices to all has been one of the key objectives of the Department of Pharmaceuticals, Government of India. With a view to achieve this objective the Government has been taking several regulatory and fiscal measures from time to time. In order to provide further relief to the common man in the area of healthcare, a countrywide Campaign for ensuring availability of generic medicines at affordable prices to all, in the name of “Jan Aushadhi Campaign”, was launched by the Department of Pharmaceuticals, in November, 2008 in collaboration with the
The poor performance of the Scheme was quite evident from the fact that, as against the target of opening one JAS in each of the 630 districts, only 157 JASs could be opened till September, 2013. Of these, only 97 JASs were operational. The Public Health Foundation of India (PHFI) was asked to study the Scheme and suggest remedial measures. Based on the Report of PHFI and ground level observations it was found that the following were mainly responsible for the scheme not being successful.

(a) Over dependence on support from State Government
(b) Poor Supply Chain management

Achievements/Shortcomings of the Original Scheme

The poor performance of the Scheme was quite evident from the fact that, as against the target of opening one JAS in each of the 630 districts, only 157 JASs could be opened till September, 2013. Of these, only 97 JASs were operational. The Public Health Foundation of India (PHFI) was asked to study the Scheme and suggest remedial measures. Based on the Report of PHFI and ground level observations it was found that the following were mainly responsible for the scheme not being successful.

(a) Over dependence on support from State Government
(b) Poor Supply Chain management

(c) Non-prescription of Generic Medicines:
(d) State Governments launching free supply of generic drugs:
(e) Lack of awareness among the Public:

III. A NEW BUSINESS PLAN – TO OVERCOME SHORTCOMINGS OF ORIGINAL SCHEME

With a view to remove the shortcomings noticed in the original Jan Aushadhi Scheme a revised New Business Plan has been worked out. The New Business Plan was approved in August, 2013. The new Business Plan takes care of major bottlenecks in implementation of the scheme so far. The proposed changes in the scheme under the New Business Plan are listed below:-

(i) Relaxed eligibility conditions for Operating entities: Jan Aushadhi Stores may be opened outside the premises of hospitals also. Moreover, any NGO/ charitable society/ institution/ Self Help group with experience of minimum 3 years of successful operations in welfare activities, supported by three years audited accounts, will be eligible for applying for opening of drug store. As far as individuals are concerned, unemployed pharmacists/doctors/registered medical practitioners would be given preference for running the stores. The applicants have to approach BPPI with a complete application along with the following particulars;

a) Own space or hired space duly supported by proper lease agreement
b) Minimum required space conforming to standards as approved by the BPPI.
c) Sale license from competent authority.
d) Proof of securing a pharmacist.
e) Financial capacity to run the store (bank statements/ audited accounts for the last three years/ a sanction letter from bank for extending loan).

(ii) Coverage of the Scheme:

In the consolidation phase, it is proposed to establish a complete supply chain in the States where Jan Aushadhi Scheme has a substantial presence. Efforts would be made to open as many stores as possible in these States such as Punjab, Haryana, Delhi, Uttarakhand, Jharkhand, Himachal Pradesh, Maharashtra, Madhya Pradesh, Andhra Pradesh, West Bengal, Uttarakhand, Chandigarh, Jammu & Kashmir, Tripura, Uttar Pradesh and Odisha. North Eastern States would be given special attention to popularize the scheme. Later, the scheme will be extended to other States depending on the response from them. It is proposed to start a minimum of 3000 stores over a period of four years.

(iii) Review of existing list of medicines:

Under the original Scheme only 319 medicines were listed for sale at the Jan Aushadhi stores. There was a need to review this list to provide maximum coverage to the newer molecules in demand, and also products under the NLEM. With this in view, a revised list of 361 medicines has been prepared, covering almost all therapeutic categories of drugs.

(iv) Supply Chain Management:
More suppliers of medicines are being roped in from other Public Sector Undertakings (PSUs) as well as private manufacturers. Procurement of drugs from private manufacturers is also necessitated by the fact that CPSUs have in-house capacity to manufacture only 138 products.

An IT-based Management Information System is to be used to ascertain availability of medicines in stores on a real-time basis, and accordingly trigger supply of medicines through a transparent procurement process and supply chain, patterned almost on the model of Tamil Nadu Medical Services Corporation (TNMSC).

(v) Sourcing of drugs:

(a) As mentioned earlier, the list of products (138 Nos), reserved for CPSUs, has been finalized in consultation with them based on their in-house manufacturing capability. In respect of these drugs, CPSUs shall have the first claim to supply.

To ensure regular and adequate supply of medicines, apart from procurement of medicines from the CPSUs, BPPI is to supplement supply by direct purchase of medicines from private sector companies through open tender process, as per the guidelines issued by Central Vigilance Commission. The list includes 276 items out of the earlier list of 361 items identified for supply from Jan Aushadhi Stores and also top selling medicines belonging to 6 Therapeutic groups namely: (a) Anti-diabetic (b) Cardiac, (c) Gastro (d) anti-infective (e) Analgesic (f) Respiratory and Vitamins. All efforts are being made to make available the supplies within a few months time.

As and when infrastructure for in-house manufacture of drugs is created in CPSUs, the private sector will be gradually phased out.

Even in respect of drugs reserved for CPSUs, these drugs may be procured from private sector or other PSUs in case the respective CPSU fails to supply medicines on time. It is to be kept in mind that stock-out situations for any drug should be avoided at any cost.

(vi) Quality Control:

BPPI would ensure that only quality drugs are supplied through the Jan Aushadhi stores. To ensure this, it is essential that manufacturers of drugs are selected carefully and after due inspection of their facilities to ensure that they conform to required standards i.e. WHO-GMP compliance. Further, samples should be sent for testing on a regular basis. Any failure on the part of suppliers to comply with quality standards should trigger initiation of stringent actions, in addition to blacklisting the firms against future contracts. Though BPPI would ensure quality control through its own channels, the ultimate responsibility to ensure quality of medicines would rest with the manufacturers.

(vii) Pricing of Drugs:

Out of the proposed list of 361 medicines, MRPs for 138 medicines, manufactured and supplied by the CPSUs, have already been fixed in consultation with NPPA. In respect of medicines procured from private manufacturers or other PSUs, MRP will be fixed on the basis of rates arrived through tender process plus trade margins and other incidental costs (including excise duty, if any, and VAT component).

As mentioned earlier, MRPs of the medicines will be decided by BPPI after taking into consideration the wholesalers’ margin of 8% and retailers’ margin (Jan Aushadhi stores) of 16% for medicines under DPCO’95 and 10% for wholesalers and 20% for retailers for the non-DPCO medicines. Similarly, MRPs of surgicals and consumables will be worked out based on the procurement rates including distribution costs.

Beyond the 12th Plan period, an additional margin not exceeding 2% will also be collected to meet administrative expenses of BPPI. As the BPPI has to be run on ‘no profit no loss’ basis, the exact percentage would be worked out based on the volume of turnover at that time.

IV. Directions of the EFC

The EFC under the Chairmanship of the then Secretary Pharmaceuticals, after detailed deliberations, approved the new Business Plan with an estimated cost of Rs. 148.82 crores, subject to the condition that no expenditure shall be made for new JAS from the present allocation till:

(i) A full-fledged procurement system is put in place and rate contracts finalized and;

(ii) IT-based supply chain management solution is operationalized on pilot basis and;

(iii) All the necessary arrangements such as warehouses, stockists, required manpower etc. are put in place to manage supply chain.

As on date, 176 JAS have been opened out of which only 96 are functional. No. of stores opened during various years is as under:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Stores Opened</td>
<td>07</td>
<td>36</td>
<td>54</td>
<td>20</td>
<td>37</td>
<td>8</td>
<td>14</td>
</tr>
</tbody>
</table>

Total Number of stores opened till 19.02.2015 = 176
V. Progress made in implementation of new business plan

(i) Availability of medicines:
- Procurement of medicines has been started from private manufacturers also, in addition to CPSUs after following the normal tender process and entering into agreements with them.
- Rate of medicines, both for CPSUs and Private Suppliers has been finalized/are being finalized.

(ii) Creation of Central ware House: A Central Warehouse has been in the IDPL Complex at Gurgaon which has started functioning in the month of May, 2014.

(iii) Management of Supply Chain: An IT based management information system software is being introduced to ascertain availability of medicines in Jan Aushadhi stores and supply of medicines through a transparent procurement process & supply chain on a real time basis.

(iv) Quality Control: 8 NABL approved laboratories have been empanelled after following the normal tendering process for testing of samples of each batch of drugs to be procured. Medicines received in the warehouse are dispatched to Super stockists / Jan Aushadhi Stores only after getting the Passed reports from the NABL approved laboratories.

(v) Appointment of Super Stockist/ C&F Agents: For supply of medicines to Jan Aushadhi stores, 06 super stockists in various states have been appointed. More Super stockists would be appointed as per the requirement.

(vi) Opening of new Jan Aushadhi stores: Expression of Interest from interested parties for opening of Jan Aushadhi Stores in the States of Orissa, Uttar Pradesh, Madhya Pradesh, Assam, Bihar and Chhattisgarh were called for. In addition, the State Govt. of Chhattisgarh, Tripura and J&K have proposed to open more Jan Aushadhi Stores. Expression of Interest are being invited in respect of some other states.

(vii) Publicity campaign: It is proposed to launch massive media campaign for educating people about use of generic medicines and the benefits of the Jan Aushadhi Campaign, especially in those States where the Jan Aushadhi Scheme has already been started so that people take full advantage of the availability of generic medicines at affordable prices at the Jan Aushadhi Stores. A beginning has been made by giving a full page color advertisement in all the newspapers in the state of Orissa. The details are being worked out in consultation with DAVP agencies.

VI. STRATEGIC ACTION PLAN:-

Given the unsatisfactory performance of the Jan Aushadhi Scheme – which has been operational since 2008, the Department is revisiting the scheme plan and formulating a strategic Action Plan 2015 with a paradigm shift to make quality medicines accessible through affordability and availability. The Strategic action plan includes (i) New Distribution System: Expansion beyond the exclusive JAS stores in retail markets through retailers and franchisee with signage exclusivity (ii) Enlargement of medicines basket, (iii) Team building with all stakeholders – Prescribers (Doctors), Doctors Associations, Medical Council of India, Chemists & Druggists Association, Consumer Association, State Governments, Regulators and all others by addressing their respective concerns (iv) Advocacy and perception management on quality of JAS medicines for brand building (v) Strengthening Bureau of Pharma Public Sector Undertakings of India (BPPI) (vi) improved Supply Chain Management (vii) Value Added Services in partnership other service providers – online/home delivery, post offices, co-operatives, insurance agencies etc. (viii) Recognition of Doctors, Distributors and retailers and NGOs actively engaged in generics.

Under the Strategic Action Plan 2015, a pilot initiative will be launched during 2015-16 to reach out all sections of society with results and will be expanded across the country in the coming 3 years covering all therapeutic groups.
Chapter 6

NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH (NIPERs)
NIPER, SAS Nagar, Mohali was initially registered as a society under the Societies Act. The faculty for the institute was appointed in 1994. In 1998, Parliament enacted National Institute of Pharmaceutical Education and Research Act, 1998. NIPER was declared as an “Institute of National importance” under the Act of Parliament on 26th June 1998. NIPER is a member of Association of Indian Universities.

The main objectives of the Institute:
1. Nurture and promote quality and excellence in pharmaceutical education & research.
2. Toning up the level of pharmaceutical education and research by training the future teachers, research scientists and managers for the industry and profession.
3. Creation of National Centers to cater to the needs of the pharmaceutical industry and other research and teaching institutes.
4. Collaboration with Indian industry to help it meet global challenges.
6. Study of sociological aspects of drug use and abuse and rural pharmacy etc.
7. Running programmes in drug surveillance, community pharmacy and pharmaceutical management.

**NIPER has ten Departments:**
1. Medicinal Chemistry
2. Pharmaceutics
3. Natural Products
4. Pharmacology & Toxicology
5. Pharmaceutical Analysis
6. Biotechnology
7. Pharmaceutical Technology
8. Pharmacy Practice
9. Pharmaceutical Management
10. Pharmacoinformatics

**Disciplines:**
The first batch of students was admitted in 1998. The NIPER offers Masters’ and Ph.D. degrees in 15 streams and caters to the various needs of pharmaceutical industry:
1. Medicinal Chemistry
2. Natural Products
3. Traditional Medicine
4. Pharmaceutical Analysis
5. Pharmacology & Toxicology
6. Regulatory Toxicology
7. Pharmaceutical Technology (Biotechnology)
8. Pharmaceutical Technology (Formulations)
9. Pharmaceutical Technology (Process Chemistry)
10. Pharmaceutics
11. Biotechnology
12. Pharmacy Practice
13. Clinical Research
14. Pharmacoinformatics
15. Pharmaceutical Management

**Infrastructure:**
NIPER conducts regular education programmes for academia and industry in various disciplines and helps the Indian Pharmaceutical Industry in solving their R&D related requirements. NIPER has upgraded facilities for achieving the highest level of efficiency in imparting education and events. There are state-of-art classrooms with installation of TV panels and laptop systems. NIPER laboratories are fully equipped with modern equipments that are equivalent to other state-of-the-art laboratories in the world. All the available facilities are of international level and standards. A Technology Development Centre has also been set up. In addition, there has been significant improvement in research infrastructure as several high value sophisticated instruments have been added which has helped in increased thrust in R&D activities.

**Central Research Facilities:**
Following central facilities provide support to the research groups within the Institute as well as from outside:
1. Central Instrument Laboratory
2. Computer Centre
3. Library and Information Centre
4. Central Animal facility
5. National Toxicology Centre (GLP compliant)
6. Technology Development Centre
7. National Bioavailability Centre (WHO accredited)
8. Impurity Profiling & Stability Testing Laboratory
9. Pharmacological & Toxicological (GLP compliant) Screening Facilities

**Seats for admission to P.G. Courses, Ph.D in NIPER, S.A.S. Nagar:**
Since 2010, NIPER, S.A.S. Nagar, has increased seats for admission to postgraduate courses and Ph.D. Programme

<table>
<thead>
<tr>
<th>Courses</th>
<th>Students admitted in year 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ph.D</td>
<td>27</td>
</tr>
<tr>
<td>M.S.</td>
<td>196</td>
</tr>
<tr>
<td>M.B.A.</td>
<td>39</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>262</strong></td>
</tr>
</tbody>
</table>
In July 2014, 256 Masters’ students [including M.S. (Pharm.), M. Pharm. and M.Tech.(Pharm.)] and 63 M.B.A. (Pharm.) students graduated from the Institute.

Academic excellence: During 2014 the Institute has published 136 articles in journals of repute. NIPER has filed 7 patents in 2014. Since the inception of academic programme, 2227 students have passed out (Masters 1615, MBA 421 & Ph.D.191).

International collaborations: The Institute entered into several International collaborations and a number of visitors from abroad and within the country visited the Institute, thus highlighting the ever-rising status of the Institute. NIPER started conducting training programs at the newly established Small and Medium Pharmaceuticals Industry Centre (SMPIC) for Small and Medium Pharmaceuticals industry on the aspects of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP), Instrumental analysis and manufacturing of APIs and Formulations. The centre also provides a focal point to industry academia interaction.

**RECENT DEVELOPMENTS AT NIPER, S.A.S. NAGAR**

**GENERAL**

1. The Institute has played mother role to all the new NIPERs started in different parts of the country by helping them in variety of ways including centralized admissions.

2. A Technology Development Centrehas been set up in the NIPER, S.A.S. Nagar.

3. The WHO accredited National Bioavailability Centrehas been established with support of Deptt. of Science & Technology, Govt. of India, which is one of the two centers of the world to conduct the bioavailability studies for oral fixed-dose combination of anti-tubercular drugs. Inspection of the facility for renewal of approval was conducted by a team of DCGI on 23/12/2014.

4. The Institute has also set up the Good Laboratory Practices (GLP) compliant National Toxicology Centre, National Centre of Pharmacoinformatics, National Centre for Safety Pharmacology and Centre for Nanotechnology with the support of Department of Science & Technology (DST) under Pharmaceutical Research & Development Support Fund (PRDSF programme).

5. NIPER, S.A.S. Nagar, has now started training programmes for Small and Medium Pharmaceutical industry on the aspects of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP), Instrumental analysis and manufacturing of APIs and Formulations. An important aspect of the training programs is the demonstration in the Technology Development Center (TDC), Central Instrument Laboratory (CIL), and Central Animal Facility (CAF), etc. Separate hands-on training modules are available for High Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Atomic Absorption Spectroscopy (AAS).

6. NIPER has more than 1840 publications, most of them in reputed, peer-reviewed, international journals.

7. The EFC documents for two plan proposals for Rs. 253.4 cr for the remaining period of XII five year plan have been submitted to Deptt. of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Govt. of India.

8. Non-Plan budget proposal of Rs. 47.93 cr has been submitted out of which Rs. 12.77 cr has been released by the Ministry for meeting the expenses till the third quarter for the year 2014-15.

9. New projects worth Rs. 0.55 cr were sanctioned till date by various funding agencies to NIPER. In addition, the Department of Pharmaceuticals has funded three proposals on (i) Target specific drug discovery research against kala azar, (ii) Target specific new drug discovery of antituberculosis agents, (iii) Studies on molecular approaches to TB-determination of the prevalence of MDR and XDR strains, drug susceptibility testing and development of new diagnostic tests (collaborative project with AIIMS, New Delhi)

(Research)

1. Neglected diseases

- Some multifunctional proteins have been identified as virulence factors in *Mycobacterium tuberculosis*.
- The role of different residues in the conserved motif of acetyl CoA synthetase (AceCS) from *Leishmania donovani* has been studied with a view to identify molecular targets on which to base future treatment strategies.
- A series of twenty six structurally diverse α-aminophosphonates have been synthesized and evaluated for in vitro anti-leishmanial activity and cytotoxicity. Seven compounds exhibited anti-leishmanial potency against the *L. donovani* promastigote with ICS0 values in the low micromolar range.
- Of a total of 35 S-benzylatedguanylthiourea derivatives synthesized, one was found to be curative and five more compounds showed promising pharmacological profile on *Plasmodium berghei* in mice.
- Two pentamidine-heterocyclic hybrids were found to exhibit potent antileishmanial activities in promastigote assay, comparable to pentamidine (a clinically used antileishmanial drug). They were found to be significantly less cytotoxic than pentamidine for human monocytic cell line and macrophages.
- A combined structure and ligand based pharmacophore modeling, shape based virtual screening, docking and MD simulation for Mtb-ASADH (aspartate β-semialdehyde dehydrogenase) was performed to identify potent inhibitors of the enzyme. Best screened hits have the characteristics of highly electronegative functional groups (-COOH and -NO2) on both sides and exhibited the H-bonding interactions with highly conserved residues Arg99, Arg249 and His256.
2. Other diseases
   - CCR2 binds to the monocyte chemotactic protein MCP-1, a CC chemokine, produced at the sites of inflammation and infection. Homology modeling and subsequent molecular modeling studies proved successful in probing the structure of human CCR2 chemokine receptor for the structure-based virtual screening and predicting the binding modes of CCR2 antagonists.
   - Structural modifications of scaffolds such as β-carboline and isoquinoline were designed to synthesize and to generate structure-activity relationship for anti-leishmanial activity and cytotoxic potential against various human cancer cell lines.
   - Extracts of Ferula asafoetida were evaluated for their pancreatic lipase enzyme inhibition activity.
   - The metabolic profile of Itraconazole (associated with serious idiosyncrasy adverse reactions of the skin like Steven-Johnson syndrome, Lyell’s syndrome and photosensitivity) in rat skin S9 fraction using LC-MS results in identification of a direct covalent adduct of the drug with GSH (drug-GSH) and a total of six metabolites (M1-M6). The study revealed that skin toxicity of itraconazole may be associated with its GSH adduct or metabolites M2, M4 and M5 (as predicted by TOPKAT).
   - Age- and gender-specific differences in experimental model of global cerebral ischemia/reperfusion injury showed significant effect on locomotor hyperactivity and Y-maze spontaneous alternations behavior indicating that age and gender might have a significant role in the behavioral (functional and cognitive) outcomes of global cerebral ischemia.
   - Study of the effect of high glucose and insulin in breast cancer cells provided the first evidence that high glucose and insulin promotes proliferation of these cells by differential alteration of GSK-3β, NF-κB, and ERα expression and histone H3 modifications, which may directly or indirectly modulate the expression of genes involved in its proliferation.
   - Chemotherapy with agents like cyclophosphamide caused decrease in the zinc levels both in the serum and testes of the treated rat. Zinc supplementation was shown to be beneficial to those rats under chemotherapeutic agents; it has improved several of the reproductive damages caused by the anticancer agent.

3. Drug development and formulation
   - Understanding kinetic and thermodynamic events is paramount for design of stable amorphous pharmaceutical systems. Taking Celecoxib as a model drug, (i) differences in molecular interactions incrystalline and amorphous state, (ii) thermodynamic events associated with amorphous state, (iii) nature of interactions in the binary systems, and (iv) solubility benefits associated with the amorphous systems, have been demonstrated.
   - Co-encapsulation of antioxidant with anticancer drugs for improving oral bioavailability, synergistic anticancer efficacy and reduced toxicity has been attempted.
   - Platforms are being designed for oral insulin delivery using nanocarrier systems.

4. Other areas
   - Chemo-enzymatic synthesis of drugs (Ranolazine, Lebulozole, Dropropizine) using lipase as biocatalyst was carried out successfully. Oxidoreductase systems from various microorganisms were utilized for the stereoinversion of (RS)-Linezolide, (RS)-methyl pyridine methanol, DL-phenyl lactic acid, etc.
   - A palladium-catalyzed regio- and chemoselective direct benzylation of primary benzanilides with 2-bromobenzyl bromides under a mild basic condition has been developed affording various substituted diarylmethanes in good yields. Utilizing the above protocol, the synthesis of the two marketed drugs Xyzal® and Femara® are currently underway.
   - Monograph on anti-inflammatory Abhaya vati was developed.
   - Study of the effect of RNA aptamers on stabilization of misfolded proteins involved in Huntington’s disease was studied. This showed improved solubilization and enhanced viability of cells expressing the protein and the selected aptamers.
   - Using rational (site-directed mutagenesis) and random (random mutagenesis) approaches, the process of generating variants of recombinant human PON1 enzyme having enhanced activity towards desirable substrate(s) is being optimized.
   - Assessment of an appropriate and reliable method to diagnose neuropathic pain including translation of screening questionnaires in local languages and validating them in Indian population has been initiated.

(Events and Activities)

1. The following awards have been granted to the Institute:
   a. Two Ranbaxy Science Scholar Awards
   b. In addition, students have received awards at various national and international symposia, in recognition of the work carried out by them.

2. The following events were conducted by the Institute:
   a. SMPIC dissolution and solubility enhancement technology in pharmaceutical formulations on 5th September, 2014
   b. International symposium on recent advances in medicinal chemistry on 8-10 September, 2014
c. Indo US conference on molecular modeling and informatics in drug design (M2ID2) on 3-6 November, 2014

d. Hindi Pakhwada from 15-30 September, 2014

e. 4th Biennial International conference on New developments in drug discovery from natural products and traditional medicines (DDNPTM) on 20-22 November, 2014

f. ITEC/SCAAP training program from 24th November-4th December, 2014

g. 7th International symposium on drug metabolism and pharmacokinetics (DMPK-2015) from 18th – 21st February, 2015

h. Pledge being administered to employees and students of NIPER, S.A.S. Nagar at the Swachchh Bharat Abhiyan on Oct. 2, 2014

**ESTABLISHMENT OF NEW NIPERS:**

In terms of the amended National Institute of Pharmaceutical Education and Research (NIPER) Act, 1998, the Government of India has set up six new NIPERs at Hyderabad, Hajipur, Ahmedabad, Rae Bareli, Guwahati and Kolkata. These New NIPERs will cater to the growing demand of the pharmaceutical industry for highly trained manpower for continuous growth of the pharmaceuticals sector with increased focus on R&D, particularly after the amendment of Indian Patent Act. At present, new NIPERs are functioning with the assistance of the Mentor Institutes.

<table>
<thead>
<tr>
<th>1. New NIPERs</th>
<th>Mentor Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Hajipur</td>
<td>Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna.</td>
</tr>
<tr>
<td>4. Hyderabad</td>
<td>Indian Institute of Chemical Technology (IICT), Hyderabad.</td>
</tr>
<tr>
<td>5. Guwahati</td>
<td>Guwahati Medical College and Hospital (GMCH), Guwahati.</td>
</tr>
<tr>
<td>6. Kolkata</td>
<td>Indian Institute of Chemical Biology (IICB), Kolkata.</td>
</tr>
</tbody>
</table>

| 7. Rae Bareli  | Central Drug Research Institute (CDRI), Lucknow. |

**Starting of Classes at New NIPERS:**

Pursuant to the approval of the Cabinet to the setting up of six new NIPERs, classes were started from the academic Session 2007-08 with the help of Mentor Institutes at Ahmedabad, Hyderabad, Kolkata and Hajipur. The classes were started at NIPER, Guwahati and Rae Bareli in 2008-09.

The students are selected through Common Admission Test conducted by NIPER, SAS Nagar, Mohali in association with these new NIPERs.

An Apex Committee under the chairmanship of Secretary (Pharma) has been formed to oversee the smooth functioning of new NIPERs till the Board of Governors of each new NIPER is formed. Likewise, State level Coordination Committee under the Chairmanship of an officer of the level of Principal Secretary of the concerned State Government has been formed for each NIPER to oversee the functioning of the new NIPERs.

**NIPER-HYDERABAD**

**VISION**

To serve as a leading global institution in the field of higher learning and research in Pharmaceutical Sciences

**MISSION**

To strive towards excellence in the field of Higher Education and Research in Pharmaceutical Sciences & Management.

**OBJECTIVES**

- Enhancement of creativity, motivation, drives and inculcates professionalism.
- To bring synergy between academic, R & D, technology and industry through training and exposure for such environment
- Bridging collaborations between pharmacy, biotechnology, information technologies and preparing for meeting global challenges
- Create a world class institute of teaching and research in the field of pharmaceutical sciences
- Develop and practice e-learning for the professionals and training for teachers, researchers, regulators in the respective field
- Expand research activities in new avenues and emerging segments
- Explore national and international collaboration in pharmaceutical sciences

**GENERAL**

- NIPERs are autonomous bodies and established under the aegis of Ministry of Chemicals & Fertilizers as a centre of excellence for higher education, research and development in pharmaceutical sciences. These institutes have been declared as “Institutes of National Importance” by Government of India through an Act of Parliament (NIPER ACT 1998 & NIPER Amendment ACT 2007).
- Maintains interactions and research collaborations with various Pharma Industries and Academic Institutions
- Qualified and well experienced faculty has been inducted into NIPERs & Mentor Institute Scientists’ render their services or expertise to NIPERs.
- Students get admitted to NIPERs through two National wide Open Entrance Examinations (GPAT & NIPER-JEE)
- Good number of students were placed in Pharmaceutical Industries and some were in Research Institutes or Universities for pursuing Ph.D. in India as well as abroad.
Programmes Offered

NIPER-Hyderabad offers M.S.(Pharm.), M.Tech(Pharm.) and MBA (Pharm.) in following disciplines:

<table>
<thead>
<tr>
<th>Discipline</th>
<th>Admitted in the Academic Year</th>
<th>Proposed in the Academic Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2013-14</td>
<td>2014-2015</td>
</tr>
<tr>
<td>M.S. (Pharm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicinal Chemistry</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>Pharmaceutical Analysis</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Pharmacology &amp; Toxicology</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>Pharmaceutics</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>Regulatory Toxicology</td>
<td>08</td>
<td>08</td>
</tr>
<tr>
<td>M.B.A.(Pharm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Management</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>M.Tech.(Pharm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Technology (Process Chemistry)</td>
<td>08</td>
<td>08</td>
</tr>
<tr>
<td>Total MS Students</td>
<td>112</td>
<td>112</td>
</tr>
<tr>
<td>Ph.D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicinal Chemistry</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Pharmaceutical Analysis</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Pharmacology &amp; Toxicology</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Pharmaceutics</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Total Ph.D Students</td>
<td>11</td>
<td>12</td>
</tr>
</tbody>
</table>

Research Areas

- Drug Discovery: Synthesis of New Chemical Entities (NCEs) for
  - Anti-Cancer
  - Anti Inflammation
  - Anti Microbial
  - Metabolic disorders
- Peptidomimetics as therapeutic agents and Drug Delivery Systems
- Computer Aided Drug Design (CADD)
- Impurity Profiling
- Analytical Method Development
- Standardization of Herbal drugs
- Stability Improvement Methods
- In vitro and In vivo Screening of New Chemical Entities (NCEs) for various activities like Antidiabetic, Antiarthritis, Anticancer, Analgesic and Anti inflammatory activity
- Drug Metabolism and Pharmacokinetic studies (DMPK)
- Therapeutic drug monitoring, adverse drug reaction and Drug-Drug interactions studies
- Novel Drug Delivery Systems
- Nano Particle Technology
- Improvement in Bioavailability
- Application of QBD in Formulation Design and Processing
- Stability Improvement Methods

Achievements & Research Accomplishments

- Third Convocation: Total No. of M.S.(Pharm.) Degrees Awarded in the Third Convocation is 73, which was held on 19th October, 2013.
- Awards: The faculty is honored with OPPI Scientist; OPPI Young Scientist and IDMA Young Pharmaceutical Analyst Awards for their research contribution.
- Research Publications: 54 Peer reviewed International / National Publications were published.
- Poster Presentations: About 35 Posters were presented at different Conference / Symposia by the faculty and students
- Recent Conference / Workshops organized:
  - International Conference on Drugs for the Future: Infectious Diseases (DFID)
  - Drug Discovery from Toxins (Dec, 2013)
  - Recent Scenario on Rare Diseases & Disorders (Sept, 2013)
  - Export Business Opportunities for Pharma Products in Africa (May, 2013)
  - Dietary Restrictions in Therapeutics (April, 2013)
• MoUs: NIPER-Hyderabad has entered into Memorandum of Understanding (MoUs) and Research agreements with several Academic and Industrial Collaborations (8 Nos.) to pursue advanced research in the areas of mutual interest and to encourage student/faculty exchange programmes.

• Grants / Projects: NIPER-Hyderabad faculty got Grants / Projects (9Nos.) with DBT, ICMR, DST and UKIERI, SERB, YISSUM, etc.

Infrastructure & Research Facilities (NIPER-Hyderabad)

• Library and Information Center, Central Computer Facility, MM / CADD facility, Animal House.

• World Class Institutional facilities of CSIR-IICT are extended to NIPER-Hyderabad.

• Upcoming Facility (NCRDBD): National Centre for Research & Development in Bulk Drugs is being set up in NIPER to start Pharma-oriented R&D center across the country, tailored to the requirements of specific sub-segments such as bulk drug industry, formulations industry etc.

Placements

• >75% of students are placed every year in Pharma Industries

• Some students get Ph D positions in India and abroad

NIPER-AHMEDABAD

The National Institute of Pharmaceutical Education and Research (NIPER) has been established under the aegis of Ministry of chemicals and fertilizers, Government of India, Dept. of Pharmaceuticals, as a centre of excellence in imparting higher education, research and development in pharmaceutical sciences and is first of its kind in the country. The Institute was declared as an Institute of National importance by Government of India through an Act of Parliament, notified on 26th June 1998. The institute is a member of Association of Indian Universities and Association of Commonwealth Universities.

Vision

To be a Nationally and Internationally recognized premier Centre of Excellence in Teaching, Research and Entrepreneurial Training in Pharmaceutical Sciences and Biomedical Technology

Mission:

• To ensure that departmental and administrative associates are provided with necessary resources to excel in learning, research, teaching and administration

• To establish National Centre of Medical Devices (NCMD) for contributing for medical technology education through collaborative programmes of mutual interest

• To evolve medical technology clusters with common facilities for creating an ecosystem for the benefit of SME’s focusing on medical technology

• Development of human resources by skill up-gradation of students through specialized courses and training

• To encourage students for innovative translational research through interdisciplinary research team

• To promote national and international collaboration with Pharmaceutical Industries, Medical Centres and Universities

• To facilitate international student and faculty exchange programmes to enhance the diversity on the campus

• To organize International and National conferences and structured workshops for the benefit of students and professionals

ACADEMIC ACTIVITIES

The students for M.S. (Pharm.) and Ph. D programme are admitted through a nationwide open competitive entrance examination (NIPER-JEE) conducted by NIPER Mohali. The prerequisite to appear for this examination is undergraduate degree and GPAT/GATE qualification. During their entire tenure students are groomed to bridge a link between academia and the industry.

NIPER-Gn offers M.S. (Pharm.) and Ph. D programme in following disciplines

• Biotechnology

• Medical Devices

• Medicinal Chemistry

• Natural Products

• Pharmaceutical Analysis

• Pharmaceutics

• Pharmacology & Toxicology

Admission of students to M.S.(Pharm.) in 2014-2015

NIPER-Gandhinagar entered into eighth academic year of its existence, from July 2014. The institute has Masters level programme in seven different disciplines in the eighth academic year, leading to M.S.(Pharm.) in Pharmaceutics, Natural Products, Biotechnology, Pharmaceutical Analysis, Medicinal Chemistry, Pharmacology & Toxicology and Medical Devices streams. The institute has currently 31 students from Batch 2013-15 and in the eighth academic year, 34 students were admitted to seven streams (Batch 2014-16).

Teaching schedule for the Academic Year 2013-14

1st Semester

Teaching started with the orientation week in last week of July 2014, wherein Experts from industry were called to orient the students. Regular teaching schedule was followed the week after. Weekly, two seminars were scheduled for the first semester students. The Mid-term exams were scheduled from 6 to 10th October 2014 and the Final Exams were scheduled from 15th to 26th December 2014.

3rd Semester

Third Semester started from the second week of May 2014. The students submitted their Project Proposals and literature survey summary in the first week of June 2013 followed by the Project
Proposal Defense. The Project Progress presentation was held in presence of SRC members from January 5-9, 2015.

<table>
<thead>
<tr>
<th>Discipline</th>
<th>No. of Students admitted (Batch 2013-15)</th>
<th>No. of Students admitted (Batch 2014-16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natural Products</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Pharmaceutics</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>Biotechnology</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Pharmaceutical Analysis</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Medicinal Chemistry</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Pharmacology and Toxicology</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Medical Devices</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

Ph. D. Programme

Currently six Ph. D. fellows are pursuing their PhD programmes at NIPER-Gandhinagar. All of them have successfully completed their coursework and are currently continuing with their laboratory experimental work. A review of their research work was recently held (six monthly evaluation) to assess the progress of their work, in presence of external examiner.

RESEARCH ACTIVITIES IN DIFFERENT DEPARTMENTS

Department of Biotechnology

- Generation of induced Pluripotent Stem Cells (iPSCs) using non viral methods and its redifferentiation
- Pharmacogenetics studies and population based genome analyses like genomic alteration in oral cancer, diabetes, tuberculosis
- Proteomics and genomics biomarkers for diabetes and its secondary complications
- Cancer research including targeted drug delivery to cancerous cells using nanoparticles, to overcome chemoresistance and prevention of relapse by Cancer stem Cells (CSCs) re-differentiation
- Expression of therapeutic protein through various expression systems, including bacterial, plants and mammalian cells
- Plant tissue culture and identification of molecular markers
- Development of novel vaccine against infectious diseases
- Gene silencing through siRNA and shRNA

Department of Pharmaceutics

- Development of specialized delivery systems including Taste masked formulation, Pellets, Microneedle, Transdermal, SLN, NLC and SMEDDS
- Physical characterization of pharmaceuticals using rheology, thermal and texture analysis, imaging techniques,
- Identification and formulation of novel adjuvants and compatibility screening
- Formulation development and stability of biotherapeutic agents
- Targeted lymphatic delivery system for Cancer, Leishmaniasis and HIV
- Solubility enhancement using nanocrystallization, complexation and cocrystallization
- Nanotechnology based drug delivery system targeting brain
- Formulation development of solid orals using Quality by Design (QbD)

Department of Natural Products

- Target Oriented Synthesis (TOS) based development of New Chemical Entities (NCEs) of natural scaffolds against Multi Drug Resistant Tuberculosis and its secondary complications
- Lead based design and development of NCEs of natural pharmacophores as antidiabetic and other autoimmune disease leads
- Diversity Oriented Synthesis (DOS) of small molecules as anti-HIV, anti-Alzheimer’s and anti-inflammatory leads
- Molecular docking and Structure Activity Relationship (SAR) study of NCEs
- Discovery of new natural products as anticancer and neuroprotective leads
- Development of National repository of secondary metabolites
- Development and standardization of herbal formulations

Department of Medicinal Chemistry

- Design and synthesis of target compounds: thiazoles, thiophenes, benzimidazoles as anti-inflammatory, anticancer and anti-diabetic agents
- Synthesis of neuroprotective molecules and their pharmacokinetics and pharmacodynamic studies
- Computer aided drug designing and study of Structure activity relationship
- Design and synthesis of target compounds as anticancer and DPP-IV inhibitor agents
- Ionic liquid mediated C-C and C=C bond forming reactions
- Synthesis of Bax activating molecules to drag cancerous cells towards apoptosis

Department of Pharmaceutical Analysis

- Analytical and bioanalytical method development and validation using traditional and Quality by Design (QbD) approaches
- Use of micro-extraction techniques in simultaneous determination of drugs
- Pharmacokinetic studies of drugs and metabolites
- Impurity profiling of drug substances
- Forced degradation studies and characterization of degradation products
- Pre-formulation (physicochemical parameters & excipient compatibility) studies
- Secondary metabolite profiling of herbal products
Department of Pharmacology and Toxicology

- Development of immunosuppressive human xenograft mice model
- Neuroprotection against cerebral ischemia, traumatic brain injury, Alzheimer’s disease, stress disorders and multiple sclerosis
- Pharmacological screening of synthetic and herbal products for antidiabetic, anticancer, antiulcer and anti-inflammatory activity
- Behavioural studies on learning & memory, depression and anxiety
- Pharmacokinetics and Pharmacodynamics and bioavailability studies of herbal drugs
- Absorption Digestion Metabolism Excretion (ADME) and toxicological studies of herbal and chemical entities
- *In-vitro* and *in-vivo* correlation

Department of Medical Devices

- Research on osteoconductive coating materials for bone tissue engineering
- Studies on anti-proliferative and antithrombotic coatings for polymeric and bare metal stents
- Development of polymer based implants for peripheral nerve regeneration
- Development of matrix for biosensor
- Surface modification of nanomaterials for biomedical applications
- Fabrication of artificial cornea and contact lens with newer approach
- Synthesis of nanoparticles for diagnostics and therapeutic applications
- Chemical modification of polymers for thrombo-resistive blood bags and catheters
- Development of microbe resistant polymer for hospital beds

National Centre for Medical Devices

Medical device industry is multi-product industry with multipurpose use. India’s medical device market is currently the fourth largest market in Asia with 700 medical device makers, and ranks among the top 20 in the world. The Indian medical device and equipment market is expected to grow $ 7.8 billion by 2016, at a CAGR of 15.5 per cent. The Indian medical devices industry forms a very small part of the total manufacturing industry accounting for only 0.2 per cent of all certified facilities. Due pioneering efforts of NIPER-Gn, the India’s first cutting edge interdisciplinary department has been established in 2012. The main goal of this department is to combine the pharmacy aspects with engineering to produce indigenous products and innovations, in which India mainly depend on western outfit. It explores huge job and research opportunities in India, since we are importing 90% of devices from other countries.

CONFERENCES/WORKSHOPS/SEMINARS ORGANIZED


HONOURS/AWARDS

- Best Poster Award: Bhavik Kansara, Anita Mahapatra, Y. Venkat Raju, Lakshmi S. Glucose uptake activation in muscle cell line (C2C12) by *Cassia auriculata*. National conference on Herbal drugs: opportunities and challenges 5-7 Nov, 2014

PUBLICATIONS/PRESENTATIONS/PATENTS

Patents filed
3. Anita Mahapatra, Neelam Chauhan, et al. Synthesis of 1,4- naphthoquinone analogues as potential agents for antidiabetic and other autoimmune diseases, Provisional Indian Patent, June 2014.

Publications

- Bhatt D, Chauhan N, Sharma A, Dhawan D, Bhatt R, Phatak S and Padh H. Plasma glucose concentration as a phenotypic


**PLACEMENT ACTIVITIES**

- To provide placement to students at reputed Pharma companies, a placement Cell (including the faculty members as well as the students of NIPER-A) has been created which is responsible for publishing a placement brochure and sending it to various Pharma companies.

- Various companies have been visiting our organization for Campus Interviews.

- For the present 2013-2015 Batch, placement activity has already been initiated and so far 4 companies have requested students brief profile for initial screening at their level. This activity is expected to pick up momentum in coming months.

**For 2012-2014 Batch:**

For campus recruitment total 15 companies contacted placement cell for placement related activities for different stream of students. Some of them visited us while remaining called students at their premises for further interviews and screening. Some of the companies which contacted us for placement includes Troikaa Pharmaceuticals Ltd, Indigene Pharma, Macleods pharma , Zydus Cadila, oxygen, Envision scientifc, RELYSYS, S3V- vascular technologies, Alembic Pharmaceutical Ltd, Piramal discovery, Intas Biopharma, Amneal Pharma, Naticon Inc, Sun pharma etc. Out of total 52 students, 46 students opted for placement, in which 14 students were placed in campus, while 24 students were placed post submission of thesis. The pay package offered by different companies ranged in between 3.25- 1.8 lakhs Per annum. As on date all the students of 2012-2014 batch have got placements in different companies except few students who have opted for higher studies.

<table>
<thead>
<tr>
<th>Stream</th>
<th>Total No of student</th>
<th>Opted for placement</th>
<th>IN Campus</th>
<th>Off Campus</th>
<th>Total Placement</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE</td>
<td>12</td>
<td>11</td>
<td>6</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>MCD</td>
<td>5</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>NP</td>
<td>9</td>
<td>9</td>
<td>0</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>MD</td>
<td>5</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>BT</td>
<td>10</td>
<td>8</td>
<td>3</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>PC</td>
<td>6</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PA</td>
<td>5</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td>52</td>
<td>46</td>
<td>14</td>
<td>10</td>
<td>24</td>
</tr>
</tbody>
</table>
NIPER-KOLKATA

The National Institute of Pharmaceutical Education & Research-Kolkata (NIPER-Kolkata) was established as an Institute of National Importance by the Government of India through Act of Parliament (NIPER Act 1998 & NIPER amendment Act 2007). The Institute is presently housed at the Indian Institute of Chemical Biology (IICB) which is the Mentor Institute – a premier Institute of the Council of Scientific & Industrial Research (CSIR), India.

Objectives: The main objectives of NIPER-Kolkata are:

- To tone up the level of pharmaceutical education and research.
- To produce leaders in the field and provide opportunities for training of future teachers and research scientists for the industry and the profession.
- To be a centre for innovation in pharmaceutical sciences and technology.
- To encourage research and studies in new and emerging areas like discovery of pharmacologically active molecules, cellular and molecular biology, immunology and immunodiagnostics, recombinant DNA technology and monoclonal antibody technology, novel drug delivery systems, chemical and biochemical process technology, etc.
- To provide scientific basis for traditional medicines.

NIPER-Kolkata was inaugurated on November 05, 2007. Since its inception the Institute has been conducting Masters' level programmes in three different disciplines, Medicinal Chemistry, Natural Products and Pharmacoinformatics, leading to M.S. (Pharm.) degree.

Admission of students in 2014-2015

Counselling for admission of students took place in NIPER-Mohali in the month of July, 2014.

<table>
<thead>
<tr>
<th>Discipline</th>
<th>No. of students</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicinal Chemistry</td>
<td>16</td>
</tr>
<tr>
<td>Natural Products</td>
<td>12</td>
</tr>
<tr>
<td>Pharmacoinformatics</td>
<td>14</td>
</tr>
</tbody>
</table>

The orientation programme for the students took place on 4th August, 2014 and the first year first semester classes commenced from 5th August, 2014.

Academic Programme

- Twenty nine Masters Students of the first batch who graduated in June, 2009 received their M.S. (Pharm.) degree scrolls in the first convocation held on 11th June, 2010. Thirty two Masters Students of the second batch who graduated in June, 2010 and the third batch of 40 students who graduated in June, 2011 received their degree scrolls in the second convocation held on 18th May, 2012.
- The fourth batch of 49 students, who graduated in June, 2012 and the fifth batch of 47 students, who graduated in June, 2013 received their degree scrolls in the third convocation held on 25th October, 2013.
- The sixth batch of 37 students graduated in June, 2014.
- The seventh batch of 49 students is doing their 3rd semester and will complete their course in June, 2015.
- The eighth batch of 42 students is doing their 1st semester.
- A total of 500 books have been purchased by NIPER-Kolkata. The Institute subscribes for SciFinder.

Placement activities:

- Most of the students of the first six batches have been absorbed in the Industries, Colleges and Research institutes. A number of students are pursuing higher studies within the country as well as abroad. Placement was achieved for these students according to their options for employment in companies as well as in centres for teaching and higher studies.
- The placement activities for the seventh batch of students have been initiated and the placement brochure has already been brought out.

Events & activities:

a) A six week workshop was conducted for the second year students by British Council to improve their language skill.

b) Each second year student is allowed to attend one scientific conference.

c) A popular lecture on “Earthquake, Tsunami and preparedness” was delivered by Prof. (Dr.) Sugata Hazra, School of oceanographic studies, Jadavpur University, Kolkata-700032 on 19th September, 2014.

Swachh Bharat Abhiyan (Clean India Mission)

A program was initiated on 2nd October, 2014 at the Mentor Institute jointly by CSIR-IICH and NIPER-Kolkata to observe “Swachh Bharat Abhiyan (Clean India Mission)”.

The faculty:

The faculty involved in teaching the M.S. (Pharm.) courses consists of visiting Teachers from Calcutta University, Jadavpur University, West Bengal State University at Barasat and West Bengal University of Technology and Scientists from Bose Institute, Central Research Institute of Ayurveda, Indian Association for the Cultivation of Science, Indian Institute of Chemical Biology, Institute of Post Graduate Medical Education & Research, and Saha Institute of Nuclear Physics and industries like TCG Life Sciences.
Staff and Officers:
NIPER-Kolkata does not have any permanent staff and officers. Retired persons have been appointed on contract basis for running the academic programme, administration, examination activities, and placement of students, students’ hostel and other activities.

Library: A total number of 922 books are available for NIPER students. All scientific journals are available online to NIPER students from the Mentor Institute library.

<table>
<thead>
<tr>
<th>Courses</th>
<th>No. of students in 6th Batch (2013-15)</th>
<th>No. of Students in 7th Batch (2014-16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M.S. (Pharm.) Medicinal Chemistry</td>
<td>18</td>
<td>19</td>
</tr>
<tr>
<td>M.S. (Pharm.) Pharmaceutics</td>
<td>15</td>
<td>13</td>
</tr>
<tr>
<td>M.S. (Pharm.) Pharmacology &amp; Toxicology</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>39</td>
<td>38</td>
</tr>
</tbody>
</table>

Events:
- **6th NIPER (RBL)-CDRI Symposium (20th - 22nd February, 2014):**
  Indian pharma industry has to focus more on R&D, so as to enable India to maintain its status in the world pharma market and move ahead to become a global leader. Keeping this in view NIPER, Raebareli initiated the series of NIPER (RBL) - CSIR-CDRI Symposium to groom its students with core competencies, ethics and values to evolve in rapidly changing scenario of the Pharma sector. This year the 6th symposium of the series was held on the topic “Current Scenario in Drug Discovery & Development” during February 20th-22nd 2014 in the new campus of CSIR – Central Drug Research Institute, Lucknow to enable the students in updating their knowledge and awareness about recent scientific developments.
  The inaugural address was delivered by Prof. Y. K Gupta, Head, Department of Pharmacology, AIIMS, New Delhi on the topic ‘Clinical Research in India”. The inaugural function was presided over by Prof. B. N. Dhawan, Ex Director, CSIR-CDRI, Lucknow. About 85 posters were presented and the session was spread over two days where the students displayed their project based presentations. The best and the second best posters were suitably awarded.
- **Second Convocation (7th April, 2014):**
  The second convocation of NIPER, Raebareli was held on April 7, 2014 in CSIR-CDRI, Lucknow. The occasion was graced by the eminent Scientist Professor Goverdhan Mehta, Padma Shri, FRs, FNA, FASc, FNASc, FTWAS, National Research Professor, School of Chemistry, University of Hyderabad, as the Chief Guest and Ms. Aradhana Johri, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India presided over the function. Academic excellence of students was rewarded with Gold & Silver medals. Chief Guest Professor Goverdhan Mehta delivered the key note address and Ms. Aradhana Johri delivered an inspiring speech with emphasis on proper employment of the pass out students.
  A total of 89 students from three batches (2009-11, 2010-12 and 2011-13), received their degrees with great pride and honour. from Ms. Aradhana Johri, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers,
Govt. of India and Chairperson, Steering Committee, NIPER – Raebareli.

The Chief Guest Professor Goverdhan Mehta presented Gold & Silver Medals to the thirteen academic toppers from three batches (2009-11, 2010-12 and 2011-13).

- **PHARMACY DAY (27th SEPTEMBER, 2014):**
  Like previous years Rx Pharmacy Day, 2014 was successfully organized at NIPER, Raebareli on 27th September, 2014 as an annual event. On this occasion a very informative lecture was delivered by Dr. Raja Roy (Professor, CBMR, Lucknow) on the topic “Use of NMR in Clinical Studies”. The second lecture was delivered by Dr. Rishi Pal Astt. Professor, Department of Pharmacology, KGMU, Lucknow on the topic “Drug discovery & Development”, which was lively, interactive and full of motivation for everyone.

- **SWACHH BHARAT ABHIYAN (2nd OCTOBER, 2014):**
  ‘Swachhta Abhiyan’ was organised in NIPER, Raebareli on 2nd October, 2014 taking ahead the legacy and responding to the Nation’s call by the Hon’ble Prime Minister, Mr. Narendra Modi followed by the communication of the same by Madam Smriti Irani, Minister of Human Resource Development, Government of India.

  The campaign started with administering of pledge by Project Director to all the faculty & staff members and students to carry out the cleanliness drive and contribute voluntarily towards cleaning of institute campus and neighborhood.

- **ANNUAL DAY CELEBRATION (14th NOVEMBER, 2014):**
  The 6th Annual Day celebration of NIPER, Raebareli was held on 14th November, 2014. The chief guest Dr. K.C. Gupta, Ex-Director, CSIR-Indian Institute of Toxicology Research (IITR), Lucknow delivered the very innovative lecture titled “Enhanced Targeted Anticancer Activity of Doxorubicin Nanoparticle in Ehrlich’s Ascites Tumors”. The function was attended by eminent scientists, technologists and academia. Students were also given awards for their participation in various extracurricular activities held in the campus during the year.

- **PUBLICATIONS:**
  The students were ably inspired for scientific publication and presentation to bring NIPER, Raebareli on scientific research platform which led to publications in reputed journals with inputs from project work and presentation of papers in conferences. A total of 41 publications in research Journal and conferences were published and presented.
Laboratory at NIPER (RBL)

(L-R) Dr. Achint Jain, Lecturer, NIPER (RBL); Dr. P. K. Shukla, Project Director, NIPER (RBL); Dr. K. C. Gupta, Ex-Director, IITR, Lucknow; Dr. S. K. Puri, Director, CSIR-CDRI, Lucknow with the winners of Annual Sports 2013-14 during 6th Annual Day Celebration held on 14th November, 2014.

NIPER HAJIPUR

NIPER Hajipur has been established to meet the dual objectives i.e. to inspire and provide opportunities for top class Pharma education to the youth of Bihar and the country on the one hand and to supply skilled manpower to our fast growing Pharma industry on the other. It is heartening to see the students reaching and crossing the every-increasing standards of excellence in their academic pursuits as well as in research projects. With a view to impart cutting-edge science related to the pharmaceutical industries and pharma-regulatory bodies’ requirements, NIPER Hajipur has started initially its inning with courses like Pharmacy Practice, Pharmaco-informatics and Biotechnology. A total of 36 students have been admitted this year, of which 15 are in Pharmacy Practice, 11 are in Pharmaco-informatics and 10 are in Biotechnology. Apart from Masters Program, 19 Ph. D. students have been admitted, of which 12 are in Biotechnology, 6 are in Pharmaco-informatics and 1 in Pharmacy Practice.

NIPER, HAJIPUR is undertaking applied and meaningful research in these areas. In coming years, NIPER, Hajipur is going to attain greater heights and would be a leading seat of learning for the modern pharmaceutical science.

The main objectives of the Institute:

- Nurture and promote quality and excellence in pharmaceutical education & research.
- Toning up the level of pharmaceutical education and research by training the future teachers, research scientists and managers for the industry and profession.
- Creation of National centers to cater to the needs of the pharmaceuticals industry and other research and teaching institutes.
- Collaboration with Indian industry to help it to meet global challenges.
- National / International collaborative research.
- Study of sociological aspects of drug use and abuse and rural pharmacy etc.
- Running programme in drug surveillance, community pharmacy and pharmaceutical management.

Departments

From the beginning NIPER Hajipur has been entrusted with the responsibility of teaching and research in the following three disciplines:

Biotechnology
Pharmacy Practice
Pharmaco-informatics

Intake of the students:

Numbers of M Pharm. / MS. Pharm. students admitted and passed during 2009 to 2016 are as follows:

<table>
<thead>
<tr>
<th>Year</th>
<th>Admitted</th>
<th>Passed</th>
<th>Left NIPER</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009-11</td>
<td>34</td>
<td>32</td>
<td>2</td>
</tr>
<tr>
<td>2010-12</td>
<td>42</td>
<td>40</td>
<td>2</td>
</tr>
<tr>
<td>2011-13</td>
<td>43</td>
<td>41</td>
<td>2</td>
</tr>
<tr>
<td>2012-14</td>
<td>21</td>
<td>19</td>
<td>-</td>
</tr>
<tr>
<td>2013-15</td>
<td>39</td>
<td></td>
<td>Continuing</td>
</tr>
<tr>
<td>2014-16</td>
<td>36</td>
<td></td>
<td>Continuing</td>
</tr>
</tbody>
</table>

Number of students admitted in Ph.D. programme:

<table>
<thead>
<tr>
<th>Year</th>
<th>Ph. D (Biotechnology)</th>
<th>Ph. D (Pharmaco-informatics)</th>
<th>Ph. D (Pharmacy Practice)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>3</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>2012</td>
<td>3</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>2013</td>
<td>3</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>2014</td>
<td>3</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>
National Institute of Pharmaceutical Education and Research (NIPER) is the first national level institute in Pharmaceutical sciences with a proclaimed objective of becoming a 'Center of Excellence' for Advanced Studies and Research in Pharmaceutical Sciences. The Government of India has declared NIPER as an 'Institute of National Importance'. NIPER, Guwahati was inaugurated on 16th September 2008 by the then Honorable Union Minister for Chemicals and Fertilizers and Steel, Shri Ram Vilas Paswan in the presence of several distinguished personals. The institute is completing 6 years of its establishment. The Central Plan outlay for 2012-13 for various projects, programmes and schemes and Central Assistance for State and Union Territory Plans has depicted that the expenditure earmarked for North Eastern Region (18.80 crore) is incurred from NIPER, Guwahati. The Government of Assam has provided approximately 89.0 acres of land for construction of new campus in Changsari, north of Guwahati city. The necessary formality to start the construction work has already been completed. Government Medical College and Hospital (GMCH) is the second largest hospital in India in respect of its bed strength and enjoys a prestigious status for its academic pursuits and patient care. It is also a tertiary care referral center for specialty and super specialty treatment. As a mentor institute, it is making all efforts to take NIPER to great heights. NIPER, Guwahati organized 1st Convocation on 6th September 2013 where degrees were awarded to the passed out students till the previous academic year since the first batch.

**Vision**

1. Enhancement of creativity, motivation, drives and professionalism.
2. To bring synergy between academics, R&D, Technology and Industries and exposure to such environment.
3. Bridging collaborations between pharmacy, biotechnology, information technology and prepare for meeting global challenges.
4. To prepare professionals to suit to the need of Pharmaceutical Industry.
6. Exposure for the students and scholars to high-tech areas such as drug discovery, pharmacogenomics, toxicogenomics, RNA and DNA technology, bioinformatics, drug design and molecular modeling, molecular biology and herbal research etc.,
7. Develop and practice learning for the professionals and training for teachers, researchers and regulators in the respective fields.
8. Create a world class institute for teaching and research in the field of Pharmaceutical sciences.

The NIPER has three Departments:

1. Pharmacology & Toxicology
2. Biotechnology
3. Pharmacy Practice

**Disciplines:**
The first batch of students was admitted in 2008. Besides catering to the various needs of pharmaceutical industry, the NIPER offers Masters degree in following 3 streams and Ph.D. degrees in 2 streams:

1. Pharmacology & Toxicology
2. Biotechnology
3. Pharmacy Practice

**Infrastructure:**
NIPER conducts regular education programmes for academia and industry in various disciplines and helps the Indian Pharmaceutical
Industry in solving their R&D related requirements. National Institute of Pharmaceuticals Education & Research has upgraded facilities for achieving the highest level of efficiency in imparting education and events. NIPER laboratories are equipped with modern equipment’s that are equivalent to other state-of-the-art laboratories in the World and students are utilizing facilities of mentor institute and others like IIT-Guwahati, State biotech hub, Gauhati university for those instruments which are not available in the institute.

Events and Activities:

NIPER, Guwahati encourages the students to participate actively in conferences, seminars, trainings and workshops. Students attended “National Seminar on Molecular Pathology of Cancer” on 10th January 2014 in Dr. B. Borooah Cancer Institute, Guwahati.

- Students attended ICPS 2014 held at SGRR ITS Dehradun, Uttarakhand.

- The students attended the “9th Annual Conference of Association of Oncologists of North East India” (AONEI), 2014 held on 1st and 2nd March 2014 in Guwahati. In the Paper presentation (Oral cum Poster) competition, students from NIPER, Guwahati were awarded the first and second prize for the papers “Evaluation of the anticancer and protective effects of morin hydrate in combination with cisplatin using peritoneal carcinomatosis models in mice” by Athira.K.V, Kasbe Prajapati, Mangala Lahkar, Ranadeep Gogoi and “Study of ras gene polymorphism in human multiple myeloma of Assam” by Nityanand Bolshette, Swathisree Karaggi, Vinayak Jamdade, Ranadeep Gogoi, Mangala Lahkar, Jina Bhattacharyy respectively.

- Further, students attended the “Academy of Clinical Experts (ACE)” meeting held in Mumbai on 26-27th July 2014. The Best Paper Award (Rs.50,000) was secured for “Toll like receptor expression pattern and polymorphism profiling in patients of multiple myeloma” by Nityanand Bolshette, Krishan Thakur, Ranadeep Gogoi, Mangala Lahkar, Jina Bhattacharyya of NIPER, Guwahati.

- Students also attended and presented paper in the first annual conference of the ‘Association of Pharmacy Teachers of India’ (APTI) Haryana state branch held at Kurukshetra University in Haryana on 22nd and 23rd August 2014. The theme of the conference was “Indian scenario of Pharmaceutical Education Challenges and Future Perspectives”.

- Twenty one students participated in the training program on “Basics of Good Clinical Practice”, organized by Clinical Development Services Agency (CDSA), an extramural unit of Translational Health Science & Technology Institute (THSTI), Department of Biotechnology, Ministry of Science & Technology, Govt. of India held at NEIGRIHMS, Shillong, Meghalaya on 28th and 29th March 2014 under the leadership of Prof.B.K.Bezbaruah, Project Director.

- A report on the brilliant achievements of Mr. Parveen Kumar, first batch Ph.D Scholar, NIPER, Guwahati was published in ‘Himachal Dushak’, a daily newspaper of Himachal Pradesh.
NIPER-Guwahati enthusiastically inaugurated the Swatch Bharat mission on October 2nd, 2014 and continuing their activities in maintaining, cleanliness and spreading the knowledge of the role of cleaning since October 2nd, 2014. Some of the Photographs taken during “Swachh Bharat Mission at NIPER-Guwahati” areas follows:

To commemorate the Birth anniversary of The Iron Man of India “Sardar Vallabhbhai Patel” “National Unity Day” was observed at NIPER-Guwahati on 31st October 2014.

Present status and future prospects:

NIPER, Guwahati students are coming up with timely publications of their research work. The students of the institute are highly motivated towards all facets of academics, research as well as their careers.

Amongst the passed out students of 2014, few are admitted in Ph.D programs in different national institutes, including NIPERs, IIT. Few students got absorbed in various pharmaceutical companies and consultancy firms, including TCS, Cognizant. The rest are establishing their careers in academics and industry.

Running a national institute under a mentor institute is itself a challenging task. However, the mentor institute, GMCH is putting its extra energy, devotion and motivation in establishing NIPER, Guwahati as a center of excellence. The management committee of NIPER, Guwahati is striving hard for the growth of the institute by developing more infrastructure and facilities and by providing more guidance in academics and orientation in research. It is hoped that the forthcoming year would unfold its unlimited achievements in every field.

Rashtriya Ekta Diwas at NIPER-Guwahati
NEW INITIATIVES

7.1 Cluster Development Programme for Pharma Sector” (CDP-PS)

7.2 New Initiatives Taken by National Pharmaceutical Pricing Authority (NPPA)

7.3 National Center for Research & Development in Bulk Drugs at National Institute of Pharmaceuticals Education & Research, Hyderabad

7.4 Collaborative TB and Kala Azar Research Project of NIPER, Mohali
CHAPTER – 7
NEW INITIATIVES

7.1 CLUSTER DEVELOPMENT PROGRAMME FOR PHARMA SECTOR (CDP-PS)

With a vision to catalyze and encourage quality, productivity and innovation in pharmaceutical sector and to enable the Indian pharmaceutical industry especially SMEs to play a leading role in a competitive global market, Hon’ble Minister of Chemicals and Fertilizers approved the introduction of Cluster Development Programme for Pharma Sector (CDP-PS) on 27.10.2014.

The CDP-PS is a Central Sector Scheme. The total size of the scheme is proposed as Rs.125 Crores for CDP-PS for 12th Five Year Plan.

2. The Scheme would be implemented on a Public Private Partnership (PPP) format through one time grant –in – aid to be released in various phases for creation of identified infrastructure and common facilities in the form of Common Facility Centers (CFC) to Special Purpose Vehicles (SPVs) set up for the purpose.

3. Assistance under the Scheme will be Rs. 20.00 Crore per cluster or 70% of the cost of the project, whichever is less for creation of common facilities. Some of the indicative activities under the Common facilities are:
   - Common Testing Facilities
   - TrainingCentre
   - EffluentTreatmentPlant
   - R&D Centres
   - CommonLogistics Centre

7.1.2 Setting up of Task Force on Enabling the Private Sector to lead the growth of Pharmaceutical Sector. A Task Force comprising representatives from Government Departments/Institutions and Industry Associations has been set up in the Department with the following Terms of Reference (ToRs):

(i) Identifying the challenges before the Indian Pharmaceutical Industry pertaining to various government departments and agencies.

(ii) Identifying ways to ensure better coordination among various Government Departments and Industry to facilitate the industry.

(iii) Identifying areas of duplication, if any, among different Government agencies and departments on issues relating to Pharmaceutical Industry including research.

(iv) Suggesting suitable changes in the administrative arrangements or administrative mandate of Government agencies and Departments to enable better and coordinated facilitation and support to the industry.

(v) Exploring the possibility of having a single window clearance type of facilitation for the industry for the required regulatory approvals.

(vi) Working out the mechanism for a regular and institutionalized forum for Government Industry partnership where the industry issues can be redressed periodically and in a time bound manner.

(vii) Exploring the possibility of linking the Indian Pharmaceutical Industry with various educational and research Institutions in the Government Sector like NIPERs, Research Institutes under Department of Health Research, Department of Biotechnology, Department of Science and Technology and others.

The Task Force to submit its report in three months.

7.1.3 Setting up of Task Force to identify issues relating to the promotion of domestic production of high end Medical Devices and Pharmaceutical Manufacturing Equipment in the Country. A Task Force comprising representatives from Government Departments/Institutions and Industry Associations has been set up in the Department with the following Terms of Reference (ToRs):

(i) Ascertaining the present status and share of domestic production and imports in different categories of medical devices and equipments used in the manufacture of Pharmaceuticals.

(ii) The impediments that exist in making India self-reliant in domestic production of medical devices and equipments used in manufacture of pharmaceuticals.

(iii) The steps necessary for promotion of domestic production of high end medical devices and pharmaceutical manufacturing equipments.

The Task Force will submit its findings in three (3) months.

7.1.4 Setting up of Task Force for development of manufacturing capabilities in each medical vertical in Pharmaceutical production. A Task Force comprising representatives from Government Departments/Institutions and Industry Associations has been set up in the Department with the following Terms of Reference (ToRs):

(i) Identifying focus areas for development of manufacturing capabilities in each medical vertical keeping in mind the specificities of each medical discipline.

(ii) Identifying the gaps in domestic manufacturing in these verticals and suggesting ways to overcome these.

(iii) Identifying the issues and support required from different government agencies and departments for achieving the manufacturing capabilities and filling the gap areas, if any, in each medical vertical.

(iv) Any other related issues which may come up during the Task Force meetings and which the Task Force may also like to include as a Term of Reference.
The Task Force will submit its findings in three (3) months

7.2 NEW INITIATIVES TAKEN BY NATIONAL PHARMACEUTICAL PRICING AUTHORITY (NPPA)

(I) Integrated Pharmaceutical Database Management System (IPDMS)

With the help of NIC, a web-enabled application called Integrated Pharmaceutical Database Management System (IPDMS) is being developed to facilitate online submission Form-II, III and V of DPCO, 2013 by all drug manufacturers. The objective is to fix/revise prices of scheduled formulations/new drugs on the basis of data provided by manufacturers themselves; monitor availability of Scheduled Formulations in every part of the country; regulate and monitor the price rise of Scheduled and non-Scheduled Formulations; enforce notified price; detect price rise violation; and recover overcharged amount along with interest from the company. Further, an ICT (Information Communication & Technology) enabled workflow system will be developed to facilitate all its functions as stated above.

The IPDMS would (i) facilitate Online submission of all DPCO forms by the companies at regular intervals; (ii) creation of uniform structure of data-base for all the companies and to build good authentic database of medicine market prices and other details; (iii) facilitate processing of forms at NPPA level with a pre-defined workflow in transparent manner; (iv) generating a large number of analytics and reports on database for supporting decision making; and (v) facilitate public awareness on availability of medicines and market price comparison on database through different information dissemination methods.

After getting security clearance from NIC, the registration process was launched on 18.09.2014. Till 13.02.2015, 351 pharma companies have already registered and 449 pharma companies are in the process of registration with the online system. So far 21,571 products have been registered and another 8053 are under process. This system would be beneficial to all stake holders, i.e., companies and a non-discretionary objective mechanism for proceeding against overcharging. It will bring about efficiency in the company. Further, an ICT (Information Communication & Technology) enabled workflow system will be developed to facilitate all its functions as stated above.

After getting security clearance from NIC, the registration process was launched on 18.09.2014. Till 13.02.2015, 351 pharma companies have already registered and 449 pharma companies are in the process of registration with the online system. So far 21,571 products have been registered and another 8053 are under process. This system would be beneficial to all stake holders, i.e., companies and a non-discretionary objective mechanism for proceeding against overcharging. It will bring about efficiency in the company. Further, an ICT (Information Communication & Technology) enabled workflow system will be developed to facilitate all its functions as stated above.

(ii) Pharma Jan Samadhan

Pharma Jan Samadhan (PJS) is a web enabled system developed by National Pharmaceutical Pricing Authority (NPPA) with the assistance of National Informatics Centre (NIC). The primary objective of PJS is to put in place a speedy and effective complaint redressal system with respect to availability and price of medicine. PJS serves as a robust e-governance tool for protection of consumer interest through effective implementation of the Drugs (Price Control) Order 2013. PJS replaces the earlier online Complaint Submission and Redressal System (CSRS) that was developed with respect to DPCO 1995.

Under PJS, Consumers, NGOs, dealers and enforcing agencies can register complaints related to:

(i) Overpricing of Medicine
(ii) Non-availability or Shortage of any medicine
(iii) Sale of New Medicine without prior price approval of NPPA
(iv) Refusal of supply or sale of any medicine without good and sufficient reason

Consequent upon registration of a complaint by the complainant, the same reaches the designated officer of NPPA who verifies the complaint and initiates appropriate action for resolving it in a time bound manner.

(iii) Consumer Awareness and Publicity Through Print, Electronic and other media:

Plan Scheme of Consumer Awareness and Publicity through Print, Electronic and Other Media is an on-going joint publicity campaign programme of the NPPA and Department of Consumer Affairs (DCA) on a 50:50 cost sharing basis. The modus operandi of the Scheme are:

i) Print Media - Issue of Advertisement through National/Regional newspapers on bi-monthly basis as per media plan of DAVP to create public awareness.

ii) Publicity through Mobile Outdoor Media covering through Outer Panels of EMU/MEMU/DMU Trains moving in and out in various States for spreading the NPPA message- Installation of panels creating general awareness while purchasing medicine.

iii) Display of Vinyl Boards/Hoarding in Govt. and Pvt. Hospitals - Permanent installation of vinyl boards in hospitals about the availability of medicines at reasonable price.

The Department of Consumer Affairs, which had earlier regretted to part finance their share for the above two components, has now agreed to the joint publicity campaign on 50:50 cost sharing basis. An amount of Rs. 2.0 crore is earmarked under Plan Head for the year 2014-15 for this purpose. NPPA has already published one advertisement in various national and regional newspapers on 08.1.2015. Another advertisement is planned to be released by March, 2015.

(iv) Compendium of Notified Ceiling Prices of Scheduled Drugs under DPCO 2013.

NPPA has prepared Compendium of Notified Ceiling Prices of Scheduled Drugs under DPCO 2013 as on 31.01.2015, which is available on NPPA’s website. Printed copies are being distributed to State Drug Controllers and other stakeholders for information dissemination/enforcement.

(v) Consultation with Stakeholders

NPPA has also initiated detailed consultations with stakeholders including civil society organizations, public health experts, State
Drug Controllers and representatives of Pharma industry & trade. Details of consultations are given below:

<table>
<thead>
<tr>
<th>Sl No.</th>
<th>Consultation with</th>
<th>Held on</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.</td>
<td>State Drug Controllers at Delhi</td>
<td>3.9.2014</td>
</tr>
<tr>
<td>3.</td>
<td>Trade Associations and representatives of FICCI and CII at Delhi.</td>
<td>17.9.2014</td>
</tr>
<tr>
<td>4.</td>
<td>Pharma Industry Associations at Delhi</td>
<td>30.9.2014</td>
</tr>
<tr>
<td>5.</td>
<td>Regional Meeting with SDCs at Delhi</td>
<td>29.12.2014</td>
</tr>
<tr>
<td>6.</td>
<td>Workshop on affordable medicines for all at Bhubaneswar</td>
<td>22.1.2015</td>
</tr>
<tr>
<td>7.</td>
<td>Meeting with officers of Maharashtra Drug Controller, DOP, Public Health Experts, reps of AIDAN Network regarding Pharmaceutical Pricing at Nagpur.</td>
<td>1.2.2015</td>
</tr>
</tbody>
</table>

7.3 NATIONAL CENTER FOR RESEARCH & DEVELOPMENT IN BULK DRUG (NCRDBD)

A scheme on National Centre for Research and Development in Bulk Drug (NCRDBD) at NIPER, Hyderabad has been approved by the SFC. The NCRDBD is proposed to become an innovation R&D provider in the field of bulk drugs in offering competitive and eco-friendly technologies in specified areas of products and processes. This centre will also provide centralized research facilities and technologies, analytical facilities and consulting services for process improvement and optimization. Special emphasis is given to empowerment of Micro Small & Medium Enterprises (MSME) sector.

7.4 COLLABORATIVE TB AND KALA AZAR RESEARCH PROJECT OF NIPER, MOHALI

Target specific New Drug Discovery for Anti Tubercular Agents is an interdepartmental collaborative project which aims at discovering high affinity ligands that can be developed into efficacious and less toxic drugs against TB. Among other things, this proposal would use technique of post genomic era in identifying the role of specific gene in causing and counteracting diseases. Phase I of the project has duration of 3 years and Phase II of 2 years. The total cost of the project is Rs. 4,88,00,000/-. The Kala Azar Project aims at discovering new drugs to fight against Kala-Azar. The focus of the Project is to putting together a concerted effort to discover high affinity ligands that can be developed into efficacious and less toxic drugs against Kala Azar. It also consists of two phases. Phase I of the project has duration of 3 years and phase II of 2 years. The cost of project is Rs. 4,88,00,000/-. The fund is to be released in four equal instalments of Rs.1.22 crore for each of these projects. The release of first instalment of Rs. 1.22 crore for both the projects was made in 2014. Based on the demand from the implementation agency, additional releases have been made during current fiscal year as well.
Chapter 8
IMPLEMENTATION OF RAJBHASHA
CHAPTER 8
IMPLEMENTATION OF RAJBHASHA

Hindi Prayog Protsahan Pakhwara

Hindi Prayog Protsahan Pakhwara was observed in the Department from 13th to 27th September, 2014 with the objective to encourage the officers and employees of the Department to progressively increase the use of Hindi in their official work and also to help the Department to create an atmosphere conducive to use of Hindi.

In addition to the message issued by the Secretary (Pharma) requesting, inter-alia, all the officers/employees to make a commitment to use of Hindi, various Hindi competitions were held during the Pakhwara and winners were awarded cash prizes.

Review of the status of use of Hindi in the offices under the Department

Periodical review of the use of Hindi in the offices under the Department was made through the quarterly reports on progressive use of Hindi received from them in compliance with the targets set in the Annual Programme for use of Hindi for the year 2014-15.

Official Language inspection of the sections in the Department of Pharmaceuticals to increase the use of official language in official work

To assess the status of the use of Hindi in the Department, OL inspection of 7 sections was conducted during the year 2014-15. Letters were written to the sections to take measures to remove the deficiencies found during the inspection.
Chapter 9

GENERAL ADMINISTRATION
9.1 Organisational Set Up
CHAPTER – 9
GENERAL ADMINISTRATION

9.1 ORGANISATIONAL SET UP OF THE DEPARTMENT

The main activities of the Department are policy making, sectoral planning promotion and Development of Pharmaceutical industries. The administrative and managerial control of the public sector undertakings engaged in the manufacture of various, pharmaceutical items and some other organization is a major function of the Department.

The Department is headed by Secretary to the Government of India who is assisted by two Joint Secretaries and one Economic Adviser.

There is an attached office namely “National Pharmaceutical Pricing Authority” which looks after Price fixation/revision of pharmaceuticals and other related matters. It also monitors the prices of decontrolled drugs and formulation and oversees the implementation of the provisions of the Drug(Price Control) Order.

Employment of scheduled castes / scheduled tribes / physically handicapped in the main secretariat of the department of pharmaceuticals

The status of employment of Scheduled Castes / Scheduled Tribes / Physically handicapped in the main Secretariat of the Department of Pharmaceuticals, as on 31.12.2014 is as under:-

<table>
<thead>
<tr>
<th>Group</th>
<th>Total No. Of Posts</th>
<th>Scheduled Castes</th>
<th>Scheduled Tribes</th>
<th>Other Backward Castes</th>
<th>Physically Handicapped</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>30</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>B</td>
<td>48</td>
<td>4</td>
<td>-</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>C</td>
<td>25</td>
<td>8</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>103</td>
<td>14</td>
<td>4</td>
<td>3</td>
<td>-</td>
</tr>
</tbody>
</table>

Officers in Group A include officers belonging to Central Secretariat Service besides officers on deputation from All India Services, Central Services and other Departments/ Undertakings. Appointment to posts in Group B and C is mostly done on the basis of nominations made by the Department of Personnel & Training.

The Department also monitors the progress of filling up of the posts reserved for the members of Scheduled Castes, Scheduled Tribes and other Backward Classes in the Public Sector Undertaking under the administration control of the Department.
Chapter 10

CITIZEN CENTRIC GOVERNANCE
10.1 Our Vision
10.2 Our Mission
10.3 Our Clients
10.4 Our Commitment
10.5 Our Services
10.6 Our Activities
10.7 RTI-2005
10.8 CPGRAMS
CHAPTER – 10
CITIZEN CENTRIC GOVERNANCE

10.1 OUR VISION:
Based on the mandate given to the Department of Pharmaceuticals through the allocated functions a vision has been fixed in concurrence with the Cabinet Secretariat, which is as follows:

“India: The largest global provider of quality medicines at reasonable prices.”

10.2 OUR MISSION:
1. Ensure availability of quality drugs at reasonable prices as per the Pharma Policy.
2. Development of Pharma Infrastructure and Innovative Development in Pharma Sector including through PPP.
3. Promote Pharma Brand India.
5. To establish NIPERs as nationally and internationally recognized brand in the field of education and research of pharmaceutical sciences for the benefit of human kind.

10.3 OUR CLIENTS
- Citizens of India
- Pharmaceuticals Industry including Small and Medium Enterprises
- Pharmaceuticals companies seeking relief under DPCOs
- NPPA/ CPSUs/NIPERs

10.4 OUR COMMITMENT
We are committed to provide impartial, sympathetic and prompt services to the public in matters relating to the pharmaceuticals industries.

Our commitment is to take prompt steps to provide quick redressal of the grievances of our personnel and public at large.

Our commitment is to formulate policies and initiate consultations with all Industry Associations/stakeholders and to amend them whenever so required.

10.5 OUR SERVICES
We formulate and implement policies relating to drugs and pharmaceuticals, dyestuff and dye intermediates.

10.6 OUR ACTIVITIES
The key activities of the Department focus on:
1. Ensure availability of drugs at reasonable prices as per provisions of the Drug Prices Control Order 2013
2. Ensure proper functioning of the Central Pharma Undertakings in control of the Department.
3. Project Based Support and Revival Schemes for CPSUs
4. Ensure proper management of M Pharma and Ph.D. programs in NIPERs
5. Develop Human Resources, Infrastructure for Pharma R&D and Industry including Public-Private-Partnerships (PPP)
6. Formulate Scheme/ Project for promoting Pharma Brand India
7. Formulate Scheme/ Project for promoting environmentally sustainable development of Pharmaceutical Industry
8. Formulation of Annual Plan, Budget and Monitoring of Budget Expenditure

The Citizen Charter of the Department has been placed on the website of the Department.

10.7 RIGHT TO INFORMATION ACT 2005
As per the provisions of the RTI Act 2005, all the relevant information relating to Department of Pharmaceuticals has been available on the website in a manner, which is easily accessible and comprehensible to the public.

Central Public Information Officers and Appellate Authorities have been nominated in the department to provide information to the public.

10.8 CPGRAMS (CENTRALIZED PUBLIC GRIEVANCES REDRESS AND MONITORING SYSTEM)
Public Grievances received offline and through CPGRAMS are monitored and disposed off regularly.
INFORMATION AND COMMUNICATION TECHNOLOGY

11.1 Local Area Network (LAN)
11.2 IT Infrastructure
11.3 Website
11.4 Video Conferencing
11.5 File Tracking System
11.6 E-Governance
11.7 Training
CHAPTER – 11
INFORMATION AND COMMUNICATION TECHNOLOGY

Under Digital India program, Department of Pharmaceuticals has taken sincere initiatives towards adoption of E-Governance to deliver information and services online. This had led to benefits in terms of transparency, easy accessibility of services, improvement of internal processes and decision support system.

An IT based Computer Centre, set up by National Informatics Centre (NIC) is operational in the Department and is equipped with latest Servers, Client machines for providing various IT related services to the Department. NIC is delivering valuable key services like Technical consultancy, Networking, application development and implementation, Internet & E-Mail, database management and Training. With NIC’s presence and expertise, Department had been instrumental in steering following IT/E-governance initiatives.

11.1 LOCAL AREA NETWORK (LAN)

All work places in the department are connected on Local Area Network (LAN) which is upgraded to make it IPv6 compliant is managed by the National Informatics Centre (NIC) to provide round the clock facilities for E-mail, intranet / internet and database access operations. The IPv6 compliant ICT hardware is available to all officers/ divisions/ sections for the use at their desktop.

11.2 INFRASTRUCTURE

Department of Pharmaceuticals in close association with NIC has focused on building up the IT infrastructure within the Ministry with the following objectives:

- Improve workflow, work management and monitoring.
- Assist in analyzing, decision making and scheduling through Management Information Systems (MIS).
- Storage of data, analysis and handling of databases.
- Provide Graphical User Interface (GUI) based environment.
- LAN for sharing the resources among users.
- Simplify dissemination of information to public and make it interactive.
- Train all personnel in making most of this technology.

11.3 WEBSITE AND SOCIAL MEDIA

As Website is an electronic medium to provide information and enhance government citizen interaction, a Web Site in English and in Hindi has been launched by the Department (http://pharmaceuticals.gov.in) and is hosted at NIC to ensure maximum reach of information and services to the citizens. It provides details of organizational set up of the department, its functions, subordinate offices, policies, publications, statistical data/information on functional parameters. Steps are being taken to redesign the website to make it more vibrant and interactive.

Website for Jan Aushadhi Scheme of the Department (http://janaushadhi.gov.in) provides details of the scheme, list of generic medicines (unbranded) which are being dispensed through the Jan Aushadhi Stores (JAS) being setup in various districts of India. Website is revamped to facilitate the visitors to know the locations of the JAS already opened. It also provides comparative prices of Generic Medicines sold at Jan Aushadhi Stores and Branded Products.

Social media had enormous potential to reach people. To improve the quality of Government decision, policy making and create awareness, Dept. has created Facebook and Twitter accounts. Various posts to create awareness regarding generic medicines, Educational and Research institutes NIPERs, etc. is posted on Facebook and twitter pages of Department.

11.4 VIDEO CONFERENCING

Video Conferencing facility is operational for Joint Secretary and above level Officers. PSUs and Educational Institutes (NIPERs) have also installed the Video Conferencing facility. VC facility enables Department to interact with PSUs and NIPER frequently to monitor their performance and communicate the decisions. Executive Video Conferencing System (EVCS) is also installed at Secretary Desk to connect to Cabinet Secretary and Secretaries of other Ministries/Departments.

11.5 FILE TRACKING SYSTEM

Department has implemented a web based File Tracking system (FTS) to keep record of its receipts being received at various locations in the department and to maintain a consistent watch over the movement of various important Files and Receipts at different levels in the process of decision-making. The system is used as a tool to curb down pendency at all levels in the Department.

11.6 E-GOVERNANCE

Taking advantage of latest ICT enabled tools, Department of Pharmaceuticals with the support of NIC has taken sincere initiatives towards adoption of best practices. Various applications have been developed and implemented by NIC to strengthen, monitor and decision making and high availability of right information at right time.

- Aadhaar enabled Biometrics Attendance System (AEBAS)
- Biometrics Attendance System records attendance of all employees (Permanent and Casual) of Department. The Dept. of Pharmaceuticals has implemented AEBAS in the first phase and 17 finger reader devices are installed at offices of JS & above level officers and at all sections. Tablet devices are also installed at all gates of Bhawans to facilitate officials/staff to mark the attendance.119 employees are registered and are marking the attendance regularly. Monthly register is generated for monitoring of attendance.
• SPARROW- Smart Performance Appraisal Report Recording online Window (SPARROW) application which allows Online submission of APAR and processing of IAS officers is implemented successfully.

• Court Cases Monitoring System – This system is repository of all court cases of Department. It also keeps the track of forthcoming Hearing dates of Cases and basic details of the case. It facilitates officials to generate useful reports.

• Online RTI-MIS – To dispose off and monitor RTI applications efficiently, Dept. has taken initiative to use Online RTI-MIS. Necessary training was imparted to concerned officials/staff to implement RTI-MIS successfully.

• CompDDO- CompDDO package implemented for processing salary of officials was upgraded to version 4.0 with additional features. This enables salary distribution through E-payment.

• Centralized Public Grievance Redress Monitoring System (CPGRAMS): CPGRAMS is implemented in the Department and all the attached office to address Public grievances received online with minimum delay.

• E-publishing of Tenders – E-publishing of tenders is implemented by uploading tenders on Central Public Procurement Portal. It has improved the accessibility of tenders.

• Other e-Governance applications like RTI Request & Appeal Management Information System and Result Framework Management System are functional in the Department to facilitate various sections.

To enhance e-Governance further following initiatives has been taken up.

• E-Office is a standard product presently consists of e-File, e-Leave, e-Tour, Knowledge Management System (KMS), Personnel Information Management System (PIMS), Collaboration& Messaging Service (CAMS) and is aimed at increasing the usage of work flow and rule based file routing, quick search and retrieval of files and office orders, digital signatures for authentication, forms and reporting components. Implementation of e-Office reduces duplicity of work, increases transparency and efficiency and reduces paper work.

• Parliament Questions and Assurances System – Repository of Parliament Questions and reminder system of Assurances is being developed to facilitate Officials to keep record of all answered question and pending assurances.

• Visitor Management System - eVisitor System is a web based solution for Visitor Management. This facilitates citizens for online registration of requests for their visit and approval is given to authenticated visitors and gate pass is issued.

11.7 TRAINING

NIC Computer Cell organises User Training for operational know how and awareness program to keep user well aware of use of latest IT technologies. Under Digital India Program, above said applications were implemented and training was imparted as and when required. Training on e-Office is being imparted to all officers/staff (including JS level officials) of the department. All employees (including outsourced) were sensitized about operations of Aadhaar enabled Biometrics Attendance System (AEBAS). Concerned sections were trained on e-Samiksha, CPGRAMS, CompDDO, E-publishing, Court Cases Monitoring System. Training on Sparrow S/w is imparted to all higher officials.
ANNEXURE
Annexure – I [A] (List of PSUs and Other Organizations)
Annexure – I [B] (Address and Name of various Organizations & PSUs
Annexure – I [C] (List of Responsibility Centers and Subordinate Organizations)
Annexure – II (Organizational Chart of NPPA)
Annexure – III (Result Framework Document 2013-14)
CHAPTER –12
ANNEXURE 1 [A]

List of Public Sector Undertakings

1. Indian Drugs & Pharmaceuticals Ltd, Dundahera Industrial Complex, Dundahera, Gurgaon, Haryana.
2. Hindustan Antibiotics Ltd, Pimpri, Pune, Maharashtra.

OTHER ORGANISATIONS

1. Bengal Immunity Limited, Kolkata, West Bengal.
2. Smith Stanistreet Pharmaceuticals Ltd. Kolkata, West Bengal.
## ANNEXURE 1 [B]

### Address and Names of Head of various Organization & PSUs under the Department of Pharmaceuticals

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Address and Organization</th>
<th>Name</th>
<th>Designation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Indian Drugs &amp; Pharmaceuticals Limited (IDPL), Gurgaon</td>
<td>Shri Praveen Kumar</td>
<td>Chairperson &amp; Managing Director</td>
</tr>
<tr>
<td>2.</td>
<td>Hindustan Antibiotics Limited (HAL), Pune-411010</td>
<td>Shri K.V. Varkey</td>
<td>Managing Director</td>
</tr>
<tr>
<td>3.</td>
<td>Karnataka Antibiotics &amp; Pharmaceuticals Limited (KAPL), Bangalore-700013</td>
<td>Shri K.M. Prasad</td>
<td>Managing Director</td>
</tr>
<tr>
<td>4.</td>
<td>Bengal Chemicals &amp; Pharmaceuticals Limited (BCPL), Kolkata-700013</td>
<td>Shri E.A. Subramanian</td>
<td>Managing Director</td>
</tr>
<tr>
<td>5.</td>
<td>Rajasthan Drugs &amp; Pharmaceuticals Limited (RDPL), Road No. 12 V.K.I Area Jaipur-302013</td>
<td>Shri S.B. Bahdrannavar</td>
<td>Managing Director</td>
</tr>
<tr>
<td>Sl. No.</td>
<td>Responsibility Centers and Subordinate</td>
<td>Landline Number</td>
<td>Email</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------</td>
<td>----------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>1.</td>
<td>Dr. K.K. Bhutani, (Officiating Director)</td>
<td>0172-2214690</td>
<td><a href="mailto:director@niper.ac.in">director@niper.ac.in</a></td>
</tr>
<tr>
<td>2.</td>
<td>Dr. Kiran Kalia, (Director)</td>
<td>079-27439375</td>
<td><a href="mailto:kirankalia@gmail.com">kirankalia@gmail.com</a></td>
</tr>
<tr>
<td>3.</td>
<td>Dr. Ahmed Kamal, (Project Director)</td>
<td>04057193157</td>
<td><a href="mailto:projectdirector@niperhyd.ac.in">projectdirector@niperhyd.ac.in</a></td>
</tr>
<tr>
<td>4.</td>
<td>Dr. Pradeep Das, (Project Director)</td>
<td>0612-2636651</td>
<td><a href="mailto:drpradeep.das@gmail.com">drpradeep.das@gmail.com</a></td>
</tr>
<tr>
<td>5.</td>
<td>Dr. Chitra Mandal, (Project Director)</td>
<td>03324735368</td>
<td><a href="mailto:Chitra_mandal@yahoo.com">Chitra_mandal@yahoo.com</a></td>
</tr>
<tr>
<td>6.</td>
<td>Prof (Dr) B.K. Bezbaruah (Project Director)</td>
<td>03612132751</td>
<td><a href="mailto:niperghy@gmail.com">niperghy@gmail.com</a></td>
</tr>
<tr>
<td>7.</td>
<td>Dr. P Shukla</td>
<td>05223290093</td>
<td><a href="mailto:pk_shukla@cdri.res.in">pk_shukla@cdri.res.in</a></td>
</tr>
</tbody>
</table>
Chairman NPPA

Member Secretary

Advisor

**Organisational Chart of NPPA**

**ANNEXURE – II**

### Chairman NPPA
- Fixation/Revision of prices of NLEM formulations based on monthly reports of IMS and action thereof, if found more than 10%.
- Issue notice to the companies for overcharging and subsequent follow up.
- Issue show cause notice, working out the overcharged amount and raise demand for recovery of the overcharged amount.
- Grant personal hearing and pass speaking/reasoned order whenever needed.
- Notification of prices in the official Gazette and maintaining the price data of NLEM formulations.
- Annual exercise in respect of market structure/number of NLEM manufacturers for each NLEM formulations.
- Coordination work related to Authority Meetings - Agenda/Minutes.
- All overcharging cases/files for the period from 2005 to 2007 under DPCO 1995, DPCO 2013 and related work.

### Member Secretary
- Enforcing and implementation of the prices of NLEM formulations fixed by NPPA.
- Monitoring of the price movement of non-NLEM formulations based on monthly reports of IMS and action thereof, if found more than 10%.
- Processing of SDOs reports received in respect of non-implementation of the prices of NLEM formulations and other DPCO related matters.
- Complaints received from individuals, NGOs, institutes related to pricing/marketing at prices higher than the price fixed by NPPA or price increase more than 10%.
- Sending reports to Overcharging Division for recovery of overcharged amount.
- Sending reports to Pricing Division to fix the prices in respect of NLEM formulations, if price is not fixed.
- Interaction/ correspondence with State Drugs Controllers in the matter related to enforcement of DPCO provisions.
- Shortage and availability of NLEM and non-NLEM formulations.
- Policy matter related to new DPCO.
- Price List collection & examination.
- Storage & Preservation of IMS Data and providing inputs to the concerned Divisions of NPPA.
- Old cases relating to Bulk Drugs.
- Production & Import Data of Bulk Drugs & Formulations.
- Related Parliament Questions/matters.
- RTI work.
- Work relating to RFD.

### Overcharging-I
- All overcharging cases/files w.e.f. 01.01.2008 onwards under DPCO 1995, and related work.
- Issue notice to the companies for overcharging and subsequent follow up.
- Collection of market based data for fixation of prices of NLEM formulations for which IMS data is not available.
- Annual revision of prices of NLEM formulations based on WPI on or after 1st April, every year.
- Annual revision of prices whenever there is a change in market structure in respect of NLEM formulations.
- Price fixation/revision of non-NLEM formulations whenever considered necessary.
- Notification of prices in the official Gazette and maintaining the price data of NLEM formulations.
- Annual exercise in respect of market structure/number of NLEM manufacturers for each NLEM formulations.
- Coordination work related to Authority Meetings - Agenda/Minutes.
- All Plan Schemes of NPPA.

### Overcharging-II
- All overcharging cases/files for the period from 2005 to 2007 under DPCO 1995, DPCO 2013 and related work.
- Issue notice to the companies for overcharging and subsequent follow up.
- Issue show cause notice, working out the overcharged amount and raise demand for recovery of the overcharged amount.
- Grant personal hearing and pass speaking/reasoned order whenever needed.
- Notification of prices in the official Gazette and maintaining the price data of NLEM formulations.
- Annual exercise in respect of market structure/number of NLEM manufacturers for each NLEM formulations.
- Coordination work related to Authority Meetings - Agenda/Minutes.
- All overcharging cases/files for the period from 2005 to 2007 under DPCO 1995, DPCO 2013 and related work.
- All Plan Schemes of NPPA.

### Legal
- Court cases under DPCO, 1987 and 1995.
- Court cases under DPCO, 2013.
- Advice to other Divisions of NPPA related to interpretation and applications of various provisions of DPCO.
- Legal matters related to establishment/matters / NPPA’s accommodation.
- NPPA’s working guidelines/procedures etc.
- Launching prosecution against the defaulting companies for violation of the provisions of DPCO.
- All overcharging cases/files for the period from 2005 to 2007 under DPCO 1995, DPCO 2013 and related work.
- Providing input to Legal Division for court cases.
- All Plan Schemes of NPPA.
- Related Parliament Questions/matters.
## Section 1:
### Vision, Mission, Objectives and Functions

### Vision

India: The Largest Global Provider of Quality Medicines at Reasonable Prices.

### Mission

1. Ensure availability of quality drugs at reasonable prices as per the Pharma Policy.
2. Development of Pharma Infrastructure and Innovative Development in Pharma Sector including through PPP.
3. Promote Pharma Brand India.
5. To establish NIPERs as nationally and internationally recognized brand in the field of education and research of pharmaceutical sciences for the benefit of human kind.

### Objectives

1. Disposal of review application as per the provisions of DPCO’95
2. Enforcement of price control measures
3. Facilitate growth of Central pharma PSUs with required support
4. Jan Aushadi Campaign - setting up of Jan Aushadhi Stores
5. Develop Pharma Human Resources through M.Phama and Ph.D programmes in NIPERS
6. Setting up of New NIPERs
7. Develop Infrastructure for Pharma R & D
8. Develop Pharma Infrastructure and Catalyze Drug Discovery and Innovation
9. Promotion of Research at NIPERs
10. Scheme on Cluster Development Programme for Pharma Sector
11. Promotion of Indian Pharmaceuticals Products / Industry
12. Capacity building of Indian Pharma Industry
13. Creation of IPR Facilitation center at Pharmexcil
14. Scholarship Scheme at NIPERs for students from foreign countries

### Functions

1. Matters relating to Pharmaceuticals and Drugs, excluding those specifically allotted to other departments.
2. Planning, development and control of, and assistance to, all industries dealt with by the Department
Section 1:
Vision, Mission, Objectives and Functions

3. Promotion of public – private – partnership in pharmaceutical related areas.

4. Development of infrastructure, manpower and skills for the pharmaceutical sector and management of related information.

5. Technological up-gradation of the pharmaceutical industry to enable them to compete in the world market and to provide better quality drugs in the indigenous market.

6. Matters related to making available drugs at reasonable prices as per the provisions of extant rules and instructions, monitoring of prices and their enforcement, etc.

7. Promotion and co-ordination of basic, applied and other research in areas related to the pharmaceutical sector.

8. Education and training including high end research and grant of fellowships in India and abroad, exchange of information and technical guidance on all matters relating to pharmaceutical sector.

9. International co-operation for developing and promoting pharmaceuticals industry, investment, research, including work related to international conferences in related areas in India and abroad.

10. Technical support for dealing with national hazards in pharmaceutical sector.


14. Matters relating to an Attached office (i). National Pharmaceutical Pricing Authority (NPPA)
## Section 2:
### Inter se Priorities among Key Objectives, Success indicators and Targets

<table>
<thead>
<tr>
<th>Objective</th>
<th>Weight</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Weight</th>
<th>Target / Criteria Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Disposal of review application as per the provisions of DPCO' 95</td>
<td>5.00</td>
<td>(1.1) Processing of review applications under DPCO, 1995, for orders by the competent authority for disposal in 90 days of receipt of Review Application in the Department</td>
<td>(1.1.1) Issue of review order after approval of the Competent Authority and uploading on the Department’s website</td>
<td>days from the date of receipt</td>
<td>5.00</td>
<td>100 90 80 70 60</td>
</tr>
<tr>
<td>2. Enforcement of price control measures</td>
<td>3.00</td>
<td>(2.1) Monitoring and Enforcing prices</td>
<td>(2.1.1) No. of Test Purchases made by NPPA/ State Drug Controllers</td>
<td>no.</td>
<td>3.00</td>
<td>5500 5000 4000 3000 2000</td>
</tr>
<tr>
<td>3. Facilitate growth of Central pharma PSUs with required support</td>
<td>9.00</td>
<td>(3.1) Revival of IDPL</td>
<td>(3.1.1) Sending proposal to the Cabinet</td>
<td>Date</td>
<td>1.50</td>
<td>28/02/2014 07/03/2014 15/03/2014 22/03/2014 31/03/2014</td>
</tr>
<tr>
<td>3.2 Second Rehabilitation of HAL</td>
<td></td>
<td></td>
<td>(3.2.1) Sending draft Cabinet Note to the Cabinet</td>
<td>Date</td>
<td>1.50</td>
<td>31/12/2013 15/01/2014 31/01/2014 15/02/2014 28/02/2014</td>
</tr>
<tr>
<td>3.3 Extension of Purchase Preference Policy</td>
<td></td>
<td></td>
<td>(3.3.1) Sending proposal to Cabinet</td>
<td>Date</td>
<td>3.00</td>
<td>15/07/2013 30/07/2013 15/08/2013 31/08/2013 15/09/2013</td>
</tr>
<tr>
<td>3.4 Project based support to PSUs for WHO-GMP compliance under Critical Assistance Scheme (WHO-GMP Compliance in various PSUs/RDPL)</td>
<td></td>
<td></td>
<td>(3.4.1) Obtaining approval of Competent Authority</td>
<td>Date</td>
<td>1.50</td>
<td>31/12/2013 15/01/2014 31/01/2014 15/02/2014 28/02/2014</td>
</tr>
<tr>
<td>3.4.2 Release of funds</td>
<td></td>
<td></td>
<td>Date</td>
<td>1.50</td>
<td>28/02/2014 07/03/2014 15/03/2014 22/03/2014 31/03/2014</td>
<td></td>
</tr>
<tr>
<td>4. Jan Aushadi Campaign - setting up of Jan Aushadi Stores</td>
<td>4.00</td>
<td>(4.1) Modification of Jan Aushadi Scheme based on the Revised Business Plan</td>
<td>(4.1.1) Approval of the Competent Authority</td>
<td>Date</td>
<td>2.00</td>
<td>31/01/2014 15/02/2014 28/02/2014 15/03/2014 31/03/2014</td>
</tr>
</tbody>
</table>

### Notes:
- **Excellent**: 100%
- **Very Good**: 90%
- **Good**: 80%
- **Fair**: 70%
- **Poor**: 60%
## Section 2:
Inter se Priorities among Key Objectives, Success indicators and Targets

<table>
<thead>
<tr>
<th>Objective</th>
<th>Weight</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Weight</th>
<th>Target / Criteria Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(5) Develop Pharma Human Resources through M.Pharmacy and Ph.D programmes in NIPERS</td>
<td>5.00</td>
<td>Intake of students for Masters and Ph. D degrees NIPER, Mohali: Ph.D – 50, MS-250, MBA- 61 Other NIPERs Ahmedabad – 53 (6) Guwahati – 41 (4) Hajipur – 21 (5) Hyderabad – 96 (12) Kolkata – 42 Rae Bareli – 39</td>
<td>[5.1.1] No. of Admission during the year</td>
<td>%</td>
<td>4.00</td>
<td>100</td>
</tr>
<tr>
<td>(5)</td>
<td></td>
<td></td>
<td>[5.2.1] Total placement of NIPER's students</td>
<td>%</td>
<td>1.00</td>
<td>100</td>
</tr>
<tr>
<td>(6) Setting up of New NIPERs</td>
<td>4.00</td>
<td>Construction of campus at Guwahati</td>
<td>[6.1.1] Commencement of construction work</td>
<td>Date</td>
<td>2.00</td>
<td>31/12/2013</td>
</tr>
<tr>
<td>(6)</td>
<td></td>
<td>Construction of campus at Gandhinagar</td>
<td>[6.2.1] Commencement of construction work</td>
<td>Date</td>
<td>2.00</td>
<td>31/12/2013</td>
</tr>
<tr>
<td>(7) Develop Infrastructure for Pharma R &amp;D</td>
<td>12.00</td>
<td>Setting up of GLP Compliant labs - Chemical &amp; Biological in PPP mode.</td>
<td>[7.1.1] Receipt of Project Reports from the consultant</td>
<td>Date</td>
<td>3.00</td>
<td>31/01/2014</td>
</tr>
<tr>
<td>(7)</td>
<td></td>
<td>Setting up of GLP Compliant Large Animal House in PPP mode.</td>
<td>[7.2.1] Receipt of Project Reports from the consultant</td>
<td>Date</td>
<td>3.00</td>
<td>28/01/2014</td>
</tr>
<tr>
<td>(7)</td>
<td></td>
<td>Establishing National Centre for R&amp;D in Bulk Drugs (NCRDBD) at NIPER, Hyderabad to strengthen advance research in Bulk drugs.</td>
<td>[7.3.1] Approval of the Competent Authority</td>
<td>Date</td>
<td>3.00</td>
<td>30/09/2013</td>
</tr>
</tbody>
</table>
## Section 2:
### Inter se Priorities among Key Objectives, Success indicators and Targets

<table>
<thead>
<tr>
<th>Objective</th>
<th>Weight</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Weight</th>
<th>Target / Criteria Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>[8.2] Preparation of Schemes for approving R&amp;D Projects of all NIPERs</td>
<td>[8.2.1] Approval of the Scheme</td>
<td>Date</td>
<td>3.00</td>
<td>31/10/2013 30/11/2013 31/12/2013 31/01/2014 28/02/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[8.3] Pharmaceuticals Technology Upgradation Assistance Scheme (PTUAS) for Pharma Medium</td>
<td>[8.3.1] Submission of the proposal to the Cabinet Committee on Economic Affairs (CCEA)</td>
<td>Date</td>
<td>8.00</td>
<td>31/01/2014 15/02/2014 28/02/2014 15/03/2014 31/03/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[8.4] Setting up of Venture Fund</td>
<td>[8.4.1] Receipt of in-principle approval of the Planning Commission</td>
<td>Date</td>
<td>3.00</td>
<td>01/03/2014 07/03/2014 14/03/2014 21/03/2014 31/03/2014</td>
</tr>
<tr>
<td>[9] Promotion of Research at NIPERs</td>
<td>9.00</td>
<td>[9.1] Getting Patents at NIPER, Mohali during the year</td>
<td>[9.1.1] No. of Patents to be filed during the year</td>
<td>No. 1.50</td>
<td>4 3 2 1 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[9.1.2] No. of Patents commercialized during the year</td>
<td>No. 1.50</td>
<td>4 3 2 1 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[9.2] Publication of Papers in international journals by NIPER, Mohali</td>
<td>[9.2.1] No. of Publications in the International Journals during the year</td>
<td>No. 3.00</td>
<td>155 150 120 110 100</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[9.3] Publication of Papers in international journals by NIPER, Hyderabad Kolkata Rae Bareli Hajipur Guwahati</td>
<td>[9.3.1] No. of Publications in the International Journals</td>
<td>No. 3.00</td>
<td>8 6 4 3 2</td>
<td></td>
</tr>
</tbody>
</table>
### Section 2:
Inter se Priorities among Key Objectives, Success indicators and Targets

<table>
<thead>
<tr>
<th>Objective</th>
<th>Weight</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Target / Criteria Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gandhinagar</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[10.2] Approval of the Scheme by EFC</td>
<td>[10.2.1] Appraisal of the proposed scheme by EFC</td>
<td>Date</td>
</tr>
<tr>
<td>[12] Capacity building of Indian Pharma Industry</td>
<td>5.00</td>
<td>[12.1] Training of Industry Personnel for compliance to WHO-GMP Standards</td>
<td>[12.1.1] Seminars/workshop at four Centres on WHO-GMP Standards compliance</td>
<td>No. of Personnel trained</td>
</tr>
<tr>
<td>[14] Scholarship Scheme at NIPERs for students from foreign countries</td>
<td>3.00</td>
<td>[14.1] Scholarship scheme for students of other countries with a focus on those countries</td>
<td>[14.1.1] Approval of the scheme by the Competent Authority</td>
<td>Date</td>
</tr>
</tbody>
</table>
## Section 2:
### Inter se Priorities among Key Objectives, Success indicators and Targets

<table>
<thead>
<tr>
<th>Objective</th>
<th>Weight</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Value</th>
<th>Weight</th>
<th>Target / Criteria Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Efficient Functioning of the RFD System</strong></td>
<td>3.00</td>
<td>Timely submission of Draft RFD 2014-15 for Approval</td>
<td>On-time submission</td>
<td>Date</td>
<td></td>
<td>2.0</td>
<td>05/03/2014 06/03/2014 07/03/2014 08/03/2014 11/03/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Timely submission of Results for 2012-13</td>
<td>On-time submission</td>
<td>Date</td>
<td></td>
<td>1.0</td>
<td>01/05/2013 02/05/2013 03/05/2013 06/05/2013 07/05/2013</td>
</tr>
<tr>
<td>* Transparence/Service delivery Ministry/Department</td>
<td>3.00</td>
<td>Independent Audit of implementation of Citizens'/Clients' Charter (CCC)</td>
<td>% of implementation</td>
<td>%</td>
<td>2.0</td>
<td>100</td>
<td>90 80 70 60</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Independent Audit of implementation of Public Grievance Redressal System</td>
<td>% of implementation</td>
<td>%</td>
<td>1.0</td>
<td>100</td>
<td>90 80 70 60</td>
</tr>
<tr>
<td>* Administrative Reforms</td>
<td>6.00</td>
<td>Implement mitigating strategies for reducing potential risk of corruption</td>
<td>% of implementation</td>
<td>%</td>
<td>1.0</td>
<td>100</td>
<td>95 90 85 80</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Implement ISO 9001 as per the approved action plan</td>
<td>% of implementation</td>
<td>%</td>
<td>2.0</td>
<td>100</td>
<td>95 90 85 80</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identify, design and Implement major innovations.</td>
<td>Timely submission of Action Plan for enabling innovation</td>
<td>Date</td>
<td></td>
<td>2.0</td>
<td>15/05/2014 16/05/2014 19/05/2014 20/05/2014 21/05/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identification of core and non-core activities of the Ministry/Department as per 2nd ARC recommendations</td>
<td>Timely submission Date</td>
<td>1.0</td>
<td>24/03/2014 25/03/2014 26/03/2014 27/03/2014 28/03/2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Improving Internal Efficiency/Responsiveness.</td>
<td>2.00</td>
<td>Update departmental strategy to align with 12th Plan priorities</td>
<td>Timely updation of the strategy</td>
<td>Date</td>
<td></td>
<td>2.0</td>
<td>10/09/2013 17/09/2013 24/09/2013 01/10/2013 08/10/2013</td>
</tr>
<tr>
<td>* Ensuring compliance to the Financial Accountability Framework</td>
<td>1.00</td>
<td>Timely submission of ATNs on Audit paras of C&amp;AG</td>
<td>Percentage of ATNs submitted within due date (4 months) from</td>
<td>%</td>
<td>0.25</td>
<td>100</td>
<td>90 80 70 60</td>
</tr>
</tbody>
</table>

* Mandatory Objective(s)
## Section 2:
Inter se Priorities among Key Objectives, Success indicators and Targets

<table>
<thead>
<tr>
<th>Objective</th>
<th>Weight</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Weight</th>
<th>Target / Criteria Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>date of presentation of Report to Parliament by CAG during the year.</td>
<td></td>
<td></td>
<td>Excellent</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Timely submission of ATRs to the PAC Sectt. on PAC Reports.</td>
<td></td>
<td></td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Percentage of ATRS submitted within due date (6 months) from date of presentation of Report to Parliament by PAC during the year.</td>
<td>%</td>
<td>0.25</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Early disposal of pending ATNs on Audit Paras of C&amp;AG Reports presented to Parliament before 31.3.2013.</td>
<td>%</td>
<td>0.25</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Percentage of outstanding ATNs disposed off during the year.</td>
<td></td>
<td></td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Early disposal of pending ATRs on PAC Reports presented to Parliament before 31.3.2013</td>
<td>%</td>
<td>0.25</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Percentage of outstanding ATRS disposed off during the year.</td>
<td></td>
<td></td>
<td>100%</td>
</tr>
</tbody>
</table>

* Mandatory Objective(s)
## Section 3:
**Trend Values of the Success Indicators**

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Actual Value for FY 11/12</th>
<th>Actual Value for FY 12/13</th>
<th>Target Value for FY 13/14</th>
<th>Projected Value for FY 14/15</th>
<th>Projected Value for FY 15/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Disposal of review application as per the provisions of DPCO’ 95</td>
<td>[1.1] Processing of review applications under DPCO, 1995, for orders by the competent authority for disposal in 90 days of receipt of Review Application in the Department</td>
<td>[1.1.1] Issue of review order after approval of the Competent Authority and uploading on the Department’s website.</td>
<td>days from the date of receipt</td>
<td>–</td>
<td>–</td>
<td>95</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>(2) Enforcement of price control measures</td>
<td>[2.1] Monitoring and Enforcing prices</td>
<td>[2.1.1] No. of Test Purchases made by NPPA/ State Drug Controllers</td>
<td>no.</td>
<td>–</td>
<td>–</td>
<td>5000</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>(3) Facilitate growth of Central pharma PSUs with required support</td>
<td>[3.1] Revival of IDPL</td>
<td>[3.1.1] Sending proposal to the Cabinet</td>
<td>Date</td>
<td>–</td>
<td>–</td>
<td>07/03/2014</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>[3.2] Second Rehabilitation of HAL</td>
<td>[3.2.1] Sending draft Cabinet Note to the Cabinet</td>
<td>Date</td>
<td>–</td>
<td>–</td>
<td>15/01/2014</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>[3.3] Extension of Purchase Preference Policy</td>
<td>[3.3.1] Sending proposal to Cabinet</td>
<td>Date</td>
<td>–</td>
<td>–</td>
<td>30/04/2013</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>[3.4] Project based support to PSUs for WHO-GMP compliance under Critical Assistance Scheme (WHO-GMP Compliance in various PSUs/RDPL)</td>
<td>[3.4.1] Obtaining approval of Competent Authority</td>
<td>Date</td>
<td>–</td>
<td>–</td>
<td>15/01/2014</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[3.4.2] Release of funds</td>
<td>Date</td>
<td>–</td>
<td>–</td>
<td>07/03/2014</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>(4) Jan Aushadi Campaign - setting up of Jan Aushadhi</td>
<td>[4.1] Modification of Jan Aushadhi Scheme</td>
<td>[4.1.1] Approval of the Competent</td>
<td>Date</td>
<td>–</td>
<td>–</td>
<td>15/02/2014</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
## Section 3:  
Trend Values of the Success Indicators

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Actual Value for FY 11/12</th>
<th>Actual Value for FY 12/13</th>
<th>Target Value for FY 13/14</th>
<th>Projected Value for FY 14/15</th>
<th>Projected Value for FY 15/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stores</td>
<td>based on the Revised Business Plan Authority</td>
<td>[4.1.2] Issue of Order Date</td>
<td>--</td>
<td>--</td>
<td>07/03/2014</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>[5] Develop Pharma Human Resources through M.Pharma and Ph.D programmes in NIPERS</td>
<td>[5.1] Intake of students for Masters and Ph. D degrees NIPER, Mohali: Ph.D – 50, MS-250; MBA-61; Other NIPERs Ahmedabad – 53 (6); Guwahati – 41 (4); Hajipur – 21 (5); Hyderabad – 86 (12); Kolkata – 42 Rae Bareli – 39</td>
<td>[5.1.1] No. of Admission during the year %</td>
<td>--</td>
<td>--</td>
<td>90</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>[5.2] Placement of successful students of NIPER, Mohali in job/Research</td>
<td>[5.2.1] Total placement of NIPER’s students %</td>
<td>--</td>
<td>--</td>
<td>90</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>[6.2] Construction of campus at Gandhinagar</td>
<td>[6.2.1] Commencement of construction work Date</td>
<td>--</td>
<td>--</td>
<td>15/01/2014</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>[7] Develop Infrastructure for Pharma R &amp;D</td>
<td>[7.1] Setting up of GLP Compliant labs - Chemical &amp; Biological in PPP mode.</td>
<td>[7.1.1] Receipt of Project Reports from the consultant Date</td>
<td>--</td>
<td>--</td>
<td>15/02/2014</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>[7.2] Setting up of GLP Compliant Large Animal House in PPP mode.</td>
<td>[7.2.1] Receipt of Project Reports from the consultant Date</td>
<td>--</td>
<td>--</td>
<td>15/02/2014</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>
## Section 3:
Trend Values of the Success Indicators

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Actual Value for FY 11/12</th>
<th>Actual Value for FY 12/13</th>
<th>Target Value for FY 13/14</th>
<th>Projected Value for FY 14/15</th>
<th>Projected Value for FY 15/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>[7.3] Establishing National Centre for R&amp;D in Bulk Drugs (NORDBD) at NIPER, Hyderabad to strengthen advance research in Bulk drugs.</td>
<td>[7.3.1] Approval of the Competent Authority</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>31/10/2013</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>[7.4] Setting up of Incubator Facilities at NIPER, Mohali</td>
<td>[7.4.1] Approval of the Competent Authority</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>31/12/2013</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>[8.2] Preparation of Schemes for approving R&amp;D Projects of all NIPERs</td>
<td>[8.2.1] Approval of the Scheme.</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>30/11/2013</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>[8.3] Pharmaceuticals Technology Upgradation Assistance Scheme (PTUAS) for Pharma Medium Enterprises</td>
<td>[8.3.1] Submission of the proposal to the Cabinet Committee on Economic Affairs (CEA)</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>15/02/2014</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>[8.4] Setting up of Venture Fund</td>
<td>[8.4.1] Receipt of in-principle approval of the Planning Commission</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>07/03/2014</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>[9] Promotion of Research at NIPERs</td>
<td>[9.1] Getting Patents at NIPER, Mohali during the year.</td>
<td>[9.1.1] No. of Patents to be filed during the year</td>
<td>No.</td>
<td>--</td>
<td>--</td>
<td>3</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>[9.1.2] No. of Patents commercialized</td>
<td>No.</td>
<td>--</td>
<td>--</td>
<td>3</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>
## Section 3: Trend Values of the Success Indicators

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Actual Value for FY 11/12</th>
<th>Actual Value for FY 12/13</th>
<th>Target Value for FY 13/14</th>
<th>Projected Value for FY 14/15</th>
<th>Projected Value for FY 15/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>[9.2] Publication of Papers in international journals by NIPER, Mohali</td>
<td>[9.2.1] No. of Publication in the International Journals during the year</td>
<td>No.</td>
<td>--</td>
<td>--</td>
<td>150</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>[9.3] Publication of Papers in international journals by NIPER, Hyderabad Kolkata Raebareli Hajipur Guwahati Gandhinagar</td>
<td>[9.3.1] No. of Publications in the International Journals</td>
<td>No.</td>
<td>--</td>
<td>--</td>
<td>6</td>
<td>--</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>[10] Scheme on Cluster Development Programme for Pharma Sector</td>
<td>[10.1] Approval of the scheme by Planning Commission</td>
<td>Submission of the draft scheme to Planning Commission</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>31/07/2013</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>[10.2] Approval of the Scheme by EFC</td>
<td>Appraisal of the proposed scheme by EFC</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>30/09/2013</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>
### Section 3: Trend Values of the Success Indicators

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Actual Value for FY 11/12</th>
<th>Actual Value for FY 12/13</th>
<th>Target Value for FY 13/14</th>
<th>Projected Value for FY 14/15</th>
<th>Projected Value for FY 15/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>(12) Capacity building of Indian Pharma Industry</td>
<td>(12.1) Training of Industry Personnel for compliance to WHO-GMP Standards</td>
<td>(12.1.1) Seminars/workshop at four Centres on WHO-GMP Standards compliance</td>
<td>No. of Personnel trained</td>
<td>--</td>
<td>645</td>
<td>400</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>(13) Creation of IPR Facilitation center at Pharmexcil</td>
<td>(13.1) Dissemination of information on IPRs and related issues to the Pharma Industry by Pharmexcil.</td>
<td>(13.1.1) Timely release of funds</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>31/01/2014</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>(14) Scholarship Scheme at NIPERs for students from foreign countries</td>
<td>(14.1) Scholarship scheme for students of other countries with a focus on those countries which are major export markets for Indian Drug Industry</td>
<td>(14.1.1) Approval of the scheme by the Competent Authority</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>31/01/2014</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

* Efficient Functioning of the RFD System
  - Timely submission of Draft RFD 2014-15 for Approval
    - On-time submission | Date | -- | 07/03/2012 | 06/03/2014 | -- | -- |
  - Timely submission of Results for 2012-13
    - On-time submission | Date | -- | -- | 02/05/2013 | -- | -- |

* Transparency/Service delivery Ministry/Department
  - Independent Audit of implementation of Citizens'/Clients' Charter
    - % of implementation | % | -- | -- | 95 | -- | -- |
  - Independent Audit of implementation of Public Grievance Redressal System
    - % of implementation | % | -- | -- | 95 | -- | -- |

* Administrative Reforms
  - Implement mitigating strategies for reducing
    - % of implementation | % | -- | -- | 95 | -- | -- |

* Mandatory Objective(s)
## Section 3:
Trend Values of the Success Indicators

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Actual Value for FY 11/12</th>
<th>Actual Value for FY 12/13</th>
<th>Target Value for FY 13/14</th>
<th>Projected Value for FY 14/15</th>
<th>Projected Value for FY 15/16</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>potential risk of corruption</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Implement ISO 9001 as per the approved action plan</td>
<td>% of implementation</td>
<td>%</td>
<td>--</td>
<td>--</td>
<td>95</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identify, design and implement major innovations.</td>
<td>Timely submission of Action Plan for enabling innovation</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>95</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identification of core and non-core activities of the Ministry/Department as per 2nd ARC recommendations</td>
<td>Timely submission</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>15/10/2013</td>
<td>--</td>
</tr>
<tr>
<td>* Improving Internal Efficiency/Responsiveness.</td>
<td>Update departmental strategy to align with 12th Plan priorities</td>
<td>Timely updation of the strategy</td>
<td>Date</td>
<td>--</td>
<td>--</td>
<td>17/09/2013</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>* Ensuring compliance to the Financial Accountability Framework</td>
<td>Timely submission of ATNs on Audit paras of C&amp;AG</td>
<td>Percentage of ATNs submitted within due date (4 months) from date of presentation of Report to Parliament by CAG during the year</td>
<td>%</td>
<td>--</td>
<td>--</td>
<td>90</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Timely submission of ATRSs to the PAC Secti. on PAC Reports</td>
<td>Percentage of ATRSs submitted within due date (6 months) from date of presentation of Report to Parliament by PAC during the year</td>
<td>%</td>
<td>--</td>
<td>--</td>
<td>90</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>Early disposal of pending ATNs on Audit Paras of C&amp;AG Reports presented to Parliament before 31.3.2013</td>
<td>Percentage of outstanding ATNs disposed off during the year</td>
<td>%</td>
<td>--</td>
<td>--</td>
<td>90</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

* Mandatory Objective(s)
## Section 3: Trend Values of the Success Indicators

<table>
<thead>
<tr>
<th>Objective</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Actual Value for FY 11/12</th>
<th>Actual Value for FY 12/13</th>
<th>Target Value for FY 13/14</th>
<th>Projected Value for FY 14/15</th>
<th>Projected Value for FY 15/16</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Early disposal of pending ATRs on PAC Reports presented to Parliament before 31.3.2013</td>
<td>Percentage of outstanding ATRs disposed off during the year.</td>
<td>%</td>
<td>--</td>
<td>--</td>
<td>90</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

* Mandatory Objective(s)
**Section 4: Acronym**

<table>
<thead>
<tr>
<th>Sl.No</th>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PH</td>
<td>Conducting hearing is a quasi-judicial process for giving an opportunity to the aggrieved party (pharma company) which is also attended by officials of NPPA and Pharma/technical experts of the Department. The PH is being presently given by the concerned Deputy Secretary handling the DPCO matters. The record note of discussion of the PH is prepared and signed by the representative of the company, NPPA, and the concerned DS and copy thereof is also handed over to the concerned party.</td>
</tr>
</tbody>
</table>
### Section 4:
Description and Definition of Success Indicators and Proposed Measurement Methodology

<table>
<thead>
<tr>
<th>Sl.No</th>
<th>Success indicator</th>
<th>Description</th>
<th>Definition</th>
<th>Measurement</th>
<th>General Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>[1.1.1] Issue of review order after approval of the Competent Authority and uploading on the Department’s website.</td>
<td>The Review order is prepared and issued after approval of Minister (C&amp;F) and also sent for updating the same on the website of the department.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>[2.1.1] No. of Test Purchases made by NPPA/State Drug Controllers</td>
<td>Purchase of Drug samples (i.e. scheduled and non-scheduled drugs) is one of the market surveillance devices to monitor the implementation of prices of drugs fixed by NPPA and to ensure enforcement of such prices by the Pharma companies in general.</td>
<td>Monitoring and Enforcing Prices</td>
<td>Purchase of Drug samples (i.e. scheduled and non-scheduled drugs) is one of the market surveillance devices</td>
<td></td>
</tr>
</tbody>
</table>
### Section 5:
Specific Performance Requirements from other Departments

<table>
<thead>
<tr>
<th>Location Type</th>
<th>State</th>
<th>Organisation Type</th>
<th>Organisation Name</th>
<th>Relevant Success Indicator</th>
<th>What is your requirement from this organisation</th>
<th>Justification for this requirement</th>
<th>Please quantify your requirement from this Organisation</th>
<th>What happens if your requirement is not met</th>
</tr>
</thead>
</table>
| Central Government |      | Responsibility Centre / Attached office | National Pharmaceuticals Pricing Authority (NPPA) | [2.1.1] No. of Test Purchases made by NPPA/ State Drug Controllers  
[1.1.1] Issue of review order after approval of the Competent Authority and uploading on the Department’s website. | NPPA is fully responsible for taking action in this regard in coordination with State Drug Controllers | This is a barometer for measuring compliance of DPCO provisions of price control. | 600 samples | The effective control on monitoring and enforcement will be termed as "not satisfactory" as per the provisions of DPCO. |
## Section 6:
### Outcome/Impact of Department/Ministry

<table>
<thead>
<tr>
<th>Outcome/Impact of Department/Ministry</th>
<th>Jointly responsible for influencing this outcome / impact with the following department(s) / ministry(ies)</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>FY 11/12</th>
<th>FY 12/13</th>
<th>FY 13/14</th>
<th>FY 14/15</th>
<th>FY 15/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Higher growth of Pharmaceuticals Industry in the Country</td>
<td></td>
<td>Growth of Pharmaceuticals Production in the Country</td>
<td>%</td>
<td>18.65</td>
<td>9.38</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Greater availability of Drugs for endemic diseases, Vector borne and parasitic diseases for which indigenous and effective drugs are not available</td>
<td>Ministry of Health and Family Welfare</td>
<td>Vector borne diseases and Parasitic Diseases for which Drugs are not available</td>
<td>No.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Reduction in Spurious Drugs</td>
<td>Ministry of Health and Family Welfare</td>
<td>Quantity of Spurious drugs detected in the market by the inspectors</td>
<td>No.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Availability of Pharmaceuticals at reasonable/Lower price in the country</td>
<td></td>
<td>Price Index of 115.4 Pharmaceuticals Medicines in the Country (Comparison vis a vis previous year will reveal the trends)</td>
<td>%</td>
<td>1.17</td>
<td>2.38</td>
<td>3.67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Setting up of Jan Aushadi Stores</td>
<td>State Government / BPPI</td>
<td>No. of Stores opened</td>
<td>No.</td>
<td>20</td>
<td>30</td>
<td>303</td>
<td>900</td>
<td>900</td>
</tr>
<tr>
<td>6 Supply of Generic Medicines to JAS</td>
<td>State Government / CPSEs / BPPI</td>
<td>Sales of medicines (Rs. in lakhs)</td>
<td>Amount</td>
<td>287.93</td>
<td>281.76</td>
<td>450</td>
<td>900</td>
<td>1350</td>
</tr>
</tbody>
</table>
Section 6:
Outcome/Impact of Department/Ministry

<table>
<thead>
<tr>
<th>Outcome/Impact of Department/Ministry</th>
<th>Jointly responsible for influencing this outcome / impact with the following department(s) / ministry(ies)</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>FY 11/12</th>
<th>FY 12/13</th>
<th>FY 13/14</th>
<th>FY 14/15</th>
<th>FY 15/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 Creation of HR professional for Pharmaceutical Industry</td>
<td>NIPERs</td>
<td>Admission of students</td>
<td>%</td>
<td>95-100</td>
<td>As per tgt</td>
<td>As per tgt</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>8 Assistance to R&amp;D in pharmaceutical sector</td>
<td>NIPERs/ Private sector</td>
<td>Success of specific schemes</td>
<td>%</td>
<td>NA</td>
<td>NA</td>
<td>As per tgt</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>9 Implementation of Notified Prices/ Enforcement of the Provisions of DPCO/95</td>
<td>NPPA</td>
<td>No. of Test Purchases/Sample of Drugs (Scheduled and Non-Scheduled) made by NPPA/ State Drug Controllers</td>
<td>Nos.</td>
<td>559</td>
<td>590</td>
<td>550</td>
<td>600</td>
<td></td>
</tr>
<tr>
<td>10 Ensure reasonableness of pricing of drugs as per provisions of DPCO/95</td>
<td>NPPA</td>
<td>Processing of review applications under DPCO, 1995, for orders by the competent authority for disposal in 90 days of receipt of Review Application in the Department</td>
<td>days from the date of</td>
<td>120</td>
<td>100</td>
<td>100</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Provision of financial support for growth of Pharma Medium Enterprises (MEs)</td>
<td>Planning Commission for approval</td>
<td>Approval of the Planning Commission</td>
<td>Date</td>
<td></td>
<td></td>
<td></td>
<td>30/06/2013</td>
<td></td>
</tr>
</tbody>
</table>
## Performance Evaluation Report

<table>
<thead>
<tr>
<th>Objective</th>
<th>Weight</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Target / Criteria Value (Weighted)</th>
<th>Achievement</th>
<th>Performance Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Disposal of review applications as per the provisions of DPCO'95</td>
<td>5.00</td>
<td>Processing of review applications under DPCO, 1995, for orders by the competent authority for disposal in 90 days of receipt of Review Application in the Department</td>
<td>Issue of review order after approval of the Competent Authority and uploading on the Department's website. days from the date of receipt</td>
<td>5.00</td>
<td>90</td>
<td>95</td>
<td>100</td>
</tr>
<tr>
<td>2 Enforcement of price control measures</td>
<td>3.00</td>
<td>Monitoring and Enforcing prices</td>
<td>No. of Test Purchases made by NPPA/State Drug Controllers</td>
<td>3.00</td>
<td>5500</td>
<td>5000</td>
<td>4000</td>
</tr>
<tr>
<td>3 Facilitate growth of Central Pharma PSUs with required support</td>
<td>9.00</td>
<td>Revival of IDPL</td>
<td>Sending proposal to the Cabinet</td>
<td>Date</td>
<td>1.50</td>
<td>28/02/2014</td>
<td>07/03/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Second Rehabilitation of HAL</td>
<td>Sending draft Cabinet Notes to the Cabinet</td>
<td>Date</td>
<td>1.50</td>
<td>31/12/2013</td>
<td>15/01/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Extension of Purchase Preference Policy</td>
<td>Sending proposal to Cabinet</td>
<td>Date</td>
<td>3.00</td>
<td>15/07/2013</td>
<td>30/07/2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project based support to PSUs for WHO-GMP compliance under Critical Assistance Scheme (WHO-GMP Compliance in various PSUs/RDPL)</td>
<td>Obtaining approval of Competent Authority</td>
<td>Date</td>
<td>1.50</td>
<td>31/12/2013</td>
<td>15/01/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Release of funds</td>
<td>Date</td>
<td>1.50</td>
<td>28/02/2014</td>
<td>07/03/2014</td>
</tr>
<tr>
<td>4 Jan Aushadi Campaign - setting up of Jan Aushadi Stores</td>
<td>4.00</td>
<td>Modification of Jan Aushadi Scheme based on the Revised Business Plan</td>
<td>Approval of the Competent Authority</td>
<td>Date</td>
<td>2.00</td>
<td>31/01/2014</td>
<td>15/02/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Issue of Order</td>
<td>Date</td>
<td>2.00</td>
<td>28/02/2014</td>
<td>07/03/2014</td>
</tr>
<tr>
<td>5 Develop Pharma Human Resources through M.Pharma and Ph.D programmes in NIPERS</td>
<td>5.00</td>
<td>Intake of students for Masters and Ph. D degrees NIPER, Morals: Ph.D – 50, MS-250, MBA-</td>
<td>No. of Admission during the year</td>
<td>%</td>
<td>4.00</td>
<td>100</td>
<td>90</td>
</tr>
</tbody>
</table>
### Performance Evaluation Report

<table>
<thead>
<tr>
<th>Objective</th>
<th>Weight</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Weight</th>
<th>Target / Criteria Value</th>
<th>Achievement</th>
<th>Performance Score</th>
<th>Weighted Score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100% 90% 80% 70% 60%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Excellent Very Good Good Fair Poor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>61 Other NIPERs Ahmedabad – 53 (6) Guwahati – 41 (4) Hajipur – 21 (5) Hyderabad – 96 (12) Kolkata – 42 Rae Bareli – 39</td>
<td>80%</td>
<td>Total placement of successful students of NIPER, Mohali in job/Research</td>
<td>%</td>
<td>1.00</td>
<td>100</td>
<td>90</td>
<td>80</td>
<td>70</td>
<td>60</td>
</tr>
<tr>
<td>6 Setting up of New NIPERs</td>
<td>4.00</td>
<td>Construction of campus at Guwahati</td>
<td>Commencement of construction work</td>
<td>Date</td>
<td>2.00</td>
<td>31/12/2013</td>
<td>15/01/2014</td>
<td>01/02/2014</td>
<td>28/02/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Construction of campus at Gandhinagar</td>
<td>Commencement of construction work</td>
<td>Date</td>
<td>2.00</td>
<td>31/12/2013</td>
<td>15/01/2014</td>
<td>01/02/2014</td>
<td>28/02/2014</td>
</tr>
<tr>
<td>7 Develop Infrastructure for Pharma R&amp;D</td>
<td>12.00</td>
<td>Setting up of GLP Compliant labs - Chemical &amp; Biological in PPP mode.</td>
<td>Receipt of Project Reports from the consultant</td>
<td>Date</td>
<td>3.00</td>
<td>31/01/2014</td>
<td>15/02/2014</td>
<td>28/02/2014</td>
<td>15/03/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Setting up of GLP Compliant Large Animal House in PPP mode.</td>
<td>Receipt of Project Reports from the consultant</td>
<td>Date</td>
<td>3.00</td>
<td>28/01/2014</td>
<td>15/02/2014</td>
<td>28/02/2014</td>
<td>15/03/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Establishing National Centre for R&amp;D in Bulk Drugs (NCRDBD) at NIPER, Hyderabad to strengthen advance research in Bulk drugs.</td>
<td>Approval of the Competent Authority</td>
<td>Date</td>
<td>3.00</td>
<td>30/09/2013</td>
<td>31/10/2013</td>
<td>31/12/2013</td>
<td>14/02/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Setting up of Incubator Facilities at NIPER, Mohali</td>
<td>Approval of the Competent Authority</td>
<td>Date</td>
<td>3.00</td>
<td>31/10/2013</td>
<td>31/12/2013</td>
<td>14/02/2014</td>
<td>14/03/2014</td>
</tr>
<tr>
<td>8 Develop Pharma Infrastructure and Catalyze Drug Discovery and Innovation</td>
<td>17.00</td>
<td>Development of new drugs for TB &amp; Kalazar by NIPER</td>
<td>Release of Funds</td>
<td>Date</td>
<td>3.00</td>
<td>31/12/2013</td>
<td>31/01/2014</td>
<td>15/02/2014</td>
<td>15/03/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Preparation of Schemes for approving R&amp;D Projects of all NIPERs</td>
<td>Approval of the Scheme.</td>
<td>Date</td>
<td>3.00</td>
<td>31/10/2013</td>
<td>30/11/2013</td>
<td>31/12/2013</td>
<td>31/01/2014</td>
</tr>
</tbody>
</table>
## Performance Evaluation Report

<table>
<thead>
<tr>
<th>Objective</th>
<th>Weight</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Weight</th>
<th>Target / Criteria Value</th>
<th>Achievement</th>
<th>Performance</th>
<th>Raw Score</th>
<th>Weighted Score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmaceuticals Technology Upgradation Assistance Scheme (PTUAS) for Pharma Medium Enterprises</strong></td>
<td>8.00</td>
<td>Submission of the proposal to the Cabinet Committee on Economic Affairs (CCEA)</td>
<td>Date</td>
<td>31/01/2014</td>
<td>15/02/2014</td>
<td>28/02/2014</td>
<td>15/03/2014</td>
<td>31/03/2014</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Setting up of Venture Fund</strong></td>
<td>3.00</td>
<td>Receipt of in-principle approval of the Planning Commission</td>
<td>Date</td>
<td>01/03/2014</td>
<td>07/03/2014</td>
<td>14/03/2014</td>
<td>21/03/2014</td>
<td>31/03/2014</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>9  <strong>Promotion of Research at NIPERs</strong></td>
<td>9.00</td>
<td>Getting Patents at NIPER, Mohali during the year</td>
<td>No. of Patents to be filed during the year</td>
<td>1.50</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>160</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No. of Patents commercialized during the year</td>
<td>1.50</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Publication of Papers in international journals by NIPER, Mohali</td>
<td>3.00</td>
<td>155</td>
<td>150</td>
<td>120</td>
<td>110</td>
<td>100</td>
<td>145</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Publication of Papers in international journals by NIPER, Hyderabad, Kolkata, Rae Bareli, Hajipur, Guwahati, Gandhinagar</td>
<td>3.00</td>
<td>8</td>
<td>6</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>45</td>
</tr>
<tr>
<td>10  <strong>Scheme on Cluster Development Programme for Pharma Sector</strong></td>
<td>6.00</td>
<td>Approval of the draft scheme by Planning Commission</td>
<td>Submission of the draft scheme to Planning Commission</td>
<td>Date</td>
<td>30/06/2013</td>
<td>31/07/2013</td>
<td>31/08/2013</td>
<td>30/09/2013</td>
<td>30/10/2013</td>
<td>27/08/2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Approval of the Scheme by EFC</td>
<td>Date</td>
<td>31/08/2013</td>
<td>30/09/2013</td>
<td>31/10/2013</td>
<td>30/11/2013</td>
<td>31/12/2013</td>
<td>21/01/2014</td>
</tr>
<tr>
<td>11  <strong>Promotion of Indian Pharmaceuticals Products / Industry</strong></td>
<td>2.00</td>
<td>Follow Up Action of Third India Pharma Summit held in November 2012</td>
<td>Implementation of two finalized proposals – (i) Seminars/ workshops on the Regulatory frameworks in African countries (ii) Seminar on Potential of Indian Pharma Sector in R&amp;D</td>
<td>Date</td>
<td>30/11/2013</td>
<td>31/12/2013</td>
<td>31/01/2014</td>
<td>28/02/2014</td>
<td>31/03/2014</td>
<td>05/11/2013</td>
</tr>
</tbody>
</table>
## Performance Evaluation Report for Department of Pharmaceuticals

### Objective Weight Action Unit

<table>
<thead>
<tr>
<th>Target / Criteria Value</th>
<th>Weight</th>
<th>Task / Activity</th>
<th>Raw Score</th>
<th>Achieved Score</th>
<th>Weighted Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective</td>
<td>100%</td>
<td>12 Capacity building of Indian Pharma industry</td>
<td>3.00</td>
<td>2.00</td>
<td>2.00</td>
</tr>
<tr>
<td></td>
<td>90%</td>
<td>13 Creation of IP Facilitation center at Pharmexcil</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>80%</td>
<td>14 Scholarship Scheme at NIPERs for students from foreign countries</td>
<td>3.00</td>
<td>1.00</td>
<td>0.79</td>
</tr>
<tr>
<td></td>
<td>70%</td>
<td>15 Efficient Functioning of the RFD System</td>
<td>6.00</td>
<td>5.00</td>
<td>4.74</td>
</tr>
<tr>
<td></td>
<td>60%</td>
<td>16 Implement mitigating strategies for reducing potential risk of corruption</td>
<td>6.00</td>
<td>1.00</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>50%</td>
<td>17 Implement ISO 9001 as per the approved action plan</td>
<td>6.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
</tbody>
</table>

### Mandatory Objective(s)

- Increase Transparency in regulatory activities
- Strengthen the regulatory framework


#### Objective 1: Efficient Functioning of the RFD System

- **Timely Submission of Draft RFD 2014-15 for Approval**
  - Date: 31/12/2013
  - Score: 2.00

- **Transparency of information on IPRs and related issues to the Pharma Industry by Pharmexcil**
  - Date: 31/12/2013
  - Score: 1.00

- **Approval of the scheme by the Competent Authority for R&D for 2014-15**
  - Date: 31/12/2013
  - Score: 1.00

#### Objective 2: Creation of IPR Facilitation center at Pharmexcil

- **Dissemination of information on IPRs and related issues to the Pharma Industry by Pharmexcil**
  - Date: 31/12/2013
  - Score: 1.00

- **Timely Release of Funds for the scheme**
  - Date: 31/12/2013
  - Score: 1.00

### Administrative Reforms

- **Transparency/Service delivery**
- **Ministry/Department**
- **Independent Audit of implementation of Citizen’s Charter (CCC)**
- **Independent Audit of implementation of Public Grievance Redressal System**

### Notes

- Raw Score: The raw score is calculated based on the prescribed criteria.
- Achieved Score: The achieved score is calculated based on the actual performance.
- Weighted Score: The weighted score is calculated by multiplying the achieved score by the weightage assigned to the objective.
Performance Evaluation Report

<table>
<thead>
<tr>
<th>Objective</th>
<th>Weight</th>
<th>Action</th>
<th>Success Indicator</th>
<th>Unit</th>
<th>Weight</th>
<th>Target / Criteria Value</th>
<th>Achievemnt</th>
<th>Performance</th>
<th>Raw</th>
<th>Weighted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Excellent</td>
<td>Very Good</td>
<td>Good</td>
<td>Fair</td>
<td>Poor</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100%</td>
<td>90%</td>
<td>80%</td>
<td>70%</td>
<td>60%</td>
</tr>
<tr>
<td>Identify, design and Implement major innovations.</td>
<td>80%</td>
<td>Timely submission of Action Plan for enabling innovation</td>
<td>Date</td>
<td>2.0</td>
<td>15/05/2014</td>
<td>16/05/2014</td>
<td>19/05/2014</td>
<td>20/05/2014</td>
<td>21/05/2014</td>
<td>N/A</td>
</tr>
<tr>
<td>Identification of core and non-core activities of the Ministry/Department as per 2nd ARC recommendations</td>
<td>100%</td>
<td>Timely submission</td>
<td>Date</td>
<td>1.0</td>
<td>24/03/2014</td>
<td>25/03/2014</td>
<td>26/03/2014</td>
<td>27/03/2014</td>
<td>28/03/2014</td>
<td>N/A</td>
</tr>
<tr>
<td>* Improving Internal Efficiency/Responsiveness.</td>
<td>2.00</td>
<td>Update departmental strategy to align with 12th Plan priorities</td>
<td>Timely updating of the strategy</td>
<td>Date</td>
<td>2.0</td>
<td>10/09/2013</td>
<td>17/09/2013</td>
<td>24/09/2013</td>
<td>01/10/2013</td>
<td>08/10/2013</td>
</tr>
<tr>
<td>* Ensuring compliance to the Financial Accountability Framework</td>
<td>1.00</td>
<td>Timely submission of ATNs on Audit paras of C&amp;AG</td>
<td>Percentage of ATNs submitted within due date (4 months) from date of presentation of Report to Parliament by CAG during the year.</td>
<td>%</td>
<td>0.25</td>
<td>100</td>
<td>90</td>
<td>80</td>
<td>70</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Timely submission of ATRs to the PAC Sectt. on PAC Reports.</td>
<td>Percentage of ATRS submitted within due date (6 months) from date of presentation of Report to Parliament by PAC during the year.</td>
<td>%</td>
<td>0.25</td>
<td>100</td>
<td>90</td>
<td>80</td>
<td>70</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Early disposal of pending ATNs on Audit Paras of C&amp;AG Reports presented to Parliament before 31.3.2013.</td>
<td>Percentage of outstanding ATNs disposed off during the year.</td>
<td>%</td>
<td>0.25</td>
<td>100</td>
<td>90</td>
<td>80</td>
<td>70</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Early disposal of pending ATRs on PAC Reports presented to Parliament before 31.3.2013.</td>
<td>Percentage of outstanding ATRS disposed off during the year.</td>
<td>%</td>
<td>0.25</td>
<td>100</td>
<td>90</td>
<td>80</td>
<td>70</td>
<td>60</td>
</tr>
</tbody>
</table>

* Mandatory Objective(s)

Total Composite Score : 33.21